













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 





Anxiety after Stroke 
Intervention Design and a Randomised Controlled Trial 
 










Doctor of Philosophy 







I declare that this thesis was written by myself, that the work contained 
herein is my own except where explicitly stated otherwise in the text, and that this 
work has not been submitted for any other degree or professional qualification 
except as specified.  
Parts of this work have been published in scientific journals, on which I am 
first author. This thesis contains extracts from the following: 
 ‘A systematic review of anxiety interventions in stroke and 
acquired brain injury: efficacy and trial design’, published in the 
January 2018 issue of Journal of Psychosomatic Research (Chun, 
Whiteley, Dennis, Mead, Carson, 2018) 
 ‘Anxiety after stroke: the importance of subtyping’, published in the 
February 2018 issue of Stroke (Chun, Whiteley, Dennis, Mead, 
Carson, 2018) 
 ‘TASK: the feasibility phase of a novel web-enabled trial, a trial 
protocol’, published in the August 2018 issue of Pilot and 
Feasibility Studies (Chun, Carson, Dennis, Mead, Whiteley, 2018) 
 ‘Anxiety after stroke, time for an intervention’, a leading opinion 
article, published in the June 2015 issue of International Journal of 
Stroke (Chun, Whiteley, Carson, Dennis, Mead, 2015). 
 
My supervisors provided comments on versions of my accepted and published 
work. I made editorial changes of these publications for inclusion in this thesis. 





I would like to express my gratitude to my magnificent team of 
supervisors, Professor Alan Carson, Dr Will Whiteley, Professor Martin Dennis, 
and Professor Gillian Mead for their guidance, insightful wisdom, and constructive 
critique throughout my fellowship. Ever since I attended the Edinburgh Stroke 
Winter School in 2014, they have been constantly instilling confidence in me, 
creating opportunities for me to learn, develop, and widen my horizons as an 
academic. From them I learnt the principles of high quality clinical research 
methodology. Their vast experience and vision inspired me to find innovative 
solutions to design efficient clinical trials. I wish to thank Professor Alan Carson 
for the training in neuropsychiatry, which enabled me to gain invaluable insights 
into the anxiety issues experienced by stroke patients. This experience provided 
the ingredients for my anxiety intervention. 
I thank my parents for an upbringing that has taught me, from an early 
age, the importance of solid hard work, perseverance, and self-discipline. These 
qualities gave me the most rewarding experiences in the past three years. I was 
fortunate to be able to find emotional support from all those around me, including 
my family, friends, and colleagues. The generosity of the research participants in 
giving up their time to help other people was a constant reminder of my purpose 
and duty as a clinical researcher—to improve patient outcomes. 
Finally, I would like to thank the Stroke Association for supporting my pre-
doctoral research training through the Princess Margaret Research Development 
Fellowship and the Chief Scientist Office of Scotland for funding my clinical 
academic fellowship and the research contained in this thesis.  






Anxiety is common and potentially debilitating after stroke. There is no 
reliable evidence to guide treatment. Barriers exist in accessing psychological 
care after stroke. Little is known about anxiety subtypes and what provokes 
anxiety in people after stroke. Treatment approaches effective in non-stroke 
populations may not be feasible or generalisable to stroke patients.  
Aims 
The first aim is to develop an intervention for treating anxiety after stroke 
and evaluate its feasibility in patients. The second aim is to test the feasibility of a 
randomised controlled trial (RCT) to evaluate the intervention’s effectiveness. 
Methods 
I used a range of clinical research methodologies: i) a systematic review 
to summarise the design of anxiety interventions in stroke and acquired brain 
injury and their efficacy; ii) a prospective cohort study to investigate the frequency 
of anxiety subtypes, anxiety-provoking stimuli, factors associated with anxiety, 
and clinical outcomes associated with anxiety after stroke; iii) a study of 
diagnostic validity and reliability of two anxiety measures, iv) complex intervention 
development using a systematic approach; v) a feasibility RCT—Treating Anxiety 
after StroKe (TASK RCT) 
Results 
My anxiety intervention was practical to deliver and acceptable to patients. 
The TASK RCT procedures were feasible at a small scale. This thesis will inform 
further refinements of the intervention and trial procedures in preparation for the 





 There are 1.2 million stroke survivors in the UK. About a quarter of them 
have anxiety. This is when anxiety or fear becomes excessive or out-of-
proportion, affecting the person’s ability to carry on with their life normally. At 
present, we do not have an effective treatment to offer these patients. Many 
people are suffering and are unable to access any psychological support. 
The research 
 Using existing scientific findings, patient interviews, and questionnaires, I 
aimed to design a new treatment for anxiety after stroke. I tested this new 
treatment in a fair scientific experiment—a clinical trial in a small group of 
patients. My research assessed whether the treatment was acceptable and 
practical to deliver in patients, and whether the trial methods could be used in the 
future at a much larger scale. 
Outcomes and expected benefits 
I successfully designed a new anxiety treatment, delivered via the Internet 
and telephone. The small group of participants found this new treatment 
acceptable and practical. They also found it acceptable and practical to 
participate in a clinical trial just by using the Internet and telephone. 
Equipped with these research findings, I will improve the design of the 
anxiety treatment and the clinical trial procedures. I will need to repeat this 
experiment in a much larger scale for many more patients across the country. 
Only a large-scale clinical trial will tell us if this treatment really is beneficial to 
stroke patients. If beneficial, we will be able to extend this treatment to everyone 





My thesis follows the programme of research which I conducted 
sequentially in the past three years, leading to the development of my anxiety 
intervention—TASK, an acronym for Treating Anxiety after StroKe. I designed 
and conducted a streamlined randomised controlled trial (RCT) equipped with 
technology-enabled procedures to evaluate the TASK intervention.  
In Chapter 1, I provide the background knowledge which my work for this 
thesis is based on.  My original research begins in Chapter 2 with a systematic 
review of RCTs of anxiety treatments in acquired brain injury in order to provide 
learning points to help me optimise intervention and trial design. Chapter 3 
reports my prospective cohort study, which aims to generate new knowledge 
about anxiety subtypes after stroke and identify common anxiety-provoking 
situations. These findings inform the content of my TASK intervention. Chapter 4 
reports a study of diagnostic validity and reliability of two anxiety measures, the 
tools for measuring anxiety in my TASK RCT. Chapter 5 describes the TASK 
intervention development using a systematic, logical, and evidence-based 
methodology. A summary of key existing scientific evidence, my research 
findings, and additional stakeholder activities is presented, with all the processes 
and outcomes of my final TASK intervention modelled in a logic diagram. Chapter 
6 reports the TASK RCT, the feasibility phase of a streamlined web-enabled trial. 
This trial evaluates the feasibility of i) novel trial procedures and ii) the TASK 
intervention. This trial represents my first step in designing scalable procedures to 
enable a centralised large-scale RCT to be conducted remotely and efficiently in 
the future.  Chapter 7 is a general discussion of all the work I carried out for this 





6SQuID Six essential Steps in Quality Intervention Development 
ABI Acquired brain injury 
ACTH Adrenocorticotrophin 
AUC Area under curve 
BAI Beck anxiety inventory  
CBT Cognitive behavioural therapy 
CENTRAL Cochrane Central Register of Controlled Trials  
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analyses  
PTSD Post-traumatic stress disorder 
RCT Randomised controlled trial 
REDCap Research Electronic Data Capture 
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Introduction: Stroke, Transient Ischaemic Attack, and Anxiety 
Publication status and acknowledgement of contribution 
This chapter contains extracts from my submitted manuscript for a book 
chapter, entitled ‘Neuropsychiatry of stroke and transient ischaemic attack’, which 
is currently undergoing editorial review. I wrote the final submitted version of this 
book chapter and the sections included in this thesis chapter with comments from 
my supervisors. 
 
This chapter contains extracts from my published and accepted 
manuscripts:  
i) Systematic review of anxiety treatments in acquired brain injury and stroke 
(Appendix A) 
ii) Anxiety after stroke: the importance of subtyping (Appendix B) 
 
I wrote the initial draft, subsequent and final versions of all published and 












1.1 Stroke and transient ischaemic attack  
Stroke is defined as ‘a clinical syndrome characterised by an acute loss of 
focal cerebral function with symptoms lasting more than 24 hours or leading to 
death, and which is thought to be due to either spontaneous haemorrhage into 
the brain substance (haemorrhagic stroke) or inadequate cerebral blood supply to 
a part of the brain (ischaemic stroke) as a result of low blood flow, thrombosis or 
embolism associated with diseases of the blood vessels (arteries or veins), heart 
or blood’ (1).  
A transient ischaemic attack (TIA), often referred to as a ‘mini-stroke’, is 
‘an acute loss of focal cerebral function or ocular function with symptoms lasting 
less than 24 hours, thought to be due to inadequate cerebral or ocular blood 
supply as a result of low blood flow, thrombosis or embolism’(2). 
In practice, TIA and stroke are clinically indistinguishable within the first 




Stroke is a sudden, potentially fatal and disabling illness. It is one of the 
leading causes of death and disability both globally and in the United Kingdom 
(UK). In the UK, stroke affects around 150, 000 people a year(3). A quarter of 
strokes are fatal within a year, and over a third of stroke survivors are living with 
severe disability(3). While primarily a disease affecting older people (over 65s), 
about one in four strokes occurs in those under the age of 65(4). Hypertension, 
atrial fibrillation, carotid artery stenosis, diabetes and smoking are the main 
modifiable risk factors for stroke and TIA.  
3 
 
Stroke represents a significant health and economic burden to the UK. 
Stroke costs the UK £9 billion a year including expenditure on health and social 
care (49%), informal care (27%), loss of productivity (15%), and benefit payments 
(9%)(5). In a survey of 500 young stroke survivors (aged 25-59), nearly 70% 
reported they were unable to return to work following a stroke(6).  
About 20% of ischaemic strokes are preceded by a TIA(7). Although its 
symptoms are only temporary, TIA carries a high risk of stroke, with the greatest 
risk being in the first few hours to days after TIA onset(8). This elevated risk of 
stroke begins to level off three months following symptom onset (Figure 1) and 
over the first 3 years to an annual risk of 2% thereafter(9). However, the risk of 
major vascular events for the subsequent 10 to 15 years remains high, with an 
annual risk of 3% for myocardial infarction (MI) or death from coronary heart 
disease(10).  
 
Figure 1. Cumulative incidence of the composite outcome (stroke, acute coronary 








1.1.2 Aetiology of stroke 
Approximately 85% of strokes are ischaemic, 10% are intracerebral 
haemorrhage (ICH), and 5% are subarachnoid haemorrhage(12). Ischaemic 
stroke and TIA share the same underlying pathophysiological mechanisms: i) 
large vessel-to-vessel thromboembolism originating from atheromatous large 
vessels such as the carotid arteries and aortic arch (50%); ii) cardioembolism 
frequently related to atrial fibrillation (20%) or other cardiac conditions e.g. 
infective endocarditis, prosthetic heart valve, atrial myxoma, and iii) small vessel 
disease (lacunar strokes) (25%) related to hypertension and diabetes(1). Giant 
cell arteritis e.g. temporal arteritis can give rise to a thromboembolic stroke and is 
suspected in the elderly presenting with a headache, monocular blurred vision 
and raised inflammatory markers. Rarer causes are carotid or vertebral artery 
dissection, paradoxical embolism through a patent foremen ovale, recreational 
drug use, inflammatory vascular disorders, hereditary disorders, and cerebral 
venous thrombosis. 
Primary ICH most commonly occurs due to small vessel disease. In 
elderly, a lobar ICH suggests underlying cerebral amyloid angiopathy. ICH can 
occur secondary to an underlying vascular abnormality e.g. intracranial 
aneurysm, arteriovenous malformation, cavernoma, brain tumour or septic 
emboli. Subarachnoid haemorrhage can occur secondary to rupture of an 
intracranial aneurysm or vascular malformation. 
 
1.1.3 Diagnosis and investigations  
Symptoms of a stroke usually occur abruptly and reach maximum severity 
rapidly at onset. Stroke syndromes present with a wide array of symptoms 
depending on the site of the vascular lesion. The Oxfordshire Community Stroke 
5 
 
Project (OCSP) classification is used widely in the UK. It broadly classifies stroke 
syndromes into those arising from the anterior circulation i.e. carotid territory and 
its branches e.g. middle cerebral artery, and those from the posterior circulation 
i.e. vertebrobasilar territory (Table 1).  
 
Table 1. The OCSP classification of stroke syndromes (1) 
 
Total Anterior Circulation 
Syndrome (TACS) 
1) Motor: 
Hemiplegia and/ or facial weakness or 
severe hemiparesis 
+/- hemisensory deficit  
 
2) Higher cerebral:  
Dysphasia (dominant hemisphere) 
Visuospatial deficit or neglect (non-
dominant hemisphere) 
 
3) Visual field: 
Homonymous hemianopia 
Partial Anterior Circulation 
Syndrome 
(PACS) 
Two of 1) 2)  3) 
 
Lacunar Syndrome (LACS) Pure motor stroke 
Unilateral weakness must involve at least 
two out of three areas of the face, whole 
arm and leg 
 




N.B. no visual field defect, no impairment in 
higher cerebral function 
Posterior Circulation 
Syndrome (POCS) 
Any of the following: 
Ipsilateral cranial nerve (III-XII) palsy with    
         contralateral motor and/or sensory deficit 
Bilateral motor and/ or sensory deficit 
Disorder of conjugate eye movement 
Cerebellar dysfunction 
Isolated hemianopia or cortical blindness 
 
The National Institute of Health Stroke Scale (NIHSS) is a 15-item 
neurological examination which enables rapid standardised neurological 
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assessment and scoring of stroke severity and is used widely in acute stroke 
practice and research(13). Routine investigations include a 12-lead 
electrocardiogram to exclude persistent atrial fibrillation, routine blood tests 
including lipid profile, brain and carotid artery imaging. Further cerebral 
angiographic imaging and cardiac investigations e.g. bubble echocardiogram, 24 
hour electrocardiogram are sometimes requested when clinically indicated. 
 
1.1.4 Management  
Hyperacute stroke management focuses on the timely delivery of 
evidence-based interventions to revascularize the blocked artery within the first 
few hours of onset of an ischaemic stroke e.g. intravenous thrombolysis in the 
first 4.5 hours(14), mechanical thrombectomy for up to 6 hours, or up to 24 hours 
with demonstrable mismatch on imaging sequences(15). All stroke patients 
requiring hospitalisation are admitted to an acute stroke unit equipped to provide 
organised stroke unit care, delivered by a multidisciplinary team of stroke 
physicians, nurses and therapists specialised in looking after stroke patients. This 
model of care reduces mortality and disability after stroke(16).  
The modified Rankin scale (mRS) is a measure of stroke outcome and is 
widely used in clinical practice and as a primary outcome in clinical trials 
evaluating effectiveness of stroke interventions. An mRS of 0-2 denotes 
functional independence or a non-disabling stroke, whereas an mRS of 3-5 
represents outcome with increasing functional dependence and a poor 
outcome(17). A simplified mRS questionnaire employing a simple algorithm has 
been shown to provide a valid and reliable determination of mRS score in-person 





Ischaemic stroke and TIA broadly share the same risk factors and 
pathogenesis. While short-term prognosis and hyperacute treatment differ, the 
two diagnoses share the same long-term secondary prevention approach: 
antiplatelet therapy, cholesterol-lowering with statins, antihypertensives, oral 
anticoagulation for atrial fibrillation, diabetic management, and lifestyle 
modifications e.g. smoking cessation, weight loss, exercise. 
Owing to the very high risk of stroke within the first few days of a TIA, all 
suspected TIAs are started on antiplatelet therapy by their general practitioner or 
emergency physician, followed by specialist assessment in emergency TIA clinics 
within four days of referral.  
 
Life after stroke 
Stroke is a life-changing illness that potentially threatens the individual’s 
survival, independence, and ability to participate in occupational and social 
activities. In National Health Service (NHS) Lothian, there are no formal ‘life after 
stroke’ services other than a period of stroke rehabilitation for those with marked 
deficits and functional impairments. Charity-employed community stroke nurses 
provide visits to stroke patients at home after their discharge from the stroke unit. 
Patients attending clinics, including TIAs and minor strokes are discharged to 
primary care with no formal follow-up. 
Neuropsychiatric complications are common post-stroke but are 
underappreciated in clinical settings(19). These include anxiety, depression, 
cognitive impairment, fatigue, apathy, and emotional lability. Post-stroke 
psychiatric co-morbidities are associated with a decreased likelihood of returning 
to work, poorer quality of life, and long-term disability(20, 21). Post-stroke 
8 
 
neuropsychiatric complications often overlap and are difficult to assess in the 
presence of aphasia or cognitive impairment. At present, there is no reliable 
evidence to guide treatments for any of these complications. 
 
1.2 What is anxiety? 
Definitions 
Anxiety refers to a universal emotional state that we, as people, all 
experience. We use the two words, fear and anxiety interchangeably in our day-
to-day life to denote this common emotional experience. Though related, the two 
words have distinguishable meanings. The Oxford dictionary defines fear as ‘an 
unpleasant emotion caused by the threat of danger, pain, or harm’, and anxiety, 
as ‘a feeling of worry, nervousness, or unease about something with an uncertain 
outcome’(22). The former refers to an unpleasant emotion in response to a 
tangible and acute threat while the latter describes a similar response to 
something that is diffuse and indeterminate. Delineating the terminology becomes 
relevant when discussing the scientific study of fear and anxiety—their 
physiological changes, neurocircuitry and behavioural models.  
This section covers the key relevant scientific knowledge of adaptive fear 
and anxiety, followed by their maladaptive counterparts—anxiety disorders, their 
clinical assessment and management. Throughout my thesis, I use the words fear 
and anxiety interchangeably to reflect the day-to-day language used by clinicians 







1.2.1 Adaptive anxiety 
Anxiety is ubiquitous across animal species and is ‘a group of adaptive 
functions by which an organism senses, evaluates and responds to cues of 
danger in its external (or internal) environment’(23). Anxiety has evolutionary 
origins, granting organisms a way to survive by adapting to changing 
circumstances. In the face of dangers or threats, people and animals experience 
an unpleasant state—anxiety. The feeling is so unpleasant that we are compelled 
to behave in a certain way. These behavioural reactions may be learnt or innate, 
and can occur with or without our conscious control. All serve to reduce the 
dangers we are facing. Consider the three examples below: 
Example 1: A person avoids walking down a quiet dark alley after a night 
out due to concerns about personal safety and the knowledge that a 
recent crime has taken place in that same location. 
Example 2: A person walks down the same alley in order to get to his 
friend’s house. He speeds up his pace on hearing a sudden loud noise 
behind him. 
Example 3: A person abruptly becomes motionless as he discovers 
himself being held at knifepoint by a robber.  
Similar behavioural reactions are also evident in other animals, and are 
conventionally classified into the ‘approach/ avoid’ and the ‘escape/ freezing’ 
behavioural models. In animal experiments, the ‘approach/ avoid’ is a model of 
anxiety to intangible threat, while ‘escape/ freezing’ is a model of fear in response 
to an actual danger. 
To illustrate the evolutionary origin of the fear response to an actual 
threat, imagine a newly hatched marine iguana, chased by a group of racer 
snakes on the Galapagos archipelago (or see it for yourself on BBC’s Planet 
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Earth II’s YouTube video: www.youtube.com/watch?v=B3OjfK0t1XM). By 
remaining motionless, the baby iguana stays undetected under the motion-
sensitive vision of the otherwise blind natural predators. When the opportunity 
arose to escape for survival, the iguana ran for its life and miraculously made it to 
safer grounds. Freezing in the face of a seemingly inescapable danger, and 
escaping for a chance of survival are both universal fear responses. To mount 
such behavioural responses, a multitude of physiological changes has to occur. 
 
1.2.2 Physiological changes  
Charles Darwin (1809-1882), an English biologist, described a man’s fear 
in his book, ‘The Expression of the Emotions in Man and Animals’ in 1871, 
 “The frightened man at first stands like a statue motionless and 
breathless or crouches down as if instinctively to escape observation. The 
heart beats quickly and violently, so that it palpitates or knocks against the 
ribs; skin instantly becomes pale… we see in the marvellous and 
inexplicable manner in which perspiration immediately exudes from it. This 
exudation is all the more remarkable, as the surface is then cold……The 
hairs on the skin stand erect and the superficial muscles shiver. The 
breathing is hurried……the salivary glands act imperfectly; the mouth 
becomes dry and is often opened and shut. One of the best marked 
symptoms is the trembling of all the muscles of the body, often first seen 
in the lips. The voice becomes husky or indistinct, or may altogether 
fail.”(24) 
These are the salient features that follow the activation of the autonomic nervous 
system, which we now know as the fight-or-flight response, a term coined by the 
American physiologist Walter Bradford Cannon (1871-1945) in 1915(25). The 
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fight-or-flight response is mediated via a series of neuroendocrine processes 
beginning in the amygdala, a structure within the medial temporal lobe. The 
amygdala activates the locus coeruleus in the pons and the hypothalamus. The 
locus coeruleus projects directly and activates the adrenoceptors in the 
preganglionic sympathetic neurons in the spinal cord. Release of acetylcholine by 
the preganglionic neurons at the ganglia trigger the release of noradrenaline from 
the postganglionic neurons that innervate various effector organs, resulting in a 
series of physiological changes that prepare our body for quite literally, fight or 
flight (Table 2). The adrenal medulla is directly stimulated by the sympathetic 
nervous system to release adrenaline and noradrenaline. These catecholamines 
exert the fight-or-flight responses by increasing glucose metabolism, cardiac 
output, and blood flow to the skeletal muscles. 
 
Table 2. Fight or flight responses—activation of the sympathetic nervous system  
 
Effector organ Physiological changes 
Eye Pupils dilatation, retraction of eyelid 
Lacrimal & salivary glands 
 
Decreased secretion  
Heart Increase in heart rate,  contractility 
Lungs Bronchodilation and decreased secretions 
Upper GI tract Decreased gastrointestinal motility; contraction 
of sphincters 
Adrenal gland 
(directly stimulated by pre-
ganglionic neuron) 
Release of catecholamines (adrenaline, 
noradrenaline)  
Skin Piloerection—hairs become erect 
 
Increased secretion in sweat glands (palms, 
plantars) 
Blood vessels Vasoconstriction of skin vasculature 
Vasodilatation of blood vessels in skeletal 
muscles 
 
Intestine Reduced intestinal motility 
 




Simultaneously, the hypothalamus activates the pituitary gland to release adreno-
corticotrophic hormone (ACTH) into the circulation, stimulating the adrenal cortex 
to release cortisol, which is loosely termed as a stress hormone. Cortisol 
increases glucose availability by converting fats and protein into glucose(26).  
Perceiving a danger, or even just anticipating one, i.e. a psychological 
stimulus, can trigger the fight-or-flight response, as can physical insults to our 
body e.g. trauma, hypothermia, hypotension, hypoglycaemia, hypoxia, pain. All of 
these are imminent threats to our survival.  
 
1.2.3 Neurocircuitry  
In response to a threatening stimulus, our brain has to produce a fear 
response in its entirety, simultaneously giving rise to the behavioural and 
physiological responses, as well as the subjective experience of the emotion that 
we know as fear. The neurocircuitry of fear involves numerous structures 
including the amygdala, hippocampus, prefrontal cortex, cingulate gyrus, 
hypothalamus, and other areas. Charney et al. conceptualised the neurocircuitry 
of fear as three components(27): i) the afferent structures for receiving sensory 
input, ii) the structures for stimulus processing, and iii) the efferent structures for 
sending signals to the effector organs that ultimately give rise to the behavioural, 
physiological, and emotional responses (Figure 2). Afferent signals arising from 
our sensory organs are relayed to the primary sensory cortices via the thalamus, 
with the exception of olfactory signals, which go directly to the entorhinal cortex. 
From the primary sensory cortices, information enters the adjacent sensory 
association cortices, then onto a complex network of structures for information 




Figure 2. Neurocircuitry of fear and anxiety, adapted from Charney et al.(27)  
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In addition to this three-component model, LeDoux et al. adds a ‘two 
systems framework’ in fear processing, in which there is one system that involves 
primarily the cortical structures, resulting in the generation of conscious feelings 
(the cognitive circuit) while another system is responsible for the physiological 
and behavioural responses i.e. the more ‘basic’ and ‘primitive’ reactions that 
occur mainly unconsciously, involving mostly the subcortical areas, also known as 
the defensive survival circuit(28).  
 
The amygdala 
Amygdala (‘almond’ in Latin) is an almond-shaped structure located in the 
medial temporal lobe. It consists of at least 13 nuclei with complex 
interconnections(29). Once sensory information of an immediate threat is relayed 
to the amygdala, the lateral nucleus of the amygdala sends signals to the central 
nucleus, which in turn triggers the behavioural and physiological responses of 
fear e.g. freezing, rise in heart rate and blood pressure, release of stress 
hormones. Observations in both animal and human studies demonstrated the role 
of the central nucleus of amygdala in mediating the autonomic and somatic 
changes observed in fear whereas the bed nucleus of stria terminalis is thought to 
be involved in the behavioural expression of anxiety to intangible threat(30).  
 
The hypothalamus 
The hypothalamus, a structure lying below the thalamus in the 
diencephalon, is made up of nuclei responsible for regulating a range of 
physiological functions related to survival—drinking, feeding, thermoregulation, 
and sleep. The hypothalamus is concerned with homeostasis—maintaining a 
constant internal environment by effecting appropriate responses in the presence 
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of internal and/ or external stimuli e.g. a surge in blood pressure, a drop in 
ambient light(26). Besides mediating the fight-or-flight response via the 
sympatho-medullary pathway, it is also responsible for mediating the response 
via the hypothalamo-pituitary-adrenal (HPA) axis. Hypothalamus releases 
cortocotrophin-releasing hormone (CRH) and vasopressin that triggers the 
pituitary gland to release ACTH into the blood. Adrenal cortex then releases 
cortisol upon activation by ACTH(26).  
 
Neurotransmitters and neuropeptides. 
Communication between the various brain regions and effector organs 
require neurotransmitters and neuropeptides. Noradrenaline, dopamine, serotonin 
(5-hydroxytryptamine), gamma-amino-butyric-acid, vasopressin, CRH, and ACTH 
are some of the key neurotransmitters and neuropeptides implicated in fear and 
anxiety(27). 
 
Anxiety to intangible threat 
Anxiety in response to intangible, potential, and anticipated threats(31) is 
more difficult to study in the laboratory as conditions that provoke this kind of 
anxiety in humans are not as easily reproduced as the discrete stimuli that 
provoke fear in animal models (e.g. electric shocks). Furthermore, human 
cognition is more complex. Animal models of anxiety to uncertain threat have 
relied on observing animals’ innate exploratory or social behaviours e.g. 
exploration of an open field or elevated maze in mice, parental separation and 
variable foraging availability in non-human primates(23). In spite of these 
limitations, it was evident that adverse rearing conditions led to prolonged 
activation of the HPA and elevated sympathetic arousal in animals(32) 
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1.3 Maladaptive anxiety—phobic and generalised anxiety 
Anxiety can become maladaptive. This is when fear or anxiety becomes 
excessive, pervasive or out-of-proportion to the danger posed by a situation. 
When anxiety is maladaptive to the extent that it interferes with the person’s 
occupational or social functioning, it may be considered an anxiety disorder. 
Anxiety is not a single unitary disorder. It can be broadly divided into two clinical 
subtypes—phobic and generalised, mirroring the division between adaptive fear 
(in response to well-defined danger) and adaptive anxiety (in response to 
intangible threat). 
 
Phobic and generalised anxiety 
Phobic anxiety is characterized by a disproportionate fear of well-defined 
situations or stimuli(33). Exposure to the feared situation triggers unpleasant 
anxiety symptoms, accompanied by marked avoidant behaviour of that feared 
situation—the hallmark of phobic anxiety(33). Whilst avoidant behaviour may 
relieve anxiety in the short-term it can become disabling if the behaviour becomes 
consolidated through conditioning e.g. becoming housebound in agoraphobia as 
a result of learning to associate ‘danger’ with ‘leaving house’. By contrast, 
generalised anxiety disorder (GAD) is diffuse and unremitting, characterized by 
persistent and multiple worries e.g. finances, health, and an inability to stop 
worrying(33).  
 
1.3.1 Diagnostic criteria and assessment  
Clinicians make a clinical diagnosis of an anxiety disorder based on widely 
accepted standardised classification systems. Commonly used systems include 
the American Psychiatric Association’s Diagnostic Statistical Manual of Mental 
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disorders (DSM) and the International Classification of Diseases (ICD-10). The 
DSM’s latest version, the DSM-V, was published in 2013(33). Its accompanying 
validated research tool, the Structured Clinical Interview for DSM disorders 
(SCID-DSM-V) became available in 2015. At the time of planning my research 
methods for this thesis in 2014, the SCID was available only for the preceding 
version, the DSM-IV-TR(34). This version was widely used and regarded as the 
‘gold-standard’ in psychiatry research. Hence, it was selected to be the diagnostic 
tool of choice in my research for this thesis. Table 3 shows the current DSM-V 
diagnostic criteria for GAD, agoraphobia, social phobia and specific phobia. I 
have highlighted the key changes made since the update from DSM-IV-TR.  
Of particular relevance to my thesis, all phobic disorders (agoraphobia, 
social phobia and specific phobia) had the criterion ‘the person recognises that 
the fear is excessive or unreasonable’ removed and replaced by the new criterion 
‘The fear or anxiety is out of proportion to the actual danger posed by the phobic 
situations and to the sociocultural context’. Agoraphobia can be diagnosed 
irrespective of the presence of panic disorder in the update. I adopted both of 










Table 3. DSM-V criteria for anxiety disorders and key changes from DSM-IV-TR  
DSM-V Key changes since DSM-IV-TR 
Generalised anxiety disorder 
A. Excessive anxiety and worry (apprehensive expectation), occurring more days than 
not for at least 6 months, about a number of events or activities (such as work or 
school performance) 
B. The individual finds it difficult to control the worry 
C. The anxiety and worry are associated with three (or more) of the following six 
symptoms (with at least some symptoms having been present for more days than not 
for the past 6 months): 1) restlessness or feeling keyed up or on edge; 2) being easily 
fatigued; 3) difficulty concentrating or mind going blank; 4) irritability; 5) muscle 
tension; 6) sleep disturbance 
D. The anxiety, worry, or physical symptoms cause clinically significant distress or 
impairment in social, occupational, or other important areas of functioning 
E. The disturbance is not attributable to the physiological effects of a substance or 
another medical condition e.g. hyperthyroidism 
The disturbance is not better explained by another mental disorder e.g. panic disorder, social 
anxiety disorder, obsessive compulsive disorder, separation anxiety disorder, PTSD, anorexia 
nervosa, somatic symptom disorder, body dysmorphic disorder, illness anxiety disorder, or 
the content of delusional believes in schizophrenia or delusional disorder 
Illness anxiety disorder—worry 
about illness, concern about pain, 
and bodily preoccupations was not 
a diagnosis before the update. 
Agoraphobia 
A. Marked fear or anxiety about two (or more) of the following five situations: 
1. Using public transportation; 2. Being in open spaces; 3. Being in enclosed spaces; 
4. Standing in line or being in a crowd; 
5. Being outside of the home alone 
B. The individual fears or avoids these situations because of thoughts that escape might 
be difficult or help might not be available in the event of developing panic-like 
symptoms or other incapacitating or embarrassing symptom  
C. The agoraphobic situations almost always provoke fear or anxiety 
 
 
New criterion E 
 
Removal of the diagnoses: panic 
disorder with agoraphobia, and 
agoraphobia without history of 




Table 3 continued 
D. The agoraphobic situations are actively avoided, require the presence of a companion, 
or are endured with intense fear or anxiety 
E. The fear or anxiety is out of proportion to the actual danger posed by the agoraphobic 
situations and to the sociocultural context 
 
F. The fear, anxiety, or avoidance is persistent, typically lasting for 6 months or more. 
G. The fear, anxiety, or avoidance causes clinically significant distress or impairment in 
social, occupational, or other important areas of functioning 
H. If another medical condition is present, the fear, anxiety, or avoidance is clearly 
excessive 
I. The fear, anxiety, or avoidance is not better explained by the symptom of another 
mental disorder .g. specific phobia, social anxiety disorder, OCD, body dysmorphic 
disorder, PTSD, separation anxiety disorder 
In the update, agoraphobia can be 
diagnosed irrespective of the 
presence of panic disorder—this is 
the diagnostic approach used in my 
methodology  
 




A. Marked fear or anxiety about a specific object or situation 
B. The phobic object or situation almost always provokes immediate fear of anxiety 
C. The phobic object or situation is actively avoided or endured with intense fear or 
anxiety 
D. The fear or anxiety  is out of proportion not the actual danger posed by the specific 
object or situation and to the social cultural context 
E. The fear, anxiety , or avoidance is persistent, typically lasting for 6 months or more 
F. The fear, anxiety, or avoidance causes clinically significant distress or impairment in 
social, occupational, or other important areas of functioning 
G. The disturbance is not better explained by the symptoms of another mental disorder, 
including agoraphobia, obsessive-compulsive disorder, posttraumatic stress disorder, 
separation anxiety disorder, or social anxiety disorder 
 
 
Removal of  the diagnostic 
criterion, ‘the person recognises 
that the fear is excessive or 
unreasonable’  
 
New criterion E 
 






Social phobia (or social anxiety disorder) 
A. Marked fear or anxiety about one or more social situations in which the individual is 
exposed to possible scrutiny by others. Examples include social interactions (e.g. 
having a conversation, meeting unfamiliar people), being observed (e.g. eating or 
drinking), and performing in front of others (e.g. giving a speech) 
B. The individual fears that he or she will act in a way or show anxiety symptoms that will 
be negatively evaluated (i.e. will be humiliating or embarrassing; will lead to rejection 
nor offend others) 
C. The social situations almost always provoke fear or anxiety 
 
Table 3 continued 
 
D. The social situations are avoided or endured with intense fear or anxiety 
E. The fear or anxiety is out of proportion not the actual threat posed by the social 
situation and to the sociocultural context 
F. The fear, anxiety, or avoidance is persistent, typically lasting for 6 months of more 
G. The fear, anxiety, or avoidance causes clinically significant distress or impairment in 
social, occupational, or other important areas of functioning 
H. The fear, anxiety, or avoidance is not attributable to the physiological effects of a 
substance or another medical condition 
I. The fear, anxiety, or avoidance is not better explained by symptoms of another mental 
disorder 
J. If another medical condition is present, the fear, anxiety, or avoidance is clearly 
unrelated or is excessive 
 
Diagnostic features remain the 
same with changes in wording for 
criteria A and B. 
 
Removal of  the diagnostic 
criterion, ‘the person recognises 
that the fear is excessive or 
unreasonable’  
 
New criterion E 
Panic disorder 
A. Recurrent unexpected panic attacks. A panic attack is an abrupt surge of intense fear 
or intense discomfort that reaches a peak within minutes and during which time four or 
more of the following symptoms occur 
 
 
Minor changes in wording only 
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 Palpitations, sweating; trembling; sensations of shortness of breath; feelings of 
choking; chest pain or discomfort; nausea or abdominal distress; feeling dizzy;  
unsteady/ light headed/ faint; chills/ heat sensations; paraesthesia; 
derealisation/depersonalisation; fear of losing control/ going crazy; fear of dying 
 
B. At least one of the attack has been followed by 1 month (or more) of one or both of the 
following: 
 Persistent concern about additional panic attacks or their consequences 
 A significant maladaptive change in behaviour related to the attacks e.g. 
behaviours designed to avoid having panic attacks, such as avoidance of exercise 
or unfamiliar situations 
C. The disturbance is not attributable to the physiological effects of a substance or 
another medical condition 
D. The disturbance is not better explained by another mental disorder e.g. social phobia, 




In the DSM-IV-TR and its accompanying SCID, post-traumatic stress 
disorder (PTSD) and obsessive compulsive disorder (OCD) were classified as 
anxiety disorders. Since the update, these two disorders have been re-
classified—PTSD in the category of ‘Trauma- and stressor-related disorders’ and 
OCD in the category of ‘Obsessive-compulsive and related disorders’. 
 
1.3.2 Epidemiology of anxiety disorders 
The Adult Psychiatric Morbidity Survey in England, a population-based 
cross-sectional survey commissioned by NHS Digital, gave the following 
estimates for anxiety disorders in 2014 (Table 4) (35). This survey used the 
Clinical Interview Schedule–Revised Score (36) and the PTSD checklist for 
diagnosis of anxiety disorders(37). GAD was the commonest anxiety disorder in 
adults while phobias were uncommon.  
Table 4. Prevalence estimates of anxiety disorders in England in 2014(35) 














 % % % % % % % % 
GAD 6.3 6.1 6.9 7.3 6.4 4.0 2.5 5.9 
Phobias 3.3 3.3 3.0 2.7 2.3 0.6 0.5 2.4 
Panic disorder 1.2 0.5 0.3 0.5 0.5 0.7 0.6 0.6 
OCD 1.8 1.4 1.6 1.6 1.5 0.3 0.3 1.3 
PTSD 8.0 5.4 4.6 4.5 3.7 1.6 0.6 4.4 
 
Risk factors 
The study of anxiety and its pathological forms supports a multifactorial 
aetiology of clinical anxiety disorders—the complex interplay of biological 
(genetic, physiological), psychological, and social or environmental factors. The 
Adult Psychiatric Morbidity Survey in England found that common mental 
disorders—GAD, phobias, panic disorder, OCD, and depression were more 
prevalent in black women, people below the age of 60 and living alone, women 
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living in large households, the unemployed, and people receiving benefits and 
smokers(35).  Co-morbidity was high amongst anxiety disorders, and between 
anxiety disorders and mood disorders including depression. 
 
1.3.3 Fear conditioning and exposure therapy 
Fear can be acquired and extinguished via ‘classical conditioning’, also 
known as ‘learning by association’. Ivan Pavlov in the late nineteenth century 
discovered that dogs learnt by classical conditioning. By repeatedly pairing the 
ringing of a bell (a neutral stimulus) with food (a natural stimulus of salivation), his 
dogs became conditioned to salivate on hearing the bell, even in the absence of 
food(38). In 1920, John Watson and Rosalie Raynor demonstrated that a nine-
month old infant known as Little Albert, could be conditioned to exhibit fear to a 
previously neutral stimulus (a white fluffy rat) by repeatedly presenting Albert the 
rat with a naturally aversive stimulus—a loud hammering sound(39). Their 
experiments also demonstrated that a phobic fear could generalise across a 
range of similar situations—Little Albert’s fear of the fluffy rat extended to other 
similarly fluffy objects, including a fur coat and a Santa Claus mask(39). Shortly 
following this, Mary Cover Jones, another American psychologist went on to apply 
the same principles of classical conditioning in a child named Little Peter, who 
had a phobia of rabbits. By repeatedly presenting him a rabbit together with his 
favourite candy while gradually bringing the animal closer to him(40), Little Peter’s 
phobia of rabbits was extinguished.  
Classical conditioning, complemented by operant conditioning(41, 42), in 
which reward leads to positive reinforcement of a behaviour, are learning 
behavioural theories fundamental to exposure therapy—a behavioural therapy. 
Systematic desensitization or graduated hierarchical exposure, is the current form 
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of exposure therapy developed by Joseph Wolpe(43). Phobic individuals confront 
their defined feared situation in gradual hierarchical steps. Through conditioning 
and habituation, the unpleasant feelings of anxiety associated with that situation 
gradually diminish. By encouraging the individual to confront their feared 
situation, exposure therapy breaks the vicious cycle of maladaptive escape and 
avoidant behaviours. These maladaptive behaviours, if not treated, are reinforced 
by the pleasant sense of relief and comfort that escape or avoidance brings. 
Exposure therapy, usually delivered as part of cognitive behavioural therapy 
(CBT), is an effective treatment for phobic disorders in the non-stroke 
populations(44, 45) and yet has never been evaluated in stroke patients with 
anxiety(46).  
 
1.3.4 Cognitive model and cognitive therapy 
In the cognitive model established by Aaron Beck in the 1960s, an 
individual’s feelings of anxiety arise from maladaptive thoughts—misconception, 
distortions (overgeneralization, exaggeration), and faulty assumptions about 
himself and/or his world. Cognitive therapy guides the individual to recognise 
these maladaptive thoughts, and helps him appraise them objectively by testing 
the validity of these thoughts with rules of evidence, logic or alternative 
explanation in a process known as cognitive restructuring(47). 
Aaron Beck described the integration of multiple components in the 
cognitive model: modes, schemas, and systems, which gave rise to the cognitive-
affective-behavioural response in a given situation(48). For example, a dangerous 
situation orientates us to respond in a ‘danger’ mode. This mode refers to the 
response arising from the synchronous activity of a network of basic systems: the 
cognitive (‘there is danger’), affective (rapidly increasing levels of anxiety), 
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motivational (an intense impulse to flee), behavioural (the action of fleeing), and 
physiological (chest, palpitations, and dizziness) systems. These basic systems 
result in a coordinated goal-directed strategy(48) (Figure 3).  
Figure 3. A synchronous response of cognitive, affective, motivational, 
physiological and behavioural response 
 
 
The basic cognitive system is responsible for information processing and 
assignment of meanings, based on a series of schemas (Figure 4). Memories, 
past learning, and fantasies mould a person’s perception of himself and other 
people, and goals and expectations(48). Based on these schemas, inferences are 
made and situation is interpreted often out of the person’s awareness.  
 




A superimposing conscious control system—also known as meta-
cognition or ‘thinking about thinking’ exerts control over the basic systems and 
can override them (Figure 5a). For example, a person with a fear of spider enters 
the ‘danger mode’ on seeing a spider. The conscious control system applies 
logic, corrects the ‘automatic’ thinking patterns from the basic cognitive system, 
pays less attention to unpleasant thoughts or memories, inhibits the impulse to 
flee, and forces the person to pick up and release the spider using a glass jar 
(Figure 5b) (48).  
Figure 5a) A superimposing conscious control system exerts control over the 
basic systems in the cognitive-affective-behavioural response 
 
 




 In a person with anxiety, the cognitive system selectively pays attention 
(selective attention) to certain stimuli associated with the perceived danger(48). 
The more he notices the stimuli, the more heightened the anxiety feelings 
(physiological and biological), and the more attention he pays to these stimuli and 
feelings (Figure 6). This leads to and reinforces the incorrect interpretation that 
these stimuli are associated with increased danger. Avoidance of these stimuli 
reinforces the belief that danger subsides once the stimuli are removed.  
Figure 6. The cognitive-affective-behavioural model for perpetuating and the 




 To understand the cognitive patterns underlying anxiety after stroke, I will 
need to explore the stimuli of anxiety, the core beliefs (e.g. perceived threat) held 
by anxious and non-anxious stroke patients, and their ‘safety-seeking’ 
behaviours. Once these have been identified, I will be able to design a way to 
help anxious stroke patients identify where their thinking has become trapped and 
guide them to discover alternative ways of looking at their situation in a more 
helpful way.  
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1.3.5 Evidence-based treatments for anxiety disorders 
Systematic reviews and meta-analyses provide the evidence base for a 
range of therapies for adult anxiety disorders(44): exposure therapies for phobic 
disorders (45), medications for GAD e.g. selective serotonin reuptake inhibitors 
(SSRI), short-term benzodiazepines, and CBT techniques e.g. cognitive 
restructuring, problem solving(49-51). More recent systematic reviews suggest 
that guided self-help CBT interventions are more efficacious than self-help only 
(bibliotherapy or computerised)(52, 53). Guided internet-based CBT is superior to 
waitlist control and as efficacious as face-to-face CBT in treating anxiety 
disorders or depression in general adults (54, 55).   
 
1.4 Anxiety after stroke and transient ischaemic attack 
Stroke is a life-changing illness that potentially threatens the individual’s 
survival, independence, and ability to participate in occupational and social 
activities. Patients with disabling strokes face uncertainties surrounding the 
likelihood of recovery and prognosis, while patients with non-disabling strokes or 
TIAs are warned of an ongoing threat of a recurrence, or worse, that of a severely 
debilitating stroke. Anxiety disorders may present in the acute setting, during 
rehabilitation or become apparent only after discharge(56).  
 
1.4.1 Epidemiology 
Anxiety is common, affecting around a quarter of stroke(56), and nearly a 
third of TIA(57). It can hamper stroke rehabilitation effort and prevent patients 
from returning to their usual activities. Patients with a ‘probable anxiety disorder’ 
at 3 months had a poorer quality of life at 1, 3 and 5 years post-stroke after 
adjusting for age, sex and stroke severity(58). Anxiety symptoms can persist for 
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up to 10 years(58). There are consistent associations between post-stroke 
anxiety and pre-stroke depression and early anxiety after stroke(59).  
 
1.4.2 Assessing anxiety after stroke 
The Hospital anxiety and depression scale is the most commonly used 
anxiety screening tool in stroke(60). However, it was not developed with stroke 
patients in mind. It does not distinguish anxiety subtypes, and has no utility in 
aphasia or cognitive impairment. Currently, there is no universal consensus as to 
how anxiety is best assessed in clinical trials or practice in stroke. Conducting 
semi-structured psychiatric interviews is time-consuming and requires specially-
trained personnel, making it impractical in clinical trials. 
 
1.4.3 Treatments for anxiety after stroke 
The most recent Cochrane update of interventions for anxiety after stroke 
included only 3 trials (n=196). These studies were limited by small sample size 
and inadequate description of their methods and controls, and so are insufficient 
as a guide for treatment(61). Despite earlier observations that phobic anxiety 
might be present after stroke(62-64), intervention studies have treated anxiety 
post-stroke as one unitary phenomenon and evaluated general approaches such 
as relaxation and antidepressants(61), which are unlikely to be effective in phobic 
anxiety. It remains uncertain as to whether what works for general adults with 
anxiety will also work in anxiety after stroke and TIA. Stroke survivors may have 
specific fears amounting to specific phobias that need defining; patients may not 
tolerate psychological treatments; efficacy of therapy may be dependent on 




1.5 Aims of my thesis 
The aims of my thesis are to develop an intervention for anxiety after 
stroke and TIA, provide some information on its acceptability and ease of delivery 
and test the feasibility of a design of a randomised controlled trial (RCT) to test 






























A Systematic Review and Meta-analysis of Anxiety Interventions in 
Stroke and Acquired Brain Injury: Efficacy and Trial Design 
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search strategies for this systematic review.  
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There is little RCT evidence to guide treatment for anxiety after stroke. 
RCTs of anxiety intervention in stroke have not yielded any definitive evidence in 
a recent Cochrane review—only three trials (2 pharmacological, 1 relaxation CD) 
with 196 participants were included(61). These studies had high risk of bias and 
were of small sample size. Aware of the lack of RCT evidence in anxiety after 
stroke I aimed to review systematically the wider evidence base encompassing 
both stroke and traumatic brain injury (TBI). To date, there is no evidence to 
suggest that the pathophysiological mechanism underlying anxiety disorders 
differs from one acquired brain injury (ABI) condition to another. It may be 
reasonable to extrapolate from one ABI to the other as both TBI and stroke 
conditions have abrupt onset, result in varying degrees of brain damage, and 
transient or long-term neurological and neuropsychiatric impairments. The last 
systematic review of anxiety interventions in TBI in 2007 included three studies, 
providing some evidence for CBT in acute stress disorder and in improving 
generalised anxiety symptomology but these studies had small sample sizes and 
were done in mild TBI only(65).  
Summarizing the key considerations in intervention and trial design 
(anxiety subtype targeted, setting and timing of intervention and outcome 
measure), and the sources of potential bias will guide the design of my TASK 
intervention and optimise the quality of the feasibility RCT. 
 
Aims 
To evaluate the efficacy of anxiety treatments and to summarize key 
aspects of trial design, I aimed to perform a systematic review of RCTs of 
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interventions for anxiety disorders in ABI conditions including stroke—ischaemic, 
haemorrhagic or subarachnoid haemorrhage (SAH), and TBI.  
 
2.2 Methods  
I followed a pre-defined protocol in conducting this systematic review and 
reported my review in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) checklist(66).  
 
2.2.1 Searches and information sources 
I searched electronically for RCTs on Medline (1946-18/8/17), Embase 
(1980-17/8/17), PsychInfo (1940-17/8/17), the Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) (inception-16/10/17), the Cochrane Stroke 
Register (16/10/17), and the Cochrane Central Register of Controlled Trials 
(CENTRAL) (inception-16/10/17) using search strategies supplied by the trials 
search co-ordinator of the Cochrane Stroke Group. I reviewed the reference list of 
key systematic reviews to date to identify additional titles(65, 67). I contacted 
authors of eligible titles that were trial protocols, conference abstracts or trial 
register entries for published or unpublished primary data.  
Search strategies 
Database: Embase  
Search dates: 1980 - 17.8.2017  
1. cerebrovascular disease/ or exp basal ganglion haemorrhage/ or exp brain 
hematoma/ or exp brain haemorrhage/ or exp brain infarction/ or exp brain 
ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or exp 
cerebrovascular accident/ or exp cerebrovascular malformation/ or exp 
intracranial aneurysm/ or exp occlusive cerebrovascular disease/ or stroke 
patient/ or stroke unit/ 
2. (stroke$ or post stroke or poststroke or post-stroke or apoplex$ or cerebral 
vasc$ or cerebrovasc$ or cva or SAH).tw. 
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3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or 
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. 
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or 
intraparenchymal or intraventricular or infratentorial or supratentorial or basal 
gangli$ or putaminal or putamen or posterior fossa or hemispher$ or 
subarachnoid) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw. 
5. hemiparesis/ or hemiplegia/ or paresis/ or exp aphasia/ or dysphasia/ or exp 
neurologic gait disorder/ 
6. (hempar$ or hemipleg$ or paresis or paretic or aphasi$ or dysphasi$).tw. 
7. brain injury/ or acquired brain injury/ or brain concussion/ or brain contusion/ or 
brain damage/ or brain stem injury/ or cerebellum injury/ or diffuse axonal injury/ 
or postconcussion syndrome/ or traumatic brain injury/ or brain hypoxia/ or head 
injury/ 
8. ((brain or cerebr$) adj5 (injur$ or hypoxi$ or damage$ or concussion or 
trauma$)).tw. 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. anxiety/ 
11. exp anxiety disorder/ 
12. exp anxiolytic agent/ 
13. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic 
disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?traumatic 
stress$ or PTSD).tw. 
14. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or 
terror)).tw. 
15. beck anxiety inventory/ or hamilton anxiety scale/ or "hospital anxiety and 
depression scale"/ or self-rating anxiety scale/ or state trait anxiety inventory/ 
16. 10 or 11 or 12 or 13 or 14 or 15 
17. Randomised Controlled Trial/ or "randomised controlled trial (topic)"/ 
18. Randomisation/ 
19. Controlled clinical trial/ or "controlled clinical trial (topic)"/ 
20. control group/ or controlled study/ 
21. clinical trial/ or "clinical trial (topic)"/ or phase 1 clinical trial/ or phase 2 clinical 
trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ 
22. Crossover Procedure/ 
23. Double Blind Procedure/ 
24. Single Blind Procedure/ or triple blind procedure/ 
25. placebo/ or placebo effect/ 
26. (random$ or RCT or RCTs).tw. 
27. (controlled adj5 (trial$ or stud$)).tw. 
28. (clinical$ adj5 trial$).tw. 
29. ((control or treatment or experiment$ or intervention) adj5 (group$ or 
subject$ or patient$)).tw. 
30. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo 
random$).tw. 
31. ((control or experiment$ or conservative) adj5 (treatment or therapy or 
procedure or manage$)).tw. 
32. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw. 
33. (cross-over or cross over or crossover).tw. 




36. (assign$ or allocat$).tw. 
37. controls.tw. 
38. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 
or 31 or 32 or 33 or 34 or 35 or 36 or 37 
39. 9 and 16 and 38 
40. limit 39 to human 
 
Database: Ovid Medline® In-process & other non-indexed citations and Ovid 
Medline ®  
Search dates: 1946 - 18.8.2017  
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or 
exp brain ischemia/ or exp carotid artery diseases/ or exp cerebrovascular 
trauma/ or exp intracranial arterial diseases/ or exp intracranial arteriovenous 
malformations/ or exp "intracranial embolism and thrombosis"/ or exp intracranial 
haemorrhages/ or stroke/ or exp brain infarction/ or stroke, lacunar/ or 
vasospasm, intracranial/ or vertebral artery dissection/ or exp hypoxia, brain/ 
2. (stroke$ or post stroke or poststroke or post-stroke or apoplex$ or cerebral 
vasc$ or cerebrovasc$ or cva or SAH).tw. 
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or 
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. 
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or 
intraparenchymal or intraventricular or infratentorial or supratentorial or basal 
gangli$ or putaminal or putamen or posterior fossa or hemispher$ or 
subarachnoid) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw. 
5. exp hemiplegia/ or exp paresis/ or exp aphasia/ or exp gait disorders, 
neurologic/ 
6. (hempar$ or hemipleg$ or paresis or paretic or aphasi$ or dysphasi$).tw. 
7. exp brain damage, chronic/ or brain injuries/ or exp brain concussion/ or exp 
brain haemorrhage, traumatic/ or brain injury, chronic/ or diffuse axonal injury/ 
8. craniocerebral trauma/ or exp head injuries, closed/ or exp intracranial 
haemorrhage, traumatic/ 
9. ((brain or cerebr$) adj5 (injur$ or hypoxi$ or damage$ or concussion or 
trauma$)).tw. 
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11. anxiety/ 
12. anxiety disorders/ or agoraphobia/ or obsessive-compulsive disorder/ or panic 
disorder/ or phobic disorders/ or exp stress disorders, traumatic/ 
13. exp Anti-Anxiety Agents/ 
14. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic 
disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?traumatic 
stress$ or PTSD).tw. 
15. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or 
worried)).tw. 
16. manifest anxiety scale/ 
17. 11 or 12 or 13 or 14 or 15 or 16 
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18. Randomised Controlled Trials as Topic/ 
19. random allocation/ 
20. Controlled Clinical Trials as Topic/ 
21. control groups/ 
22. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase 
ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/ 
23. double-blind method/ 
24. single-blind method/ 
25. Placebos/ 
26. placebo effect/ 
27. cross-over studies/ 
28. randomised controlled trial.pt. 
29. controlled clinical trial.pt. 
30. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase 
iii or clinical trial phase iv).pt. 
31. (random$ or RCT or RCTs).tw. 
32. (controlled adj5 (trial$ or stud$)).tw. 
33. (clinical$ adj5 trial$).tw. 
34. ((control or treatment or experiment$ or intervention) adj5 (group$ or 
subject$ or patient$)).tw. 
35. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo 
random$).tw. 
36. ((control or experiment$ or conservative) adj5 (treatment or therapy or 
procedure or manage$)).tw. 
37. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw. 
38. (cross-over or cross over or crossover).tw. 
39. (placebo$ or sham).tw. 
40. trial.ti. 
41. (assign$ or allocat$).tw. 
42. controls.tw. 
43. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 
or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 
44. 10 and 17 and 43 
45. limit 44 to humans 
 
Database: PsychINFO  
Search dates: 1940 -17/8/17  
  1. cerebrovascular disorders/ or cerebral haemorrhage/ or exp cerebral 
ischemia/ or cerebrovascular accidents/ or subarachnoid haemorrhage/ 
2. (stroke$ or post stroke or poststroke or post-stroke or apoplex$ or cerebral 
vasc$ or cerebrovasc$ or cva or SAH).tw. 
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or 
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. 
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or 
intraparenchymal or intraventricular or infratentorial or supratentorial or basal 
gangli$ or putaminal or putamen or posterior fossa or hemispher$ or 
subarachnoid) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw. 
37 
 
5. hemiparesis/ or hemiplegia/ or exp aphasia/ 
6. (hempar$ or hemipleg$ or paresis or paretic or aphasi$ or dysphasi$).tw. 
7. traumatic brain injury/ or brain damage/ or brain concussion/ or exp head 
injuries/ 
8. ((brain or cerebr$) adj5 (injur$ or hypoxi$ or damage$ or concussion or 
trauma$)).tw. 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. exp anxiety/ 
11. exp anxiety disorders/ 
12. anxiety management/ 
13. state trait anxiety inventory/ or taylor manifest anxiety scale/ 
14. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic 
disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?traumatic 
stress$ or PTSD).tw. 
15. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or 
terror)).tw. 
16. 10 or 11 or 12 or 13 or 14 or 15 
17. clinical trials/ or treatment effectiveness evaluation/ or placebo/ 
18. (random$ or RCT or RCTs).tw. 
19. (controlled adj5 (trial$ or stud$)).tw. 
20. (clinical$ adj5 trial$).tw. 
21. ((control or treatment or experiment$ or intervention) adj5 (group$ or 
subject$ or patient$)).tw. 
22. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo 
random$).tw. 
23. ((control or experiment$ or conservative) adj5 (treatment or therapy or 
procedure or manage$)).tw. 
24. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw. 
25. (cross-over or cross over or crossover).tw. 
26. (placebo$ or sham).tw. 
27. trial.ti. 
28. (assign$ or allocat$).tw. 
29. controls.tw. 
30. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
31. 9 and 16 and 30 
32. limit 31 to human  
33. limit 32 to yr="1940 -Current" 
 
Database: Cochrane Central Register of Controlled Trials (CENTRAL) 
Search dates: Inception to 16.10.17  
#1 [mh ^"cerebrovascular disorders"] or [mh "basal ganglia cerebrovascular 
disease"] or [mh "brain ischemia"] or [mh "carotid artery diseases"] or [mh 
"cerebrovascular trauma"] or [mh "intracranial arterial diseases"] or [mh " 
intracranial arteriovenous malformations"] or [mh "intracranial embolism and 
thrombosis"] or [mh "intracranial haemorrhages"] or [mh ^stroke] or [mh "brain 
infarction"] or [mh ^"stroke, lacunar"] or [mh ^"vasospasm, intracranial"] or [mh 
^"vertebral artery dissection"] or [mh "hypoxia, brain"]  
#2 (stroke* or poststroke or "post-stroke" or apoplex* or cerebral next vasc* 
or cerebrovasc* or cva or SAH):ti,ab  
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#3 ((brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* 
or intracerebral or infratentorial or supratentorial or middle next cerebr* or mca* or 
"anterior circulation" or "basilar artery" or "vertebral artery") near/5 (isch*emi* or 
infarct* or thrombo* or emboli* or occlus* or hypoxi*)):ti,ab  
#4 ((brain* or cerebr* or cerebell* or intracerebral or intracran* or 
parenchymal or intraparenchymal or intraventricular or infratentorial or 
supratentorial or basal next gangli* or putaminal or putamen or "posterior fossa" 
or hemispher* or subarachnoid) near/5 (haemorrhage* or haemorrhage* or 
haematoma* or hematoma* or bleed*)):ti,ab  
#5 [mh ^hemiplegia] or [mh paresis] or [mh aphasia] or [mh "gait disorders, 
neurologic"]  
#6 (hempar* or hemipleg* or paresis or paretic or aphasi* or dysphasi*):ti,ab  
#7 [mh "brain damage, chronic"] or [mh ^"brain injuries"] or [mh "brain 
concussion"] or [mh "brain haemorrhage, traumatic"] or [mh ^"brain injury, 
chronic"] or [mh ^"diffuse axonal injury"]  
#8 [mh ^"craniocerebral trauma"] or [mh "head injuries, closed"] or [mh 
"intracranial haemorrhage, traumatic"]  
#9 ((brain or cerebr*) near/5 (injur* or hypoxi* or damage* or concussion or 
trauma*)):ti,ab  
#10 (68-#9)  
#11. [mh ^anxiety] 
#12. [mh ^”anxiety disorders”] or [mh ^agoraphobia] or [mh ^”obsessive-
compulsive disorder”] or [mh ^”panic disorder”] or [mh ^”phobic disorders”] or [mh 
“stress disorders, traumatic”] 
#13. [mh “Anti-Anxiety Agents”] 
#14. (anxiety or anxieties or anxious or agoraphobi* or phobi* or panic next 
disorder* or panic next attack* or (obsess* near/3 compuls*) or post next 
traumatic next stress* or PTSD):ti,ab 
#15. (feel* near/5 (apprehens* or dread or disaster* or fear* or worry or 
worried)):ti,ab 
#16. [mh ^”manifest anxiety scale”] 
#17. {or #11-#16} 
#18. #10 and #17 
 
Database: EBSCO Health CINAHL Plus 
Search dates: Inception to 16.10.17  
#S1. (MH "Anxiety+") OR (MH "Anxiety Disorders+") 
#S2. (MH "Stroke") OR (MH "Stroke Patients") 
#S3. (MH "Brain Injuries+") OR (MH "Right Hemisphere Injuries") OR (MH "Left 
Hemisphere Injuries") 







2.2.2 Eligibility criteria 
I included RCTs that evaluated interventions designed to target anxiety 
symptoms/ anxiety disorder as a primary outcome, with any comparator group 
(placebo, usual care, waitlist control, active comparator). I included RCTs that 
recruited participants aged 18 or over with ABI conditions: ischaemic or 
haemorrhagic stroke; SAH, confirmed by brain imaging with or without a lumbar 
puncture; moderate-to-severe TBI as defined according to the Scottish 
Intercollegiate Guidelines Network(69). I excluded mild TBI, a clinical group that 
was difficult to diagnose reliably(70). Where studies were carried out in a mixed 
sample, I included only those that recruited over 70% of stroke/SAH/ moderate-
to-severe TBI. I excluded trials that recruited exclusively military veterans. No 
language restrictions were applied. 
 
2.2.3 Data extraction and analysis 
RN and I screened titles and abstracts independently and excluded 
ineligible titles. We assessed full text for eligibility and resolved discrepancies 
through discussion. A neuropsychiatrist was consulted if a consensus could not 
be reached. RN and I extracted data independently using an electronic data 
extraction form. I collated the final data. I assessed studies that were only 
available in Chinese. I recorded characteristics of the study population: ABI 
diagnosis, age, sex, exclusion of specific deficit, baseline anxiety level, and 
intervention type (e.g. psychotherapy, pharmacotherapy, other). 
Quality assessment  
I reported the level of bias across six domains of study design for the 
included studies: (A) random sequence generation, (B) allocation concealment, 
(C) blinding of participants and personnel, (D) blinding of outcome assessment 
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(E) incomplete outcome data, and (F) selective reporting. I categorised the level 
of bias into ‘low’, ‘high’ or ‘unclear’ and recorded justification for the judgement for 
each domain in accordance with the Cochrane Risk of Bias Tool 
(http://methods.cochrane.org/bias/assessing-risk-bias-included-studies).  
Efficacy of intervention  
I estimated effect size for each comparison by calculating the 
standardised mean difference (SMD) with 95% confidence intervals (CI) using the 
mean and standard deviation (SD) of the post-intervention anxiety severity. I 
carried out meta-analysis for studies of the same intervention type using inverse 
variance and random-effects models. All analysis was performed using the 
Cochrane Review Manager (RevMan) Version 5.3(71). Where data were not 
reported in study publication I contacted the corresponding authors for further 
information.  
Key study characteristics and potential bias in trial design 
I summarized the key study characteristics: anxiety type targeted, the 
setting and timing of intervention, outcome measures, the type of comparator, 
and ways that could have introduced or minimised potential bias in study design. 
 
2.3 Results 
The electronic searches yielded 8218 titles after removal of duplicates 
(Figure 7). Of the 59 full text articles reviewed, 14 eligible studies with 928 
participants were included. Sample size ranged from 17 to 206. Four studies were 
































Total titles identified 
n = 11126 
Records after duplicates removed 
n = 8218 
Titles and abstracts screened  
n = 8218 
Full text articles assessed for eligibility 
n =59 
Excluded 45 studies: 
15 not RCT 
11 did not target anxiety 
5 not ABI 
2 mild TBI 
3 military veterans only  
8 duplicated publication 
1 study* eligible but excluded 






*Lamas K, ‘Does touch massage facilitate recovery after stroke?’ 
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2.3.1 Characteristics of study population 
Table 5 summarizes the characteristics of the study population in the 14 
included studies. 12 studies recruited stroke patients only (ischaemic and primary 
haemorrhage)(72-83), one study recruited stroke and moderate-to-severe 
TBI(84), and one study recruited moderate-to-severe TBI only(85). No study 
recruited patients with SAH. The mean age ranged from 48 to 72 years in studies 
of stroke patients only, and from 35 to 58 years in the two studies that included 
TBI patients. More men than women were recruited in all included studies. 12 
studies excluded patients with communication difficulties due to aphasia or 
cognitive impairment(72-74, 76-82, 84, 85); one yoga exercise intervention 
excluded participants who were unable to ambulate independently(77).  
Seven studies required participants to have a baseline diagnosis of 
anxiety disorder or ‘emotional distress’ either made on standardised diagnostic 
criteria e.g. DSM-IV-TR, or by meeting a defined cut-off on a rating scale(72, 73, 
79, 82-85). Six studies did not specify a baseline anxiety level for inclusion (74-
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78, 80). One study of a preventative intervention excluded the diagnosis of GAD 
on DSM-IV-TR at baseline(80).   
 
2.3.2 Methods for assessing anxiety 
Studies used different anxiety rating scales at baseline and outcome 
assessment: Hamilton Anxiety Rating Scale (HAMA) in five studies (72, 73, 75, 
81, 83), Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A) in 
three studies (79, 80, 85); State-Trait Anxiety Inventory (STAI) in three studies 
(76-78); Depression Anxiety Stress Scales (DASS) in one study(84); Zung Self-
rating Anxiety Scale (SAS) in one study(74); Beck Anxiety Inventory (BAI) in one 
study(82).  
 
2.3.3 Study quality assessment 
None of the 14 studies scored ‘low’ risk of bias across all six domains (A-
F) of study design (Figure 9). Three studies scored ‘low’ risk across five domains 
(80, 81, 85). Two studies scored ‘low’ risk across four domains(82, 84). One 
studies scored ‘low’ risk across three domains(77). Eight studies scored ‘low’ risk 
on fewer than three of the six domains(72-76, 78, 79, 83), including six studies 
that scored ‘high’ risk or ‘unclear’ risk across all six domains(72-76, 83). 
 
2.3.4 Efficacy of intervention  
The 14 included studies provided 19 comparisons: eight 
psychotherapy(74, 80-82, 84, 85), five pharmacotherapy(72, 73, 75, 81), one 
combined pharmacotherapy and psychotherapy(72), two exercise(76, 77), and 
three other interventions(78, 79, 83). I carried out meta-analyses for 
psychotherapy and pharmacotherapy studies (Figure 9). 
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NA 206 Psychotherapy (n=103)  
 
‘One weekly sessions, each lasting 20-
30 minutes, for 5-6 weeks, delivered by 






NA NA NA NA SAS 
I)  34(8) 



















90 1) Paroxetine (n=31) 
 
‘20mg daily for 12 weeks’ 
 
2) Imipramine (n=32) 
 
‘incremental regime of 50-150mg daily 
for 12 weeks ‘ 
 
 





















1) 18.2 (4.6) 
2) 18.9 (4.4) 
 
C) 17.9 (2.24) 
 
Required diagnosis of 
mixed anxiety and 



















81 1) paroxetine  
(n=27) 
‘20mg daily for 6 weeks’ 
 
2) paroxetine + psychotherapy  
(n=27) 
 
‘Paroxetine 20mg daily  + weekly 
psychotherapy session lasting 30-60 






















1) 14.0 (2.8) 
2) 13.9 (2.9) 
 
C) 13.8 (2.8) 
 
Required diagnosis of 
mixed anxiety and 





















NA 94 Buspirone butylbromide (n=47)  
 
‘A 2-week course of buspirone 
butylbromide (first week 20-30mg/day, 






57.8 (6.4) 59.2 
(5.8) 
36 38 HAMA 
I) 22.7 (5.2) 


















67 acupuncture (n=34) 
 
‘acupuncture once a day for 2 courses 




‘0.4-0.8mg 3 times 








I) 22.31 (3.1) 
C) 22.3 (3.2) 
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Resistance exercise training  
(n=14) 
 
‘4 familiarization sessions + 3 
pre-treatment sessions + 12 
treatment sessions delivered 3 
times a week, focused on 
walking & strength training.  
 
Duration: each session lasted 
45-60minutes with minimum 









































10m or more 
17 Yoga and exercise (YEX) 
(n=9) 
 
‘90-minute group yoga class 
once per week for 6 weeks 
plus 24 individual 40-minute 








once per week 














I) 36.8 (11.6) 


























27 1) Motivational interviewing 
(MI) + Cognitive Behavioural 
Therapy (CBT) (n=9) 
 
‘3 weekly MI sessions + 9 
weekly CBT sessions’ 
 
2) Non-directional counselling 
(NDC) + CBT (n=10) 
 
‘3 weekly NDC sessions  + 9 
weekly CBT sessions’ 
 
Both delivered by clinical 




Usual care and 





















1) 11.9 (3.3) 
2) 13.0 (5.0) 
 
 
















































Type of intervention (I) and control (C), number 













Time of intervention 
























149 1) Escitalopram (n=47) 
 
‘5 or 10mg per day  for 12 
months’ 
 
2) Problem solving therapy (PST) 
(n=53) 
 
‘manual-based, 6 treatment 
sessions (weeks 1, 2, 3, 4, 6 and 
10), plus 6 reinforcement 






















1)  7.1 (5.6) 
2) 8.3 (5.4) 
 
































33 1) Coping skills (n=11) 
 
‘cognitive and behavioural 
exercises, delivered by clinical 
psychologist’ 
 
2) Self-management  
(n=12) 
 
‘ Information provision and 
activities to learn problem 














1) and 2) consist 
of 8 one-hour 
face-to-face 



















1) 5.3 (2.9) 
2) 5.7 (0.5) 
 























Type of intervention (I) and control (C), number 












Time of intervention since 
injury in sample 
mean (SD) 























27 Brief positive psychotherapy 
(n=14) 
 
‘One-to-one weekly sessions with 
psychologist for 8 weeks—
Psychoeducation  about ABI and 
positive psychology (Week 1), 
therapeutic exercises and 
homework (Weeks 2-7), midpoint 
review at (Week4), final review 





















 36 39 DASS-21 anxiety 
 
I) 17.6 (9.7) 
C) 21.1 (9.4) 
 
 
Had to score 
moderate-to-above 
on at least 
depression or 
anxiety subscale 
on DASS-21  
median: 






















21 I:  relaxation CD 
 
‘self-help autogenic relaxation 
CD, five times per week for a 
month with diarly sheets; each 
session 20-minute in length, 
instructions on body awareness’ 
 
Waitlist  67.8 (7.5)  62.4 (8.4) 40 50 HADS-A 
I) 10.9 (3.4) 
C) 10.5 (3.5) 
 
Had to score at 



















59 I: Forest therapy 
 
‘4-day and 3-night program at 
recreational forest area, 
consisting of 1) promoting 
positive emotion through 
mediation, 2) experiencing the 
forest through all five sense and 
3) walking in the forest’ 
Urban group 
 




activities in the 
urban area’ 
62.1 (8.3) 59.5 (9.7) 37 28 STAI 
I) 38.1 (11.0) 
































and could not 
be corrected 
28 Computerised cognitive 
behavioural therapy (cCBT) 
(n=19)  
 
‘An 8-module online course--
‘Beating the Blues’, one module 









‘ An 8-module 
online course-
‘ForamenReha
b’, one module 
per week for 8 
consecutive 
weeks’ 
   
62.1 
(11.4) 
64.6 (8.1) 47 11 BAI 
I) 11.2 (7.6) 




distress’: BDI  







years   
(IQR 0.6-
4.1) 





I indicates intervention; C, control; n, number; SD, standard deviation; IQR, interquartile range; NA, data not available; DASS, 
Depression Anxiety Stress Scales; DSM-IV, Diagnostic Statistical Manual of Mental Disorders, fourth edition; BDI, Beck Depression 
Inventory; BAI, Beck Anxiety Inventory; CCMD, Chinese Classification of Mental Disorders, third version; HAMA, Hamilton Anxiety 
























       Both the intervention and  active control are delivered 
via computer, facilitated by a researcher via 
telephone/email/face-to-face 
 





Table 5 continued 
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Figure 9. Effect sizes, meta-analysis, and bias assessment for included studies 
 
 
ABI, acquired brain injury; IV, inverse variance; CI, confidence intervals; UC, usual care; TBI, traumatic brain injury; CBT, cognitive behavioural 
therapy; CRT, cognitive remediation therapy. Risk of bias: (A) Random sequence generation (selection bias); (B) Allocation concealment (selection 
bias); (C) Blinding of participants and personnel (performance bias); (D) Blinding of outcome assessment (detection bias); (E) Incomplete outcome 




Six studies provided eight comparisons of psychotherapy interventions, 
the contents of each are summarized in Table 5.  Data were not available for 
three comparisons after contacting study authors. Meta-analysis of the five 
comparisons showed an overall positive effect favouring psychotherapy 
intervention over control (SMD: -0.41 [95%CI -0.79, -0.03]). I2 statistic of 28% 
suggests a low-to-moderate level of heterogeneity across studies (Figure 9). The 
only study that demonstrated an effect favouring ‘psychotherapy’ over usual 
care(74) received ‘unclear’ risk of bias across all six domains of study design. The 
remaining four neutral comparisons (one ‘brief positive psychotherapy’ versus 
usual care(84), one ‘motivational interviewing & CBT’ versus usual care(85); one 
‘non-directional counselling & CBT’ versus usual care(85), one ‘computerised 
CBT’ versus computerised cognitive remediation therapy(82)) received ‘low’ risk 
of bias across at least three domains of study design; all had small sample sizes. 
One comparison not included in my analysis reported that group receiving 
placebo was four times more likely to develop GAD compared to ‘problem-
solving’ therapy (adjusted hazard ratio: 4.00 [95%CI 1.84, 8.70])(21). The other 
two comparisons not included in my analysis reported a non-statistically 
significant reduction in adjusted mean HADS-anxiety score with psychotherapy: 
‘coping skills’ versus usual care (-0.5, [95%CI -2.0, 1]); ‘self-management’ versus 
usual care (-0.6, [95%CI -2.0, 0.8]) (20).  
 
Pharmacotherapy  
Four studies provided five comparisons of pharmacotherapy versus 
control, data were not available in one comparison after contacting study 
author(81). Meta-analysis of these four comparisons showed an overall effect 
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favouring pharmacotherapy intervention over control (SMD: -2.12 [95%CI -3.05, -
1.18]). I2 statistic of 89% suggests a high level of heterogeneity across studies. 
Two of these comparisons were between paroxetine, an SSRI and usual care 
(72, 73). One comparison was between imipramine, a tricyclic antidepressant 
(TCA) and usual care(73). One study compared buspirone, an azapirone 
anxiolytic with usual care (75). All four comparisons were from three studies 
which scored ‘high’ risk or ‘unclear’ risk of bias across all domains of study 
design. The study without available data for analysis reported that group receiving 
placebo was four times more likely to develop GAD compared to escitalopram 
(adjusted hazard ratio: 4.95 [95%CI 1.54-15.93])(81).  
 
Combined pharmacotherapy and psychotherapy  
One comparison of combined paroxetine and psychotherapy with usual 
care demonstrated a large effect favouring combined therapy (SMD -4.79 [95%CI 
-5.87, -3.71])(72). This study scored ‘unclear’ and ‘high’ risk of bias across all six 
domains of study design. 
 
Exercise intervention 
Two studies evaluated exercise interventions, One study compared yoga 
and exercise with exercise only and showed a neutral effect(77). One study on 
resistance exercise reported lower state anxiety favouring resistance exercise 
over usual care but data were unavailable for calculating SMD after contacting 
the study author(76). Both studies had small sample sizes. The yoga study 
scored ‘low’ risk of bias across three domains of study design and the study on 





One study compared acupuncture with alprazolam (83), one study 
compared relaxation CD with waitlist control(79). Both of these studies were 
neutral. The study of acupuncture scored ‘unclear’ risk of bias across all six 
domains, and the study of relaxation CD scored ‘high’ risk of bias across more 
than three domains of study design. One study compared forest therapy with 
urban control and demonstrated an effect favouring forest therapy (SMD: -2.00 [-
2.59, -1.41]). This study scored ‘high’ risk of bias on four domains of study design. 
All three studies had small sample sizes.  
 
2.3.5 Characteristics of study design 
Anxiety subtype targeted  
One study specified GAD as the target of its interventions (escitalopram; 
problem solving therapy)(81). No study targeted phobic disorder. Two studies of 
pharmacotherapy (SSRI, TCA), and combined pharmacotherapy (SSRI) and 
psychotherapy specified a diagnosis of ‘mixed anxiety and depression’ as an 
inclusion criterion and had positive results (72, 73). Two studies of psychotherapy 
(brief positive psychotherapy; computerised CBT) targeted ‘emotional distress’—
anxiety and/or depression and were neutral (82, 84). One study of acupuncture 
and alprazolam targeted ‘post-stroke neurosis’ which is now a defunct 
diagnosis(83). The remaining eight studies targeted ‘anxiety’ without 
subtyping(74-80, 85), three of them were positive(74, 75, 78). 
 
Setting of intervention 
Seven studies were carried out in the community(76-79, 81, 82, 85), three 
studies in an inpatient setting(72, 73, 75), two in outpatient clinic(83, 84), and one 
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commenced in an inpatient setting then continued in the community(80). One 
study did not report setting of the intervention (74). Only one community-based 
study was positive (78). All three inpatient studies and the study with unknown 
setting were positive.  
 
Timing of intervention since injury 
Seven studies specified time since injury as an inclusion criterion: ‘acute 
stroke’(72); within 3 months(81);  between 3-36 months(84); anytime within 5 
years(82); at least 6 months(77);  at least one year(76, 78).  The actual time of 
intervention since injury in the studied sample ranged from 15 days to 13 years. 
Of the five positive studies, three did not report timing of intervention since injury 
in studied samples, one study reported intervention at 21 days from injury(72), 
and one reported intervention at 140-150 months (11-13 years)(78).  
 
Timing of outcome measures 
Eight studies measured anxiety outcome at the end of the intervention(72, 
73, 75-78, 83, 85). Other studies measured primary outcome at various time 
points post-intervention: 2 weeks; 8 weeks; 12 weeks; 12 months. Four of the five 
positive studies measured primary outcome at the end of intervention(72, 73, 75, 
78) and one measured at two weeks post-intervention(74). 
 
Comparator  
‘Usual care’ was the most commonly used control condition. Four studies 
used an active comparator(77, 78, 82, 83) and one study used a placebo 
control(81). Four of the five positive studies used ‘usual care’ as control 
conditions(72-75) and one used an active control(78).  
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2.3.6 Summary of sources of potential bias in study design 
A) Random sequence generation 
Studies scoring ‘unclear’ risk of bias in this domain only reported that 
patients were randomly allocated but did not give detail on how, and by whom the 
randomisation sequence was generated. Studies scoring ‘low’ risk reported the 
type of randomisation carried out e.g. computerised randomisation, stratified 
randomisation with blocking, random number generator, and by whom the 
randomisation was performed e.g. person external to the study/ independent of 
the study 
 
B) Allocation concealment 
Studies scoring ‘high’ risk of bias did not report how allocation sequence 
was concelaed. Studies scoring ‘low’ risk reported methods that would prevent 
the study team from knowing the allocation in advance e.g. allocation informed 
via mailed letters by external person who carried out randomisation, study 
personnel were blinded to randomisation block length with randomisation 
performed externally, use of opaque/ sealed envelopes pre-filled by person 
independent of the study.  
 
C) Blinding of participants and personnel 
Most studies scored ‘high’ risk in this domain as blinding of participants 
was rarely attempted. The most common comparator group was ‘usual care’. I 
considered participant blinding sufficient in the study that used computerised CRT 
as a comparator of computerised CBT, and the study that used placebo as a 




D) Blinding of outcome assessment 
Studies scoring ‘high’ risk reported outcome assessment being performed 
by the same study personnel that delivered the interventions. Studies that scored 
‘low’ risk reported methods to blind outcome assessment e.g. a second research 
assistant performed outcome assessment using a standard script to prevent 
unblinding, use of self-rated questionnaires and data entry by blinded assessor. 
 
E) Incomplete outcome data 
All studies scoring ‘high’ risk lost follow-up data (attrition ranged from 2 – 
22%) and did not perform intention-to-treat analysis. Reasons for attrition were: 
personal reasons, additional health concerns/ injury unrelated to intervention, 
improved mood, other commitments, lack of time, found it distressing to talk about 
difficulties, wish to discontinue involvement.  
 
F) Selective reporting 
I examined the published trial protocol, if available, for each included 
study to detect whether selective reporting was present. One study scoring ‘high’ 
risk reported results on anxiety from the same study in an earlier publication that 
evaluated the intervention for depression prevention. 
 
2.4 Discussion 
2.4.1 Key findings 
My findings suggest efficacy of psychotherapy and pharmacotherapy 
interventions in the treatment of anxiety after ABI. The positive effect sizes were 
driven entirely by studies of low quality. These findings alone are not definitive 
evidence to guide treatment of anxiety after stroke.  
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2.4.2 Limitations and strengths of this review 
Limitations 
Data for calculating SMDs were missing in four comparisons despite 
contacting corresponding authors. I included one mixed ABI (strokes in >85% of 
intervention and control groups), and one TBI-only samples. Almost all studies 
excluded patients who had communication impairments e.g. dysphasia, cognitive 
impairment, and varied in settings, timing since injury, timing of outcome 
measures, limiting the generalisability of my findings. 
Strengths 
Compared to previous systematic reviews in stroke and TBI (65, 67) I 
opted to include studies from a broader ABI population encompassing stroke 
(ischaemic, primary haemorrhage, SAH) and moderate-to-severe TBI, and 
included a wider continuum of baseline anxiety levels (i.e. not limited to patients 
with a baseline anxiety diagnosis). This approach led to more studies to be 
included in my review, and enabled meta-analysis of the same type of anxiety 
interventions for the first time. Furthermore, I found studies that were better 
reported and of better quality which were excluded in the previous reviews. This 
enabled a summary of key aspects of trial design and measures to minimise bias 
in order to help guide trialists, including myself, in designing high quality RCTs in 
the future. 
 
2.4.3 Implications for intervention design 
Anxiety subtype targeted  
Studies have targeted ‘mixed anxiety and depression’, ‘emotional distress 
(anxiety and/or depressive symptoms)’, or ‘anxiety’. Only one study specified the 
prevention of GAD as the target of intervention. No studies targeted phobic 
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disorder. Phobic disorders e.g. agoraphobia may be more common after 
stroke(56).  
Intervention design should reflect the treatment approaches known to be 
effective at treating these anxiety subtypes in non-stroke populations. Anxiety 
with a phobic element invariably requires some form of behavioural therapy with 
exposure work, while generalised anxiety is treated with other CBT techniques 
e.g. cognitive restructuring, problem solving, and/or medications e.g. SSRI. 
Although the content of psychotherapy interventions varied across the included 
studies, the majority of interventions consisted of some form of, or a combination 
of psychoeducation, skills learning e.g. problem solving, positive psychology, 
therapeutic exercises, and CBT.  Interventions for anxiety after stroke should 
encompass components that aim to address the symptomology of both phobic 
and generalised anxiety subtypes. A variety of anxiety rating scales were used to 
assess primary outcome in the included studies. These are validated for 
generalised anxiety and none for the phobic subtype. The choice of outcome 
measures should reflect both types of anxiety symptomology given that phobic 
disorder may also be common after stroke.  
 
Setting and timing of intervention, and timing of outcome measures 
Most of the positive studies were carried out in an inpatient setting and 
measured primary outcome immediately post-intervention. This approach does 
not address the consistent finding from other studies that anxiety continues to be 
frequent at six-months or more post-stroke(56) and cannot generalise to patients 
who have returned to living in the community. An anxiety intervention should aim 
to relieve anxiety and its debilitating impact on stroke patients in the long-term. 
Determining the best time of outcome measure should be based on this goal and 
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be balanced against the feasibility of study procedures to ensure completion of 
long-term follow-up. My supervisors and I felt it reasonable to measure outcome 
at the end of the intervention and then after a period with no treatment to see 
whether any benefits would be sustained. 
 
2.4.4 Implications for trial design  
Most of the positive studies in this review were poorly reported across all 
aspects of study design on the Cochrane bias assessment tool. All trialists should 
adhere to standardised reporting guidelines e.g. Consolidated Standards of 
Reporting Trials (CONSORT) checklist on RCTs, and the TiDier (Template for 
Intervention Description and Replication) checklist when evaluating complex 
interventions, both of which can be found on the EQUATOR (Enhancing the 
QUAlity and Transparency of health Research network) website: 
http://www.equator-network.org/reporting-guidelines/consort/. 
 
Participant blinding and control conditions 
Most of the included studies did not attempt participant blinding. ‘Usual 
care’ was the commonest comparator in this review and in four out of the five 
positive studies. The description of what constituted ‘usual care’ was minimal 
across the included studies. ‘Usual care’ and waitlist controls have been shown to 
exaggerate effect size in meta-analyses of trials evaluating psychotherapy(90). A 
recently published transparent decision framework helps guide trialists select the 
appropriate type of control based on several factors: participants’ interests 
(expected benefit, or harm or worsening of symptoms induced by the control 
condition), the researchers’ interests (available resources, maximizing validity of 
findings), and trial purpose (e.g. phase 2, phase 4) (91). Placebo is the gold-
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standard comparator for pharmacotherapy intervention. In a trial of psychotherapy 
or other non-pharmacological intervention, an active comparator or another 
established treatment that is known to be effective and widely available in the 
‘real world’ would be more appropriate as a control in phase 3 or phase 4 
(pragmatic/ real world) trials(91).  
 
Other measures to minimise bias 
Some included studies provided examples of good practice in minimizing 
bias in other domains: external personnel to randomise patient; allocation 
concealment to ensure study personnel could not foresee allocation while 
recruiting; use of outcome assessors blinded to allocation; use of standard script 
at telephone follow-up to prevent unblinding; use of self-completed outcome 
measures; data input by blinded external assessor; reporting missing data and 
methods for handling missing data; intention-to-treat analysis; publishing protocol 
on trial registries.  
Studies should also provide detailed description of the experimental 
intervention and control condition to ensure standardised procedures are given to 
all participants of each arm e.g. use of manuals. Adherence to the allocated 
treatment and any deviation from standardised procedures should be recorded 
and reported. 
 
2.4.5 Summary of key points from this chapter 
 There is low quality evidence to suggest psychotherapy and 
pharmacotherapy may be effective interventions in the treatment of 
anxiety after stroke  
 The evidence is from underpowered studies that carried high risk of bias.  
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 Trials have not distinguished between different anxiety subtypes, and 
have not tailored the treatment to specific type 
 Large-scale well-designed definitive trials are needed to establish whether 
pharmacotherapy or psychotherapy works  
 Compared to pharmacological interventions, psychological or behavioural 
interventions pose unique challenges in trial methodology, both in its 
execution and in bias minimisation 
 My review highlighted the key strengths and weaknesses of existing 
anxiety intervention and trial design. These findings will help me design 
the TASK intervention to be clinically relevant and feasible, as well as 






Anxiety after stroke: the importance of subtyping—a prospective 
cohort study 
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editorial changes to the published version in this chapter and added Section 3.5, 












Anxiety is common, affecting around a quarter of stroke(56), and nearly a 
third of transient ischaemic attack(TIA)(57). It can hamper stroke rehabilitation 
effort and prevent patients from returning to their usual activities. Despite earlier 
observations that phobic anxiety might be present after stroke(62-64), 
intervention studies have treated anxiety post-stroke as one unitary phenomenon 
and evaluated general approaches such as relaxation and antidepressants(67), 
which are unlikely to be effective in phobic anxiety. Clinical trials have not yielded 
any definitive evidence to guide treatment for anxiety after stroke(67). It is well 
recognised in non-stroke populations that phobic and generalised anxiety 
disorders need different treatment approaches. 
Phobic and generalised anxiety 
Phobic anxiety is characterized by a disproportionate fear of well-defined 
situations or stimuli(33). Exposure to the feared situation triggers unpleasant 
anxiety symptoms, accompanied by marked avoidant behaviour of that feared 
situation: the hallmark of phobic anxiety(33). Whilst avoidant behaviour may 
relieve anxiety in the short-term it can become disabling if the behaviour becomes 
consolidated through conditioning e.g. becoming housebound in agoraphobia as 
a result of learning to associate ‘danger’ with ‘leaving house’. Treatment of phobic 
disorders requires systematic, repeated, hierarchical exposure to the specific 
anxiety-provoking stimulus(45). By contrast, GAD is diffuse and unremitting, 
characterized by persistent and multiple worries e.g. finances, health, and an 
inability to stop worrying(33). SSRI, benzodiazepines (in short term only), and/ or 
other CBT techniques e.g. cognitive restructuring, problem solving are effective at 




To determine the target for anxiety treatment after stroke, I need to know 
the proportions of anxiety subtypes; if phobic, the specific stimuli; the factors 
associated with anxiety; the impact of anxiety on functional outcomes and quality 
of life. I aim to report i) the frequency of phobic disorder and GAD at three months 
after stroke and TIA, ii) avoidant behaviour of specific anxiety-provoking 
situations, iii) the predictors of anxiety and, iv) the associations with dependence, 
quality of life, and social participation. 
 
3.2 Methods 
3.2.1 Sampling and recruitment 
Prospective recruitment 
I screened consecutive eligible patients admitted to the acute stroke unit 
and TIA clinics in NHS Lothian—the sole provider of stroke and TIA services for 
the city of Edinburgh, Midlothian and East Lothian regions in Scotland, between 
9th September, 2015 and 28th June, 2016. I included participants who (i) were 
aged 18 or over, (ii) had a new clinical diagnosis of stroke, ‘definite’, or ‘probable 
TIA’, (iii) had mental capacity to give informed consent, and (iv) were able to 
communicate in English on the telephone. I excluded patients with subarachnoid 
haemorrhage, subdural and extradural hematoma, ocular TIA, patients at terminal 






Definitions of stroke and TIA 
I used clinical diagnosis of stroke or TIA made by consultant stroke 
clinicians according to the following:  stroke—the sudden loss of focal cerebral 
function, lasting 24 hours or longer, thought to be caused by an inadequate blood 
supply to part of the brain (ischaemic stroke), or spontaneous haemorrhage into 
the brain substance (primary intracerebral haemorrhagic), where brain imaging 
was normal or showed evidence of recent ischemia or haemorrhage(1); TIA—a 
clinical time-based definition of symptoms lasting fewer than 24 hours; TIA was 
‘definite’ when a diagnosis of TIA was the only one considered for the symptoms, 
and ‘probable’ when a TIA was the most likely of a number of differential 
diagnoses.  
 
3.2.2 Baseline characteristics 
I used hospital electronic health records to gather data on age, sex, 
diagnosis on discharge, vascular territory of stroke/TIA, and the NIHSS score, a 
measure of neurological impairment on admission(92). I assigned an NIHSS of 
zero to all TIAs. I recorded whether the participants lived alone pre-stroke or TIA, 
had a past history of stroke or ischaemic heart disease, and past diagnosis of 
anxiety or depression by checking the electronic heath records first, then 
confirmed at the time of interview. 
 
3.2.3 Assessment of anxiety and other neuropsychiatric disorders  
At three months, I performed a semi-structured psychiatric interview using 
the telephone version of the SCID for DSM-IV-TR(34).  The SCID for DSM-IV-TR 
65 
 
has fair to excellent inter-rater agreement for diagnosing both anxiety disorders 
and depression between experienced and newly trained clinicians(93), and 
between its telephone and face-to-face versions(94). The following conditions 
were screened using the relevant SCID modules: panic disorder, agoraphobia, 
social phobia, specific phobia, GAD, OCD, PTSD, minor and major depressive 
episodes. All SCID diagnoses were made according to the SCID coding system 
and after confirmation with AC at weekly meetings. Participants who were unable 
to talk on the telephone had face-to-face interviews at home or at an outpatient 
clinic. I measured cognition with the telephone Montreal Cognitive Assessment 
(T-MoCA)(95).  The T-MOCA is a brief screening tool for mild cognitive 
impairment with feasibility and validity in a stroke and TIA sample(95). It has a 
total score of 22 and differs from the standard MoCA by omitting the visuospatial, 
executive and naming items. 
 
3.2.4 Modified Fear Questionnaire to assess avoidant behaviour  
One week before the SCID interview, I sent the participant a modified 
Fear Questionnaire (FQ) (Table 6) for completion by post or online. The original 
FQ consists of an agoraphobic subscale (5-item), a social phobia subscale (5-
item), and a blood/injury phobia subscale (5-item)(96). Each item denotes a 
situation, and is rated according to the level of avoidance from zero (would not 
avoid it) to eight (always avoid it). I replaced the blood/injury items with six other 
specific situations that my supervisors and I encountered in our clinical practice—
i) physical exertion, ii) having sex, iii) being alone at home, and ‘any of your 
normal day-to-day activities for fear of having iv) a headache, v) another stroke, 
or vi) a fall’. During the interview, I also recorded positive responses to a list of 11 
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pre-defined anxiety-provoking stimuli (Table 7), similar to the ones on the 
modified FQ. Professor Alan Carson and I derived these additional anxiety-
provoking stimuli from the shared clinical experience of our multidisciplinary 
stroke team in neuropsychiatry and post-acute stroke settings. 
Table 6. Modified FQ  
How much would you avoid each of the situations below because of fear or 
other unpleasant feelings?  
Choose a number from the scale below 
Write the number you choose in the space opposite each situation 
 
Please enter ‘0’ if the situation never arises, and you are not avoiding it for 
fear or other unpleasant feelings 












 Situation Number 
from 0-8  
1.  Eating or drinking with other people                                      
                                                                                                ________ 
2.  Being alone at home 
                                                                                                ________ 
3.  Any of your normal day-to-day activities for fear of having 
another stroke or ‘mini-stroke’ 
 
 ________ 
4.  Travelling alone or by bus 
                                                                                                ________ 
5.  Walking alone in busy streets 
                                                                                                ________ 
6.  Being watched or stared at 
                                                                                                ________ 
7.  Going into crowded shops 
                                                                                                ________ 
8.  Talking to people in authority 
                                                                                                ________ 
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9.  Any of your normal day-today activities for fear of 
having a fall                                                                         
 
10.  Being criticised 
                                                                                                ________ 
11.  Going alone far from home 
                                                                                                ________ 
12.  Physically exerting yourself 
                                                                                                ________ 
13.  Speaking or acting to an audience 
                                                                                                ________ 
14.  Large open spaces 
                                                                                                ________ 
15.  Having sex 
                                                                                                ________ 
16.  Any of your normal day-to-day activities for fear of 
having a headache 
 
  
          ________ 
 
 
3.2.5 Factors associated with anxiety disorder at three months after 
stroke/TIA 
I pre-specified age, sex, living alone pre-stroke/TIA, and a past diagnosis 
of anxiety or depression as potential factors associated with having anxiety 
disorder at three months after stroke/TIA. 
 
3.2.6 Measures of dependence, quality of life and social participation 
Measures of dependence, quality of life and social participation were 
completed at the time of SCID with the simplified mRS questionnaire(18) (Table 
8) and its scoring algorithm (Figure 10), the EuroQoL-5D5L (EQ5D-5L)(97) (Table 





Table 7. Eleven pre-specified questions on anxiety-provoking situations or stimuli 














1) travelling more than a certain distance 
from home 
2) going out of the house alone  
3) going into a crowded place like a busy 
store, cinema, restaurant 
4) using public transport e.g. travelling on 
buses or trains 
5) standing in a queue 
Social situations  
 
6) Was there anything that you have been afraid to do or felt 
uncomfortable doing in front of other people, like speaking, eating, 
or writing? 
Other specific situations/ 
stimuli 
 
Does any of these 





Have you been 




7) physical exertion 
8) being alone at home 
 
 
9) having headaches 
10) having another stroke 
11) falling  
 
 
Table 8. Simplified mRS  
 
Please tick Yes or No for each of the following questions 
 
  Yes 
 
  No 
 
Could you live alone without any help from another person? 
(This means being able to bathe, use the toilet, shop, prepare 








Can you do everything that you were doing right before your 
































I obtained license to reuse this figure in my thesis from Wolters Kluwer Health, 






















Table 9 continued  
 
UK (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol 
Group 
The EuroQol Group grants permission to reproduce the sample version of EQ5D 







3.2.7 Statistical analyses and sample size calculation 
I used descriptive statistics to summarize data, confidence intervals for 
proportions, and univariable and multivariable logistic regression to calculate 
unadjusted and adjusted odds ratios (OR) for associations. Group differences 
  
If you are retired or choose not to work for reason unrelated to your 
problem, tick 
   
0             1              2               3               4              5              6             7             8         
 
Not at 
all        slightly  
     
definitely  markedly  
very 
severely  
        Score 0-8 
Because of my (problem) my ability to work is impaired '0' means 
'not at all impaired' and '8' means very severely impaired to the 
point I can't work    
      
 
Because of my (problem) my home management (cleaning, 
tidying, shopping, cooking, looking after home or children, paying 
bills) is impaired.   
       
 
Because of my (problem) my social leisure activities (with other 
people e.g. parties, bars, clubs, outings, visits, dating, home 
entertaining) are impaired    
      
 
Because of my (problem), my private leisure activities (done 
alone, e.g. reading, gardening, collecting, sewing, walking 
alone) are impaired)     
      
 
Because of my (problem), my ability to form and maintain 
close relationships with others, including those I live with, is 
impaired     
       
           
       
Total WSAS 
score   
Table 10. Work and social adjustment scale 
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were assessed using univariable logistic regression, t-, and Mann-Whitney tests 
as appropriate to data type. Only returned FQs were analyzed for avoidant 
behaviour. All items on the online questionnaire must be scored to permit 
submission, preventing any unscored items. Any unscored item on a returned 
postal questionnaire was given the most conservative interpretation and imputed 
zero, assuming that the item was irrelevant or did not elicit any anxiety symptoms. 
I carried out all statistical analyses using STATA14(99). I aimed for a target 
sample size of approximately 200 to achieve a desired precision of +/- 0.05 
around an estimated frequency of post-stroke anxiety of 0.20.  
 
3.2.8 Reporting standards and ethics approval 
I reported the study in accordance with Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guidelines. I obtained a 
favourable opinion from the South East Scotland Research Ethics Committee 












I recruited 201 participants between 9/9/15 and 28/6/16. 26/201 
participants did not have SCID at three months—three had died, one was on 
palliation for terminal cancer, four had lost mental capacity, nine withdrew 
consent for SCID, and nine were not contactable (Figure 11).  













Participants lost to follow-up were more likely to live alone (losses: 15/26, 
58%; analysed: 60/175, 34%, p=0.024), otherwise they were similar to those who 










26 missing SCID at 3 
months: 
  4 lost capacity 
4 died/ terminal 
9 unable to contact for SCID 
9 withdrew consent for project 
SCID 
 
147 returned Fear Questionnaire  
201 consented 
175 had SCID at 3 months post-
stroke/TIA  





Table 11. Baseline characteristics of prospective cohort analysed (n = 175) and 




Loss to SCID 
follow-up 
chi square  
(or other 
specified)  





26   
Age mean 69·6 
 
72·2  p=0·276 
(unpaired t-
test) 
 SD 11·6  11·2    
median  71·4 
 
75·7    
IQR 61·6-78·2 
 
64·5-82·4   
Age group 
   
   
Below 65 
 
40 23% 7 27%  
65-75 
 
44 25% 6 23% 
Above 75 
 
91 52% 13 50% 
 
Sex 
   
   
Female 
 
70 40% 9 35% p=0·597 
Male 
 
105 60% 17 65%     
    
Diagnosis 
  
    
Ischaemic 
 





5 3% 2 8%  
TIA (probable or 
definite) 
 
61 35% 7 27%  
   




    
NIHSS median 0  1    
IQR 0-2  0-3   
       








53 30% 10 38%  
Posterior 
 
35 20% 2 8%  
Unknown 
 
5 3% 0 0%     




    
Lived alone 
before stroke 
Yes 60 34% 15 58% p=0·024 
No 115 66% 11 42%  
      
Independent 
before stroke 
Yes 169 97% 26 100%  




      
Orientated 
speech 
Yes 170 97% 25 96% p=0.790 
No 5 3% 1 4%  
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Table 11 continued Prospective 
analysed  
 Loss to SCID 
follow-up 
chi square  
(or other 
specified) 
  All %  %  
Able to lift arms Yes 168 96% 26 100%   
No 7 4% 0 0%  
 
Able to walk Yes 168 96% 25 96% p=0·970  
No 7 4% 1 4%  
Past diagnosis 
of depression or 
anxiety disorder 
  
    
Depression only 
 
30 17% 2 8% p=0·111 
Anxiety only 
 











123 70% 24 92%  
 
In the analysed sample (Table 12), 175 participants (mean age [SD]: 70 
[12]; women: 70/175, 40%) had SCID at three months post-stroke/TIA. The 
majority had ischaemic stroke, a third had TIA, and few had primary ICH 
(ischaemic stroke: 109/175, 62%; TIA: 61/175, 35%; primary ICH: 5/175, 3%). I 
recruited similar numbers from the acute stroke unit and TIA clinic (acute stroke 
unit: 80/175, 46%; TIA clinics: 95/175, 54%). My sample therefore consisted of 
patients with mild stroke and TIA (NIHSS median [IQR]: 0 [0-2]). Nearly all 
participants were interviewed by telephone (telephone: 168/175, 96%; face to 









Table 12. Baseline characteristics of prospective cohort, by anxiety disorder at 3 











3.3.1 Frequency of anxiety disorders and psychiatric co-morbidity at 
three months after stroke or TIA  
 
A fifth of my sample had at least one anxiety disorder at three months 
after stroke/TIA (38/175, 22% [95%CI 16-29]). Phobic disorder was the most 
frequent anxiety subtype (‘phobic disorder only’: 18/175, 10%; ‘both phobic 
disorder and GAD’: 13/175, 7%; ‘GAD only’: 7/175, 4%) (Figure 12a, Table 13). 
PTSD appeared as a co-morbidity in ‘phobic disorder only’ cases (6/18), ‘GAD 
only’ cases (1/7), and ‘both phobic disorder and GAD’ cases (4/13) (Table 13). 
Half of all people with anxiety disorder also had a minor or major depressive 
episode (20/38, 53%) (Figure 12b). I found no difference in cognitive function 
between patients with anxiety disorder and those without (tMoCA median, IQR: 
[anxiety disorder] 18, 16-21; [no anxiety disorder] 19, 17-20, p=0.692). Of the TIA 
patients, 18% (11/61) had an anxiety disorder, 10% (6/61) had ‘phobic disorder 






Figure 12. (a) Number of cases (sample frequency) of phobic disorder and GAD, 




Table 13. Sample frequencies of SCID-diagnosed phobic disorder, GAD and 




3.3.2 Avoidant behaviour and anxiety-provoking situations  
84% (147/175) returned completed FQ for analysis. Non-responders were 
younger than the FQ sample analysed (mean age: [non-responders] 64.8 +/-14.9; 
[FQ analysed] 70.5 +/-10.6, p=0.017) but did not differ statistically in other 
characteristics (Table 14). Participants with an anxiety disorder at three months 
reported significantly higher level of avoidant behaviour across all situations on 
the FQ compared to participants without (Figure 13). 
 
Table 14. Baseline characteristics of sample with modified FQ data (n=147) and 
non-responders (n = 28) in prospective cohort 









n=147 % n=28 %  




 SD 10.6  14.9   
 median  72.0  63.5   
 IQR 63.3-78.3  56.0-77.0   
Sex       
Female  59 40% 11 39% p=0.933 
Male  88 60% 17 61%  
       
Diagnosis       
Ischaemic  88 60% 21 75%  
Primary 
intracerebral 
haemorrhage  4 3% 1 4% p=0.243 
TIA (probable or 
definite)  55 37% 6 21%  
Neurological 
impairment       
NIHSS median 0  1   
 IQR 0-2  0-3   
Hemisphere       
Left anterior 
circulation  67 46% 15 54%  
Right anterior 
circulation  45 31% 8 29% p= 0.803 
Posterior  31 21% 4 14%  
Unknown  4 3% 1 4%  
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Table 14 continued      
Number of patients (%) 
FQ data 







n=147 % n=28 %  
Pre-stroke/TIA 
Status       
Lived alone 
before stroke Yes 48 33% 12 43% p=0.304 
 No 99 67% 16 57%  
Independent 
before stroke Yes 143 97% 26 93% p=0.287 
 No 4 3% 2 7%  
Post-stroke/TIA 
status       
Orientated 
speech Yes 144 98% 26 93% p=0.191 
 No 3 2% 2 7%  
Able to lift arms Yes 141 96% 27 96% p=0.898 
 No 6 4% 1 4%  
Able to walk Yes 141 96% 27 96% p=0.898 
 No 6 4% 1 4%  
 
Past diagnosis of 
depression or anxiety 
disorder 
     
Depression only  24 16% 6 21%  




9 6% 2 7% p=0.837 
No past diagnosis 
of anxiety or 
depression  
104 71% 19 68%  
  





Yes 29 20% 9 32% p=0.160 





Figure 13. Avoidant behaviour in agoraphobic, social and other specific situations (n= 147) 
  
Thick lines represent median; boxes represent interquartile range; whiskers represent range. FQ indicates Fear Questionnaire. 
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Similarly, during SCID, positive responses to all of the 11 pre-defined 
situations were more common in participants with anxiety disorder compared to 
those without (Figure 14). The fear of stroke recurrence had the most positive 
responses in those with anxiety disorder (31/38, 82%) and in those without 
(40/137, 29%). I listed any additional anxiety-provoking situations reported by 
participants during SCID (Table 15).  
 
Table 15. Other anxiety-provoking situations reported during SCID 
 Has anxiety disorder  
 






People watching me,/ 





Being in the shower when 
alone at home 
 
Being alone while looking 





Any funny or odd feeling 
makes me think it is going 
to be a stroke 
 
Mobility concerns when out 
alone due to weakness and 
poor balance 
 
Not recovering from physical 
impairment e.g. weakness, 
handwriting 
 
Not being able to return to 
usual activities/ responsibilities 
e.g. looking after spouse, 
returning to occupation 
 
Worry about getting dementia 
 
Embarrassed about not being 
able to use fork in a restaurant  
 
Any funny or odd feeling make 




































8) Being alone at home
7) Physical exertion
6) Situations with other people e.g.…
5) Standing in a queue
4) Using public transport
3) Going into crowded place
2) Going out of the house alone
1) Travelling more than a distance from home







3.3.3 Associations with dependence, health-related quality of life, and 
social participation at three months 
 
Despite similar baseline neurological impairment (NIHSS 0-4: [anxiety 
disorder] 95% vs [no anxiety disorder] 92%, p=0.575), participants with anxiety 
disorder were more dependent (mRS3-5: [anxiety disorder] 55% vs [no anxiety 
disorder] 29%, p<0.0005), reported more problems across all health-related 
quality of life domains on the EQ-5D5L (Figure 15), and more restriction in social 
participation (median WSAS, IQR: [anxiety disorder] 19.5, 10-27; [no anxiety 
disorder] 0, 0-5, p<0.001). 
 
3.3.4 Factors associated with anxiety at 3 months after stroke/TIA 
The odds of having an anxiety disorder at 3 months after stroke or TIA 
decreased by a third per decade increase in age (adjusted odds ratio (OR) 0.64, 
95%CI 0.45-0.91), and increased four-fold when there was a past diagnosis of 
anxiety or depression (adjusted OR 4.38, 95%CI 1.94-9.89) (Table 16). Sex or 
living alone pre-stroke/TIA was not statistically associated with anxiety disorder at 
three months. 
 
Table 16. Unadjusted and adjusted ORs of pre-defined predictors for the 









Figure 15. Baseline NIHSS, mRS and EuroQol-5D-5L domains, by anxiety 
disorder at 3 months post-stroke/TIA (n=175).  
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3.4 Discussion  
3.4.1 Key findings  
In my sample of stroke and TIA patients, a fifth had an anxiety disorder 
diagnosed at psychiatric interview at three months. I found phobic disorder to be 
the predominant anxiety subtype after stroke or TIA. Anxious patients reported 
more avoidance in agoraphobia-related, social and other specific situations or 
stimuli—physical exertion, having sex, being alone at home,  activities related to 
fear of having a headache, another stroke, or a fall. PTSD was more common 
than I had anticipated. Younger age and having a past history of anxiety or 
depression increased the likelihood of developing anxiety post-stroke/TIA. 
Despite having a similar level of neurological impairment at baseline, participants 
with anxiety disorder were more dependent, had poorer health-related quality of 
life, and were more restricted in social participation at three months after stroke or 
TIA compared to those without anxiety disorder.  
 
3.4.2 Potential bias in our methodology 
As the interviewer, I was a stroke clinician who received training in 
performing the SCID. I minimised any variability in diagnosis by having all final 
diagnoses discussed and confirmed with AC, a consultant neuropsychiatrist, at 
weekly meetings. A systematic review of studies assessing the agreement 
between diagnostic telephone and face-to-face psychiatric interviews found good 
agreement (kappa 0.69-0.84) between the two versions in psychiatric 
populations(100), supporting the use of telephone SCID for anxiety disorders and 
depression. However, there are no such comparability data in stroke. The use of 
telephone SCID in our study could have influenced the accuracy of the ‘true 
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estimates’ of our SCID diagnoses. SCID diagnosis was made based on formal 
diagnostic criteria and coding system, taking into account detailed narrative of the 
patient’s experience. Temporary distress experienced by the participant at the 
time of SCID, if any, was unlikely to influence the final diagnosis. My final sample 
size of 175 fell short of the 200 I intended to recruit. This impacted slightly on the 
precision of the frequency estimate for ‘any anxiety disorder’, from +/- 0.05 to +/- 
0.06. 
I noted a high proportion of previous anxiety or depression in our sample. 
Case ascertainment relied on participants’ recollection of any past diagnosis 
made throughout their lifetime. This method could have led to overestimates and 
was not sufficiently reliable to inform us to what extent the participant suffered 
from anxiety prior to their stroke, or if they had ‘trait’ anxiety. Case ascertainment 
from primary care records would provide a more reliable estimate.  
 I had losses of follow-up in the prospective cohort. More people lived 
alone in the losses compared to those who underwent SCID. This could have led 
to underestimates of anxiety disorder and depression, as living alone was 
associated with a higher psychiatric morbidity in the general population(101). I 
lost FQ data through non-responders and they were younger compared to the FQ 
sample analysed. While over a quarter of participants completed the FQ online as 
their preferred method, I did not test the agreement between the two versions. 
Our population was at the milder end of the stroke spectrum.  
 
3.4.3 Interpretation 
My frequency estimate falls within the range of frequencies reported in a 
recent meta-analysis of anxiety post-stroke: 18-25%(56). I found phobic disorder 
to be the predominant anxiety subtype post-stroke/TIA, and quantified for the first 
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time, the avoidant behaviour of specific anxiety-provoking situations in people 
with anxiety post-stroke/TIA. My study is the first to have assessed the frequency 
of anxiety subtypes using diagnostic interview in TIA patients(102). Similar to my 
main analysis, phobic disorder was the most frequent anxiety subtype post-TIA. 
My frequency estimate of anxiety disorder post-TIA is similar to that reported 
using a rating scale cut-off for ‘definite anxiety’ in a regional stroke registry(57).  
Earlier studies suggested phobic anxiety might be present after stroke(62-
64), yet clinical trials of anxiety intervention did not translate this finding, treating 
anxiety post-stroke as one unitary phenomenon. Thus far, only general 
approaches such as relaxation and antidepressants have been evaluated in 
stroke(67), which are unlikely to be effective in patients with predominantly phobic 
anxiety. My findings suggest the need to evaluate exposure techniques—an 
approach known to be effective in phobic disorder in non-stroke populations(45), 
but one that has never been evaluated in stroke. I identified the specific 
situations/ stimuli avoided in our anxious participants which could be potential 
targets for psychotherapy e.g. CBT.  
 
Fear of stroke recurrence 
The fear of stroke recurrence was the most commonly reported anxiety-
provoking stimulus in my participants, with or without anxiety disorder. In my 
interviews, I found this anxious anticipation—the experience of anxiety by thinking 
about an event in the future, to have led to differential behaviours in our 
participants. In some, this anticipatory anxiety brought about a desire for better 
health and increased positive health behaviours, e.g. complying with medications 
and doctor’s advice on lifestyle, giving up smoking. In others, this anticipatory 
anxiety became disproportionate, and perpetuated maladaptive avoidant 
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behaviours of specific situations e.g. travelling alone, crowds, physical exertion, 
social gatherings. The fear of stroke recurrence, accompanied by a sense of 
complete loss of control in a public place appeared to underlie the agoraphobia in 
my participants. These maladaptive thinking patterns and avoidant behaviours 
are potential targets for cognitive restructuring and exposure therapy in a CBT 
intervention. In exposure therapy, phobic patients confront their specific feared 
situation in a graduated hierarchical fashion, until the unpleasant anxiety feelings 
diminish. The individual’s realization that catastrophe has not occurred despite 
confronting his/her feared situation e.g. taking the bus, can be used to help 
challenge a maladaptive belief e.g. ‘I’m going to have a stroke if I travel on the 
bus’. 
 
Psychiatric co-morbidity  
Psychiatric co-morbidity was common in my sample and their symptoms 
should be considered in the treatment of anxiety post-stroke/TIA. Few studies 
have estimated the frequency of clinical diagnosis of PTSD post-stroke/TIA(103).  
Frequency of PTSD was estimated in my study using the SCID in which the 
patient’s stroke or TIA was considered a significant stressful event that met the 
entry criterion for PTSD. This method could have inflated the frequency of PTSD 
observed. Furthermore, it is arguable whether PTSD diagnostic criteria are 
appropriate at all for use in stroke patients given how common the diagnosis of 
stroke/TIA is, and at only three months after the event, it would be difficult to 
ascertain whether the patient is suffering from PTSD or emotional distress from 
an ongoing stressor. Like phobic and generalised anxiety, PTSD has specific 
treatment strategies in non-stroke populations—trauma-focused CBT and eye 
movement reprocessing(104, 105). These now need to be tested in stroke. My 
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finding on PTSD adds weight to my general thesis that treating anxiety as a 
unitary condition after stroke will lessen the likelihood of finding effective 
treatments. In PTSD, individuals persistently re-experience the traumatic event in 
the form of distressing flashbacks, intrusive thoughts and nightmares(33). In my 
cases of PTSD, emotional distress was provoked by bodily sensations or 
situations that reminded the individuals of their index event e.g. headaches, odd 
sensation in affected limb, meeting people who were likely to enquire about the 
index event. Panic disorder was nested within my phobic and GAD cases. It 
refers to a tendency to have panic attacks—the most extreme and unpleasant 
form of anxiety state with marked autonomic symptoms and the feeling of 
‘impending catastrophe’. Panic disorder is usually managed with CBT, and/ or 
medications. Consistent with the literature(56, 106), concurrent depression was 
common amongst anxiety cases, reaffirming the need to manage depression in 
those with anxiety post-stroke. My frequency estimate of post-stroke depression 
was half of what was usually reported(107). This is probably because our sample 
consisted of mainly mild stroke and TIA patients, and that stroke severity and 
physical disability are the most consistent predictors for post-stroke 
depression(108).  
 
Factors associated with anxiety post-stroke/TIA 
The likelihood of developing anxiety after stroke or TIA increased in 
younger people and in those with a history of anxiety or depression, consistent 
with anxiety in the general population. The observed relationship between age 
and anxiety in both stroke and non-stroke populations could be a cohort effect in 
which generational factors rather than age alone might be implicated. For 
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example, stoicism might be a characteristic of people born in the 40s while 
younger people might have less resilience and more anxiety as a generation.  
 In contrast to the general population, men were as likely as women to 
develop anxiety post-stroke/TIA. I found no statistical significant association 
between lesion location and anxiety post-stroke/TIA. 
 
Associations with dependence, quality of life and social participation 
My study findings on dependence, quality of life and social participation 
challenge the pervasive view amongst stroke clinicians that these patients are not 
disabled by their seemingly ‘minor’ cerebrovascular event. Anxiety disorders, 
PTSD and depression can be profoundly disabling and need to be considered as 
important outcomes in stroke and TIA.  
 
Implications for future research 
The lack of evidence-based anxiety interventions is a barrier to improving 
outcomes in patients with anxiety post-stroke/TIA. Trialists must recognise the 
need for different treatment approaches for phobic and generalised anxiety. 
Given the predominance of phobic disorder post-stroke/TIA, exposure therapy 
needs to be evaluated in a clinical trial in this population. Individually tailored CBT 
is feasible in clinical trial setting of post-stroke depression(109, 110) and may be 
similarly applied in anxiety post-stroke/TIA. 
  
3.4.4 Generalisability 
My sample is different from the population of patients with stroke, in that 
all the participants could communicate by telephone, hence in general had mild 
deficits. Based on the Scottish Stroke Care Audit registry data, I would expect 
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around a fifth of the NHS Lothian stroke population to have communication 
difficulties. Furthermore, competing research studies were recruiting patients with 
more severe deficits at the same time as this study’s recruitment. I recruited half 
of my sample from clinic where patients tended to have mild or resolution of 
neurological symptoms. I therefore consider my sample as representative of the 
mild stroke and TIA population with limited generalisability to severe stroke, or 
those who have significant communication difficulties. The tMOCA scores in my 
sample are consistent with findings in a similar sample of stroke and TIA 
patients(95), and suggest the presence of mild cognitive impairment, a known 
manifestation of mild stroke and TIA(111). 
 
3.5 Implications for my anxiety intervention design 
In designing the content of my TASK intervention, I will consider adapting 
exposure therapy for treating phobic anxiety and cognitive therapy techniques 
such as cognitive restructuring and problem solving for generalised anxiety. 
Phobic disorder, regardless of the focus of the phobia e.g. agoraphobia, social 
phobia, fear of physical exertion, should be treated with graduated hierarchical 
exposure therapy. My TASK intervention will aim to teach participants to apply 
exposure therapy techniques to confront their feared situations, whatever these 
might be. Considering how common agoraphobia appeared in my sample, I will 
include content specifically relating to the treatment of agoraphobia in my 
intervention.  
Fear of stroke recurrence was the commonest anxiety-provoking thought. 
It appeared to be what perpetuated much of the observed avoidant behaviour in 
my anxious participants. It was of course reasonable for people to fear a life-
threatening and potentially disabling health event such as stroke. Why then did 
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some participants go on to have an overwhelming fear that dominated their daily 
life, restricting their activities, when others managed to live life as usual despite 
being aware of a risk of stroke recurrence? Based on my interviews, it appeared 
that participants with anxiety disorder, whether phobic or generalised, had a 
grossly distorted view of their risk of stroke recurrence. Consequently, these 
participants feared having a debilitating stroke on a regular basis. When asked to 
quantify their own stroke risk, the anxious participants reported perceiving their 
daily stroke risk to be as high as 50% to 80%. No wonder they were anxious!  
‘Your risk of having another stroke is higher than the general population 
now that you have had a TIA or stroke’ is what we, as stroke clinicians tend to 
convey to our patients in order to emphasise the urgency for clinic assessment 
and secondary prevention. This is an anxiety-increasing message which serves to 
‘stress’ patients into engaging in healthy behaviours. This stress, however, could 
lead to anxious patients becoming pre-occupied with their risk of stroke 
recurrence in a maladaptive way. The Yerkes-Dodson law demonstrated that 
performance e.g. memory, task performance is related to arousal or stress in an 
inverted U-shaped curve(112). Someone who is not aroused at all does not 
perform a task well. By increasing his arousal or stress, his performance 
improves up to a point. Once an optimal level of performance is reached, further 
increase in stress leads to a decline in performance. This relationship might 
explain why some patients may require an anxiety-reducing message in their 
health interests while others may need an anxiety-increasing message. In 
choosing the health ‘message’ stroke clinicians must balance increasing anxiety 




Most clinicians, including myself, generally refrain from the use of 
quantified long-term stroke risk derived from population-based observational 
studies (2 to 5 % annual stroke risk) when speaking to patients. Exactly why we 
do not wish to give this information to our patients is unclear. In my experience, 
non-specialist clinicians may not be familiar with the research evidence, some 
clinicians are not sure if patients would find this information meaningful, and 
others worry about patients misinterpreting the given risk, which may fuel further 
anxiety. Evidence suggests that primary care and hospital physicians 
overestimate the risk of stroke recurrence following a TIA(113). It is possible that 
clinicians are contributing to the development of anxiety post-stroke/TIA by 
unintentionally encouraging a distorted view of stroke risk amongst patients.  
Participants without anxiety disorder seemed able to convince themselves 
that they had done everything they could to minimise their future stroke risk e.g. 
taking medications, living a healthy lifestyle.  They were able to carry on with their 
daily life without thinking too much about their risk of recurrence.  
In my TASK intervention, I plan to take anxious participants through a 
checklist of all the steps they could take to minimise their stroke risk including 
smoking cessation, adhering to medications, being physically active, taking 
medications etc. 
My anecdotal experience suggested that anxious stroke/TIA patients 
found great relief from hearing me say ‘the majority of people do not go on to 
have another stroke after their TIA or minor stroke’. I found all anxious patients to 
be pleasantly surprised, often breathing a great sigh of relief, after learning that 
their long-term risk of stroke recurrence per year was as low as 2 - 5%, not 50 - 
80%. Perhaps clinicians should now feel more relaxed at providing a quantified 
stroke risk so that our patients can go home with a more realistic view of their risk 
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of stroke recurrence in the long term. In my TASK intervention, I plan to 
incorporate my findings and experience to help anxious patients correct their 
distorted view of stroke risk by educating them with a realistic risk, and offering 
them the reassuring and evidence-based advice that ‘the majority of people do 
not go on to have another stroke after their TIA or minor stroke’. 
Some of my anxious participants reported that headaches or other 
physical sensations such as stabbing pain, the odd tingle, and dizziness could 
provoke anxiety as they often associated these symptoms with having another 
stroke. In some cases, these symptoms could lead to repeated admissions to the 
emergency department and repeated brain imaging. Residual deficits from the 
initial stroke, common post-stroke phenomena e.g. hyperaesthesia over the 
affected side, headaches, and anxiety could all give rise to, or accentuate bodily 
symptoms. Most of the recurrent symptoms these participants reported were not 
typical of an acute stroke. In my TASK intervention, I aim to include educational 













Diagnostic Accuracy and Reliability of Two Anxiety Measures 
Publication status and contribution 
I am currently preparing this chapter for submission for a peer review 
publication.  
I designed and conducted this study as part of the the observational study 
in Chapter 3. I recruited additional participants by retrospective postal invitations 
for this study. I designed the methods with input from my supervisors and 
performed all study procedures including data collection and analyses. Professor 
Alan Carson provided training and supervision of my SCID interviews. He 
confirmed all psychiatric diagnoses made in this study. Francesca Wright, a final 
year medical student assisted with data entry in this study.  Dr Will Whiteley and 
Dr Cat Graham (statistician), provided guidance on my statistical analysis plan, 
data analysis and data visualisation. 















I demonstrated in Chapter 3 that phobic disorder was frequent and could 
occur in the absence of GAD after stroke and TIA. Based on my systematic 
review in Chapter 2 and findings from a recent systematic review of anxiety 
screening tools in stroke(60), I found that only generalised anxiety measures had 
been used and validated in stroke. An anxiety questionnaire that enquires about 
generalised anxiety symptomology only may not detect phobic anxiety if it does 
not enquire about specific phobic situations or maladaptive avoidance. While the 
use of SCID is considered a ‘gold-standard’ tool for diagnosing anxiety disorders 
in research, its use requires specialist training and is too time-consuming to be 
feasible in a clinical trial setting. Brief self-completed anxiety measures offer 
feasible alternatives for use in an RCT. In my TASK RCT, I will need valid, 
reliable and feasible measures for both phobic disorder and GAD. 
 
Validity and reliability of an anxiety measure 
Validity and reliability represent the quality of a measurement scale. 
Validity is defined as the extent to which a test measures what it is intended to 
measure(114). Criterion validity refers to whether scores on an index test agree 
with a ‘gold standard’ measurement of the same construct(114). One way of 
measuring criterion validity of an index test is to assess its diagnostic accuracy, or 








Figure 16. Contingency table for index test result and disease status 
 
 
Sensitivity is the probability of having a positive test given that the 
individual has the disease (Figure 16). Specificity refers to the probability of 
having a negative test given that the individual does not have the disease. 
Sensitivity and specificity can be expressed mathematically as follows: 
 
Sensitivity:       
Probability (Test + | Disease +)  = True Positive/ (True Positive + False Negative) 
 
Specificity:       
Probability (Test - | Disease -)  = True Negative/ (True Negative + False Positive) 
 
A highly sensitive test will have few false negatives. When a highly sensitive test is 
negative, it is highly probable that the person does not have the disease. Therefore, 
the test is helpful at ‘ruling out’ the disease. A highly specific test will have few false 
positives. When a highly specific test is positive, it is highly probable that the person 
has the disease. Therefore, the test is helpful at ‘ruling in’ the disease.  
In addition to sensitivity and specificity, the positive predictive value (PPV) 
is the probability that the patient has the disease given that he tested positive. 
Negative predictive value (NPV) is the probability that the patient does not have 
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the disease given that he tested negative. The PPV is influenced by the prevalence 
of the disease. As such, test for a rare disease i.e. disease with a low pre-test 
probability, will have a low PPV. 
 
PPV:   
Probability ( Disease +  |  Test + ) = True Positive/ (True Positive + False Positive) 
 
NPV:                      
Probability (Disease -  |  Test - ) = True Negative / (True Negative + False Negative) 
 
Selecting an optimal cut-off for an index test  
To assess the diagnostic accuracy of an index test, a cut-off score is 
selected above which the individual is said to be test positive. Ideally, an optimal 
cut-off would have a high sensitivity and a high specificity. However, increasing 
the sensitivity of a test may compromise its specificity due to increasing number 
of false positives. Similarly, increasing the specificity may compromise the 
sensitivity due to increasing number of false negatives. A number of factors have 
to be considered when deciding whether to compromise sensitivity or specificity 
for an imperfect test, and by weighing up the advantages and disadvantages or 
‘costs’ of compromising one or the other. For example, an excess of false 
positives could lead to more people being diagnosed with a disease they do not 
have, and being offered treatment they do not need. This could have the 
untoward consequences of inducing anxiety or other distressing emotions in 
patients receiving the diagnosis, patients going through unnecessary treatment 
and developing possible harmful side effects.  The economic costs of providing 
an excess of unnecessary treatments to false positive patients should also be 
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considered. On the other hand, maximising specificity while compromising 
sensitivity would leave some patients with the disease undetected and thus 
untreated. The untreated disease burden to the patients, their carers, and the 
health service should be considered.  
 
Receiver operator characteristic curve and area under curve 
The trade-off between sensitivity and specificity can be displayed 
graphically with the receiver operator characteristic (ROC) curve, in which 
sensitivity, the true positive rate, is plotted against (1 – specificity), the false 
positive rate. The area under curve (AUC) represents the discriminating ability of 




Reliability refers to the consistency or stability of the measure across time, 
patients, or observers (114). In other words, reliability testing assesses the extent 
to which a score is free of random error(114). Reliability can be assessed by its 
reproducibility or ‘agreement’ between two observers (inter-observer reliability), or 
in repeated assessments by the same observer (intra-observer or test-retest 
reliability).  
Another way of assessing reliability of a test is to assess whether all items 
within a scale measure the same construct—internal consistency(115). One 
approach is to see if sets of items within a test correlate with each other, for 
example by splitting the test into two halves (split-half reliability). A more common 
approach is to see if all possible item pairs contained within a test correlate with 
each other. The higher the inter-correlations among items, the more equivalent 
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the items are, so the more reliable the test. Cronbach’s coefficient alpha is 
commonly used as a marker of internal consistency(116). The formula for the 






A Cronbach’s alpha of 0.70 or higher is generally considered ‘acceptable’; 0.80 to 
0.90 as ‘good’; 0.9 or higher as ‘excellent’ in psychometric research(118).  
 
My aim 
To assess the diagnostic accuracy and reliability of two anxiety measures 
in a sample of stroke and TIA patients: the 7-item GAD questionnaire (GAD-7), 
and the modified FQ. 
 
4.2 Methods 
4.2.1 Sampling and recruitment 
This study was carried out on the sample of participants recruited for my 
prospective cohort study from 9/9/2015 to 28/6/2016, reported in Chapter 3. I 
recruited additional participants by postal invitations from the NHS Lothian’s 
stroke and TIA discharge database from 1/12/2014 to 6/8/2015. The inclusion 
criteria are the same as my study in Chapter 3. All participants completed a 
questionnaire containing the index tests—the GAD-7 (Table 17) and modified FQ 
(Table 6) by post or online based on their preference, at three to nine months 
α = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑡𝑒𝑚𝑠  ×   𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑖𝑡𝑒𝑚 𝑝𝑎𝑖𝑟𝑠





post-stroke/TIA. All participants then received the ‘gold-standard’ telephone 
psychiatric diagnostic interview from me one week later.  
 
4.2.2 Index tests 
i) GAD-7 
The GAD-7 is a brief 7-item measure of GAD derived from the DSM-IV 
diagnostic criteria for GAD(119). It is commonly used and has been assessed in 
primary care for test-retest reliability and convergent validity with other anxiety 
measures(119). It has a diagnostic criterion validity for GAD at cut-point 9/10 
(sensitivity of 89% and specificity 82%) in a primary care sample (119). Each item 
denotes an anxiety symptom and is scored on a Likert scale from 0 (not at all) to 
3 (nearly every day) (Table 17). The GAD-7 has a total maximum score of 21. An 
online version of GAD-7 demonstrated similar reliability and validity(120).  
 
ii) The FQ-agoraphobia subscale and social phobia subscales 
I described the modified FQ (Table 6) in Chapter 3. In this study, I 
assessed the FQ-agoraphobia and FQ-social phobia of the original FQ, but not 
the FQ-specific phobia subscale. The FQ-agoraphobia subscale demonstrated 
good internal consistency in a previous phobic non-stroke sample (Cronbach 
alpha = 0.86)(121). 
FQ-agoraphobia subscale items: 
1. Going alone far from home 
2. Walking alone in busy streets 
3. Going into crowded shops 
4. Travelling alone or by bus 
5. Large open spaces 
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The FQ-social phobia subscale items: 
1. Being watched or stared at 
2. Talking to people in authority 
3. Eating or drinking with other people 
4. Being criticised 
5. Speaking or acting to an audience 
 
Each item denotes a situation, and is rated according to the level of avoidance 
from zero (would not avoid it) to eight (always avoid it). Each subscale has total 
maximum score of 40. FQ has not previously been validated in stroke or TIA 
samples. 
 
4.2.3 ‘Gold-standard’ psychiatric diagnostic interview 
SCID is widely accepted as the ‘gold-standard’ psychiatric diagnostic 
interview in psychiatry research and has fair to excellent inter-rater agreement for 
diagnosing anxiety disorders and depression between experienced and newly 
trained clinicians(93), and between its telephone and face-to-face versions(94). I 
used the telephone version of SCID-DSM-IV-TR, including the modules on panic 
disorder, agoraphobia, social phobia, specific phobia, and GAD(34). All SCID 
diagnoses were made according to the SCID coding system and after 
confirmation with a neuropsychiatrist at weekly meetings. Participants who were 







Table 17. GAD-7 questionnaire 
 





 Pfizer, the copyright holder, states that no permission is required to reproduce, translate, display or 
distribute the GAD-7 
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Blinding of interviewer to index test results 
All returned postal questionnaires remained sealed and online 
questionnaires were stored in a protected database at the Edinburgh Clinical 
Trials Unit. I was unable to access the questionnaire data until after all study 
interviews were complete. 
 
4.2.4 Statistical analyses 
I analysed the sensitivity, specificity, PPV and NPV with 95% confidence 
intervals at a selected cut-point for each index test using STATA14(99). I plotted 
the ROC curve and analysed the AUC for each index test. I computed the inter-
item correlations for all pairs of items for each index test and the Cronbach’s 
alpha statistic for each index test using R statistical software.   
 
Selection of cut-point 
On deciding a clinically useful cut-point for each index test, I considered it 
more important that the test had a high sensitivity rather than a high specificity. 
This was so that the test could maximise detection of participants who were 
anxious and reduce the number of anxious participants being missed. By 
compromising the specificity, participants who were not anxious might be falsely 
identified as anxious by the test. I considered this a reasonable trade-off as I was 
planning to design the TASK intervention to be a low-intensity guided self-help 
psychological intervention, which was likely to be acceptable for all and unlikely to 
carry risk of significant harm even if given to patients who were not anxious. 
Furthermore, I intended to design the TASK intervention to be easily scalable at 
low financial costs. For this study, I considered a sensitivity of at least 80% and 




All items on the online questionnaire must be scored to permit submission, 
preventing any unscored items. Any unscored item on a returned postal 
questionnaire was given the most conservative interpretation and imputed zero, 
assuming that the item was irrelevant or did not elicit any anxiety symptoms.  
 
Sample size 
The estimated sample size needed for the diagnostic accuracy test was 
175, assuming the prevalence of anxiety would be 20%, and the test had a 
sensitivity of 0.70 and 95% confidence intervals of +/- 0.15. 
 
4.3 Results 
I performed 213 SCIDs in total (175 in the prospective cohort and 38 in 
the postal recruits, median time since stroke/TIA: 111 days) (Figure 17).  
 





Paired data (Table 18) were available from 180 participants (mean age 
70+/- 10.9; male: 61%; stroke 69%, TIA 31%). 33 did not return index test 
questionnaire. Non-responders were younger (non-responders: 65.6 years +/-
14.3, analysed: 70.0 years +/-10.9, p=0.046) but did not differ significantly in other 
characteristics (Table 18). Analysed participants completed index tests at a 
median of one day (IQR 0-5 days) before SCID. More than a quarter of 
participants completed index tests online (28%, 51/180). Almost all participants 
had telephone SCID (telephone: 173/180, 96%; face-to-face: 7/180, 4%). A fifth of 
the analysed sample had an anxiety disorder on SCID (‘any anxiety disorder’: 
















Table 18. Characteristics of sample analysed in this diagnostic accuracy study 













 n=180 % n=33 %  
Age 
mean 70·0  65·6  
t-test, 
p=0·046 
 SD 10·9  14·3   
 median 71·3  64·2   
 




Sex       
Female  71 39% 14 42% p=0·748 
Male  109 61% 19 58%  
       
Recruitment 
method 
      
 Prospective 147 82% 28 84% p=0.661 
 Postal 33 18% 5 16%  
       
Diagnosis of any 
anxiety disorder 
on SCID 
Yes 37 21% 11 33% p=0·106 
 No 143 79% 22 67%  
Diagnosis       




 4 2% 1 3% p=0·520 
TIA (probable or 
definite) 
 55 31% 6 18%  
       
Severity of stroke       
NIHSS median 1  1   
 IQR 0-2  0-3   
Pre-stroke/TIA 
Status 
      
Lived alone before 
stroke 
Yes 59 33% 15 45% p=0·160 
 No 121 67% 18 55%  
Independent 
before stroke 
Yes 176 98% 31 94% p=0·221 
 No 4 2% 2 6%  
Past diagnosis of 
depression or 
anxiety disorder 
      
Depression only  31 17% 6 18%  




 10 6% 3 9%  
No past diagnosis 
of anxiety or 
depression 
 128 71% 22 67%  
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4.3.1 Diagnostic performance of index tests 
Figure 18 displays the ROC curves plotted from all cut-points of all the 
index tests (Table 19). Table 20 summarises the diagnostic performance of GAD-
7 and FQ-Agoraphobia at selected clinically useful cut-points. 
GAD-7 
For detecting any GAD, GAD-7 had an AUC of 0.94 (95%CI 0.89-0.98) 
and gave more than one clinically useful cut-points (At cut-point >=5: sensitivity 
93.8%, specificity 76.8%; at cut-point >=6: sensitivity 87.5%, specificity 84.2%) 
(Table 20). For detecting any phobic disorder, GAD-7 had an AUC of 0.88 
(95%CI 0.82-0.93). A lower cut-point of GAD-7 at >=4 gave a sensitivity of 83.9% 
and specificity of 73.2%.  
FQ-agoraphobia 
For detecting any phobic disorder, the FQ-agoraphobia had an AUC of 
0.86 (95%CI 0.80-0.92). At a cut-point of >=7, sensitivity was 87.1% and 
specificity was 77.9%.  
FQ-social phobia  
FQ-social phobia did not have a clinically useful cut-off for detecting 




Figure 18. ROC curves and AUC for each index test 
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Table 20.  Diagnostic performance of GAD-7, FQ-Agoraphobia at selected cut-offs in detecting anxiety subtypes diagnosed on 
psychiatric interview (n = 180) 
 
 For detecting any GAD   For detecting any phobic disorder 
     
 GAD-7   GAD-7 FQ-Agoraphobia 
Median score (IQR) 2 (0-5)   2 (0-5) 2 (0-10) 









       
















(77.6 – 89.4) 




























4.3.2 Reliability of index tests 
Internal consistency  
All seven items on the GAD-7 are positively correlated with each other 
(Table 21). The item-rest correlation shows each item to be positively correlated 
with the total test score with that item omitted (>0.60) (Table 21). Cronbach’s 
coefficient alpha of 0.92 indicates ‘excellent’ internal consistency of GAD-7. All 
five items of the FQ-Agoraphobia are positively correlated with each other (Table 
22). The item on ‘open space’ has the weakest item-pair, item-test and item-rest 
correlation. Cronbach’s coefficient alpha of 0.85 indicates ‘good’ internal 
consistency of the FQ-Agoraphobia. 
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Table 21.  Item-test, item-rest and inter-item correlations and Cronbach’s alpha of GAD-7  
                                                           
                           item-test     item-rest        
Item         |  Obs  Sign correlation   correlation      
-------------+--------------------------------------- 
GA1Edge      |  180    +       0.86        0.80           
GA2Control   |  180    +       0.88        0.83           
GA3Worry     |  180    +       0.85        0.79           
GA4Relax     |  180    +       0.89        0.84             
GA5Restless  |  180    +       0.73        0.63             
GA6Annoy     |  180    +       0.74        0.64                    
GA7Awful     |  180    +       0.81        0.73           
-------------+--------------------------------------- 
 
Average inter-item correlation:                         0.62 
Number of items in the scale:                           7 
Scale reliability (Cronbach’s alpha) coefficient:       0.92 
 
Inter-item correlations (obs=180 in all pairs) 
 
                 GA1Edge   GA2Control GA3Worry   GA4Relax  GA5Restless  GA6Annoy  GA7Awful 
    GA1Edge       1.00 
 GA2Control       0.79       1.00 
   GA3Worry       0.80       0.82       1.00 
   GA4Relax       0.69       0.72       0.69       1.00 
GA5Restless       0.43       0.55       0.46       0.74       1.00 
   GA6Annoy       0.55       0.56       0.52       0.60       0.51       1.00 






   
 
 
Table 22.  Item-test, item-rest and inter-item correlations and Cronbach’s alpha of FQ-Agoraphobia 
                                                             
                             item-test     item-rest        
Item         |  Obs  Sign   correlation   correlation      
-------------+------------------------------------------ 
FQAg1Street  |  180    +       0.90        0.83             
FQAg2Bus     |  180    +       0.81        0.68             
FQAg3Crowd   |  180    +       0.84        0.73             
FQAg4Far     |  180    +       0.85        0.75             




Average inter-item correlation:                        0.52 
Number of items in the scale:                          5 
Scale reliability (Cronbach’s alpha)coefficient:       0.85 
 
 
Inter-item correlations (obs=180 in all pairs) 
 
             FQAg1Street   FQAg2Bus   FQAg3Crowd  FQAg4Far  FQAg5Open 
FQAg1Street       1.00 
   FQAg2Bus       0.75       1.00 
 FQAg3Crowd       0.75       0.57       1.00 
   FQAg4Far       0.76       0.67       0.64       1.00 




4.4 Discussion  
4.4.1 Key findings  
This is a secondary analysis to assess the diagnostic validity of GAD-7 
and FQ against ‘gold-standard’ clinical diagnosis made on diagnostic psychiatric 
interview in a stroke and TIA sample. Our findings support the diagnostic validity 
and internal consistency of GAD-7 and FQ-agoraphobia post-stroke/TIA. The 
GAD-7 has a similar AUC to FQ-agoraphobia in detecting phobic disorder. 
 
4.4.2 Potential bias in my methodology 
I received training from a neuropsychiatrist in performing the ‘reference-standard’ 
SCID in this study. The reference standard diagnosis was made in a uniform 
fashion with the neuropsychiatrist at weekly meetings. A systematic review of 
studies assessing the agreement between diagnostic telephone and face-to-face 
psychiatric interviews found good agreement (kappa 0.69-0.84) in psychiatric 
populations(100), supporting the use of telephone SCID for anxiety disorders and 
depression. However, there were no such comparability data in stroke. Telephone 
SCID limited the interviewer’s ability to observe non-verbal signs, facial 
expressions, body language or any other idiosyncrasies that may help inform a 
psychiatric diagnosis. The use of telephone SCID as the reference standard thus 
limited the generalisability of this study’s sensitivity and specificity values. While 
over a quarter of participants completed the FQ online as their preferred method I 
did not test the agreement between the two versions. My sample was at the 
milder end of the stroke spectrum. I lost paired data in this study through 
unreturned index tests. These non-responders were younger than the sample 





My findings support the use of GAD-7 in detecting GAD and the FQ-
agoraphobia subscale in detecting phobic disorders in stroke and TIA patients.  
Discrepancy in GAD-7 cut-points between stroke and primary care samples 
For detecting GAD in my sample, I found the threshold for a clinically 
useful cut-point to be at >=5 or >=6. These cut-points were lower than the 
threshold of >=10, a cut-point validated in a large primary care sample (n = 
2740)(119). My sample size was small and so it was possible that the optimal cut-
points for GAD-7 in this study were due to chance. My sample of stroke and TIA 
patients differed from a primary care sample in a number of ways that could 
explain this discrepancy. The primary care sample was multi-ethnic, much 
younger, had a higher proportion of women and a lower frequency of anxiety 
disorder than my sample. These factors could have influenced the likelihood and 
degree of scoring for each item on the GAD-7. It was also possible that anxious 
stroke and TIA patients who volunteered to take part in my research study, 
entitled 'Anxiety after Stroke', were primed, so were more likely to give higher 
scores on the GAD-7. 
 The ‘gold-standard’ interview used in the primary care study was different 
from the SCID interview used in my study. This could have led to variability in 
how the 'gold-standard' diagnosis of GAD was made. A structured interview 
format used in the primary care study was more rigid and did not allow for further 
clinical questioning by the interviewer. On the other hand, SCID followed a semi-
structured format and allowed further clinical information to be gathered, which 
would provide a more accurate ‘gold standard’ diagnosis. Few in the primary care 
sample would have had a stroke or TIA. Raters in the primary care study, who 
were likely to have none or little experience in interviewing stroke and TIA 
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patients, would not have been aware that some stroke and TIA patients attributed 
their generalised anxiety as a normal response to their stroke event, and so might 
not report their symptoms unless they were probed further by the interviewer. As 
such, raters using a more rigid structured interview might only be able to give a 
diagnosis of GAD when the anxious symptoms were severe. On the other hand, 
my semi-structured SCID interview enabled patients to elaborate on their 
symptoms, providing more and richer clinical information. This might have led to 
the diagnosis of the milder forms of GAD.  
 
Detecting phobic disorder after stroke/TIA 
Currently, there are no anxiety measures validated for phobic disorder in 
stroke/TIA—the predominant anxiety subtype post-stroke/TIA that can occur in 
the absence of GAD(122). Other frequently used anxiety measures, for example, 
the Hospital Anxiety and Depression Scale, do not contain items on phobic 
disorder. My study findings offer preliminary data on the diagnostic validity of the 
FQ-Agoraphobia subscale for assessing phobic disorder in stroke and TIA 
patients. However, my data should be replicated before widespread use of this 
measure. A limitation in using the FQ-agoraphobia subscale to measure phobic 
anxiety after stroke is that it measures specifically the avoidance of agoraphobic 
situations. While agoraphobia accounted for most of the phobic cases after 
stroke/TIA in our recent prospective cohort(122), there were other specific phobic 
situations post-stroke that were reported: social situations, physical exertion, 
having sex, being home alone(122) that are not assessed by FQ-Agoraphobia. A 
desirable item/ scale for phobic disorder would measure the presence of phobic 
avoidance irrespective of the situation. 
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The GAD-7 had a slightly higher AUC for detecting phobic disorder than 
the FQ-Agoraphobia even though the GAD-7’s sensitivity and specificity were 
marginally poorer than the FQ-Agoraphobia. These findings could be due to 
chance but other explanations include individuals presenting with mixed 
generalised and phobic anxiety and GAD-7’s ability to detect some of the phobic 
anxiety symptomology. ‘In the past two weeks, how often have you been 
bothered by i) nervousness, ii) restlessness, or iii) feeling afraid as if something 
awful might happen?’ on the GAD-7 could elicit positive responses in a phobic 
individual who regularly confronts his feared situation/ stimulus. These symptoms 
on the GAD-7 need not be present if the phobic individual avoids confronting or 
imagining the feared situation completely. It is possible that GAD-7 could detect 
some phobic individuals who regularly experience the symptoms on the 
questionnaire while missing others who do not.  
 
Generalisability 
My sample is probably representative of the mild stroke and TIA 
population but not of severe stroke, those who have significant communication 
difficulties, or those who do not wish to take part in the study. 
 
4.5 Implications for trial design 
GAD-7 and FQ-agoraphobic subscale demonstrated validity and reliability 
for detecting GAD and phobic disorder in stroke and TIA patients. My findings on 
the FQ are preliminary only. Further validation is required to assess 
reproducibility. Further analysis on the measures’ sensitivity to change over time 
and in response to intervention could help me determine their suitability as 
outcome measures in a definitive RCT. The ability to detect the full spectrum of 
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phobic situations post-stroke/TIA remains limited so further research into scale 
development for phobic disorder post-stroke/TIA is needed. 
 
4.6 Deriving 5 dichotomised anxiety screening items to be used for 
the RCT 
 I planned to design my intervention to be suitable for a broad spectrum of 
anxiety severity, ranging from very mild to very severe, and capturing both 
generalised and phobic subtypes. Using both the GAD-7 and FQ for screening 
eligibility in potential participants would be too burdensome. Furthermore, using 
any given cut-point on a questionnaire to screen for eligible anxious patients 
would miss those with milder symptoms.  
I aimed to use my data on GAD-7 and FQ to derive five simple anxiety-
screening items to be used for screening eligibility in my RCT. I would add a sixth 
item, a free-text box for potential participants to enter any anxious problem that 
they felt needed treating. I aimed to select those anxiety screening items which 




I carried out this secondary analysis using the same dataset. First, I 
dichotomised all items on the GAD-7 and FQ so that all responses were binary 
(1= ‘Yes’, 0= ‘No’). For both scales, scores above zero were converted to a 
positive response (1 = ‘Yes’) (Table 23).  
I performed an exploratory principal factor analysis on this set of 
dichotomised items (GAD-7 + FQ = 23 items) in STATA14 to examine the factor 
structure. In principal factor analysis, the factor loadings are computed using the 
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squared multiple correlations as estimates of the communality (variance shared 
with other variables)(99). 
 
Table 23 Dichotomising GAD-7 and FQ   
GAD-7 During the past 2 weeks, how often have you 
been bothered by any of the following problems? 
 
0=not at all 
1=several days 





past 2 weeks, 
I have been 
bothered by’ 
 
0=Not at all 
1-3=Yes I 
have 
 Q1 “feeling nervous, anxious or on edge?   
 Q2 “not being able to stop or control worrying?”  
 Q3 “worrying too much about different things?”  
 Q4 “trouble relaxing”  
 Q5 “being so restless that it is hard to sit still?”  
 Q6 “becoming easily annoyed or irritable?”  
 Q7 “feeling afraid as if something awful might happen?”  
Fear Q How much would you avoid each of the situations below because of 
fear or other unpleasant feelings? 
 




















fear or other 
unpleasant 
feelings’ 
0 = no 
>1 = yes 
Agoraphobia Q8 “going alone far from home”  
 Q9 “walking alone in busy streets”  
 Q10 “going into crowded shops”  
 Q11 “travelling alone or by bus”  
 Q12 “large open spaces”  
Social Q13  “being watched or stared at”  
 Q14 “talking to people in authority”  
 Q15 “eating or drinking with other people”  
 Q16 “being criticised”  
 Q17 “speaking or acting to an audience”  
specific Q18 “physically exerting yourself”  
 Q19 “having sex”  
 Q20 “being alone at home”  
 Q21 “any of your normal day-to-day activities for fear of having a headache” 
 Q22 “any of your normal day-to-day activities for fear of having a stroke” 
 Q23 “any of your normal day-to-day activities for fear of having a fall” 
 
 
Given that the two scales were designed to detect two anxiety subtypes, I 
would expect to find at least two factors to explain the most variance of the total 
score, reflecting the two dimensions of these items. An eigenvalue represents 
how much of the variance of the item a factor explains. Factors with eigenvalues 
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of >1 would be retained by convention(123). In addition, I would examine the 
internal consistency of each of these items, discarding those with the lowest 
values. The final selection of items would be based on the findings from these 
psychometric analyses and their clinical relevance.  
Results 
Principal factor analysis found a two-factor structure (only two factors with 
eigenvalues more than 1) with the first factor accounting for most of the variance 
(72%) (Table 24). The factor loadings showed that all 23 items loaded on Factor 1 
(Table 25). All items had more weight on Factor 1 than any other factors. The 
GAD-7 items loaded on Factor 1 but negatively on Factor 2. The agoraphobic 
(Q8-12) and social phobic (Q13-17) items of the FQ loaded on both Factor 1 and 
Factor 2 but all items loaded with more weight on Factor 1. All items showed high 
internal consistency (Cronbach alpha’s >0.90) (Table 26). Question 12 from the 
agoraphobic subscale (‘large open space’) and Question 17 from the social 
phobic subscale (‘speaking or acting to an audience’) had the lowest item-test 













Table 24. Principal factor analysis of my set of dichotomised items 
 
Factor analysis/correlation       Number of obs    =        180 
    Method: principal factors     Retained factors =         13 
    Rotation: (unrotated)         Number of params =        221 
    -------------------------------------------------------------------------------- 
         Factor  |   Eigenvalue   Difference        Proportion   Cumulative 
    -------------+--------------------------------------------------------- 
        Factor1  |      8.93773      7.41416            0.7188       0.7188 
        Factor2  |      1.52357      0.62783            0.1225       0.8413 
        Factor3  |      0.89574      0.18401            0.0720       0.9134 
        Factor4  |      0.71174      0.18285            0.0572       0.9706 
        Factor5  |      0.52888      0.23174            0.0425       1.0131 
        Factor6  |      0.29715      0.03803            0.0239       1.0370 
        Factor7  |      0.25912      0.04253            0.0208       1.0579 
        Factor8  |      0.21659      0.05713            0.0174       1.0753 
        Factor9  |      0.15945      0.03450            0.0128       1.0881 
       Factor10  |      0.12496      0.07157            0.0100       1.0982 
       Factor11  |      0.05338      0.03388            0.0043       1.1025 
       Factor12  |      0.01950      0.00806            0.0016       1.1040 
       Factor13  |      0.01145      0.02123            0.0009       1.1049 
       Factor14  |     -0.00978      0.03838           -0.0008       1.1042 
       Factor15  |     -0.04817      0.00592           -0.0039       1.1003 
       Factor16  |     -0.05409      0.03504           -0.0043       1.0959 
       Factor17  |     -0.08912      0.03905           -0.0072       1.0888 
       Factor18  |     -0.12817      0.02535           -0.0103       1.0785 
       Factor19  |     -0.15352      0.01026           -0.0123       1.0661 
       Factor20  |     -0.16378      0.04098           -0.0132       1.0529 
       Factor21  |     -0.20476      0.01490           -0.0165       1.0365 
       Factor22  |     -0.21966      0.01414           -0.0177       1.0188 












Table 25. Factor loadings (pattern matrix) and unique variances 
Dichotomized items from GAD7 and FQ Factor1   Factor2   Factor3 |   Uniqueness  
Q1 “feeling nervous, anxious or on edge? 
Q2 “not being able to stop or control worrying?” 
Q3 “worrying too much about different things?” 
Q4 “trouble relaxing” 
Q5 “being so restless that it is hard to sit still?” 
Q6 “becoming easily annoyed or irritable?” 
Q7 “feeling afraid as if something awful might 
happen?” 
 
Q8 “going alone far from home”  
Q9 “walking alone in busy streets”  
Q10 “going into crowded shops”  
Q11 “travelling alone or by bus”  
Q12 “large open spaces”  
   
Q13  “being watched or stared at” 
Q14 “talking to people in authority”  
Q15 “eating or drinking with other people”  
Q16 “being criticised”  
Q17 “speaking or acting to an audience”  
    
Q18 “physically exerting yourself”  
Q19 “having sex”  
Q20 “being alone at home”  
Q21 “any of your normal day-to-day activities for 
fear of having a headache” 
Q22 “any of your normal day-to-day activities for 
fear of having a stroke” 
Q23 “any of your normal day-to-day activities for 
fear of having a fall” 
0.6430   -0.4319   -0.0152 |      0.3998   
0.7159   -0.4113   -0.1877 |      0.2831   
0.7160   -0.4729   -0.1941 |      0.2261   
0.7364   -0.3478   -0.0936 |      0.3280   
0.6462   -0.1527   -0.0652 |      0.5548   
0.5450   -0.2317   -0.2138 |      0.6035   
0.6551   -0.2235    0.0926 |      0.5123   
 
 
0.7071    0.1087    0.0083 |      0.4881   
0.7537    0.1708    0.0909 |      0.3944   
0.7146    0.1525   -0.0378 |      0.4647   
0.6736    0.1680    0.2422 |      0.4594   
0.4678    0.2553    0.0595 |      0.7125   
 
0.6068    0.3580   -0.3223 |      0.3998   
0.6290    0.3159   -0.0515 |      0.5019   
0.5772    0.2028    0.0808 |      0.6191   
0.6349    0.3278   -0.2766 |      0.4129   
0.4457    0.2873   -0.3610 |      0.5885   
         
0.5109    0.1182    0.1529 |      0.7017   
0.4828    0.2493    0.0141 |      0.7045   
0.5031   -0.0346    0.0892 |      0.7377   
0.6500   -0.0337    0.2786 |      0.4987   
 
0.5947   -0.0336    0.3890 |      0.4938   
 















Table 26. Inter-item correlation of all 23 dichotomised items  
 
‘bin’ indicates the questionnaire item has been dichotomised (binary) 
 
Interpretation 
All 23 dichotomised items address a common anxiety latent trait (Factor 
1). Questions 8-19 address an additional second latent trait (Factor 2). These 
items are from the FQ, and are related to avoidant behaviour of a particular 
situation, suggesting that this second latent trait may be a ‘phobic trait’. These 
findings are consistent with my knowledge that the set of items is made up of two 
questionnaires representing two anxiety subtypes. Not all variance could be 
explained by Factors 1 and 2 and it is unclear, based on the data available, what 
latent construct Factor 3 represents.  
 Question 12 ‘large open space’ and Question 17 ‘speaking or acting to an 
audience’ had the weakest internal consistency and will be excluded from my final 
item selection. This leaves 21 items to choose from.  
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Final selection of anxiety screening items for my RCT 
Based on the data analysis, I considered the remaining 21 questions to be 
eligible to be included in the final selection. I selected Question 3 ‘worrying too 
much about different things?’ from the GAD-7; Question 9 ‘walking alone in busy 
streets’ and Question 10, ‘going into crowded shops’ from the FQ-agoraphobia 
subscale; Question 15 ‘eating or drinking with other people’ from the FQ-social 
phobia subscale; Question 21 ‘any of your normal day-to-day activities for fear of 
having a headache’ from the specific phobia subscale to be the final anxiety 
screening items. In addition to these five items, I would add a free-text item, ‘what 
anxiety problem(s) are you experiencing?’ 
 
Discussion 
I performed this secondary analysis in order to derive five simple anxiety 
screening items suitable for use for eligibility screening for my RCT. My method 
combined a data-driven approach with clinical experience in assessing anxiety 
after stroke and TIA. The goal of this analysis was so that I could have a brief set 
of anxiety screening items that would be quick and easy to complete by potential 
participants. The selected items aimed to maximise inclusiveness of anxiety 
subtypes and of severity at trial recruitment. The additional free-text item hopes to 
capture any remaining anxious patients who respond negatively to the five 
selected items. 
This secondary analysis was performed in a small sample. The 
psychometric data could be chance findings and were only exploratory. Most of 
the items appeared to agree with the a priori impression that anxiety had two 
dimensions (generalised and phobic). I applied my clinical judgement in the final 




TASK (Treating Anxiety after StroKe) Intervention Development 
Publication status and acknowledgement of contributions 
I submitted this chapter as a supplementary file to the TASK trial protocol, 
which has been published in the August 2018 issue of Pilot and Feasibility 
Studies.  
My supervisors and I conceived the idea of designing a novel anxiety 
intervention that could be delivered remotely to stroke and TIA patients, one 
which would have the potential to overcome the barriers in accessing 
psychological therapy post-stroke. I followed this vision when designing the TASK 
intervention.  
I wrote and designed all the content of the TASK intervention, including 
the graphics, interactive online tasks, and all online multimedia content with 
comments from my supervisors.  
My colleagues Dr Gordon Blair and Dr Akila Visvanathan assisted at a 
patient advisor group meeting to co-produce the content of the TASK intervention. 
 My supervisors provided guidance in complex intervention development 
and patient involvement. I also attended a postgraduate course on ‘Developing 











It was clear to me, as I was conducting my research for Chapter 2 and 3, 
that the TASK intervention was going to be a psychological intervention adapted 
for stroke and TIA patients rather than a drug or single medical/ surgical 
procedure. A psychological intervention falls within the definition of a complex 
intervention (see below). I attended, as an auditing student, a postgraduate 
module of the Masters of Public Health on ‘Developing and Evaluating Complex 
Public Health Interventions’ at the Usher Institute. This course elaborated the 
well-known principles of the Medical Research council’s (MRC) framework for 
complex intervention development and evaluation (Figure 19). It provided me with 
a systematic, logical and evidence-based methodology in developing a complex 
intervention, known as the Six essential Steps in Quality Intervention 
Development (6SQuID).  
 
5.1.1 What is a complex intervention? 
The MRC guidance describes a complex intervention as one containing 
several interacting components, characterised by the following(124):  
 A number of interacting components within the experimental and control 
interventions 
 A number of behaviours required by those delivering or receiving the 
intervention 
 A number of groups or organisational levels targeted by the intervention 
 A number of and variability of outcomes 





5.1.2 MRC framework for complex intervention development and 
evaluation  
 
The MRC guidance states that the development of a complex intervention 
involves three key processes (Figure 19): 1) identifying existing evidence, 2) 
identifying and developing theory, and 3) modelling process and outcome(124).  
 
Figure 19. Key elements of the development and evaluation process in the MRC 
framework 
 
I obtained license to reuse this figure in my thesis from the BMJ Publishing 
Group, Ltd. (License number 4345361482437. License date 10 May, 2018) 
 
5.1.3 Six Steps in Quality Intervention Development  
6SQuID is a systematic, logical and evidence-based approach to 
developing complex intervention(125). It breaks down the intervention 
development process into six essential steps (Table 27), elaborating the MRC 
framework. 
In Chapter 1, I covered the relevant existing literature on anxiety in both 
general adults and people after stroke. My research in Chapters 2, 3 and 4 
generated new knowledge on the topic of anxiety after stroke and TIA. In this 
132 
 
chapter, I summarise briefly all of the work undertaken thus far, thereby laying the 
theoretical foundation for my TASK intervention.  
 
Table 27. The six essential steps in complex intervention development  
1. Define and understand the problem and its causes 
2. Clarify which causal or contextual factors are modifiable and have the 
greatest scope for change 
3. Identify how to bring about change: theory of change 
4. Identify how to deliver the change: theory of action 
5. Test and refine on a small scale 




5.2 TASK intervention development by 6SQuID 
5.2.1 Step 1: Define and understand the problem and its causes 
 
Epidemiology of anxiety after stroke 
There are more than 150,000 strokes per year, and 1.2 million stroke 
survivors in the UK(126). Anxiety affects a quarter of stroke patients, equivalent to 
around 25, 000 patients per year. Anxiety is associated with dependence, poorer 
quality of life and restricted participation in work and social activities after even 
mild stroke and TIA. Stroke and TIA patients can present with two main anxiety 
subtypes—phobic and generalised. I found phobic disorder to be the predominant 
anxiety subtype after stroke and TIA. Younger people and those with a previous 
history of anxiety or depression are more likely to develop anxiety after stroke. 
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Longitudinal data in stroke suggest that anxiety post-stroke could last up to 10 
years(58). When left untreated, anxiety disorder does not tend to resolve in non-
stroke populations.  
 
Assessment and treatment approaches for anxiety  
In non-stroke populations, systematic repeated hierarchical exposure 
therapy, i.e. confronting the feared situation in small gradual steps, is an effective 
treatment for phobic disorders(44, 45), and yet it has never been evaluated in 
stroke patients with anxiety(46). Medications e.g. SSRIs, benzodiazepines (in 
short term only) and cognitive therapy are effective treatments for GAD(49, 50). 
Currently, there is no definitive RCT evidence to guide treatment for 
anxiety after stroke. Anxiety assessment tools used in previous RCTs of stroke 
patients were measures of generalised anxiety, which may not detect individuals 
with phobic disorder. In Chapter 4, I demonstrated that GAD-7, a well-validated 
and reliable tool in primary care derived from the DSM-IV criteria for GAD, was 
also clinically useful for detecting GAD in a stroke and TIA sample. My study also 
provided some preliminary findings to support the clinical usefulness of the FQ-
agoraphobia subscale in stroke and TIA patients.  
 
Pathophysiology of anxiety 
The study of anxiety and its pathological forms, in humans and animals, 
supports a multifactorial aetiology of clinical anxiety disorders—the complex 
interplay of biological (genetic, physiological), psychological, behavioural and 
social (environmental) factors. Studies of classical conditioning—a learning 
behaviour, and of maladaptive thinking (cognitive) patterns helped establish the 
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theoretical basis for CBT, which has been the mainstay and a first-line treatment 
for a range of anxiety disorders in general adults, supported by RCT evidence.  
 
What provokes the maladaptive behaviour and maladaptive thinking 
patterns in stroke and TIA patients? 
 
Based on the findings from my prospective cohort and patient narratives, 
most stroke and TIA patients perceived stroke to be a sudden and potentially life-
threatening event that carried a high risk of recurrence. The finding that phobic 
disorder was predominant after stroke or TIA, and the high levels of avoidant 
behaviour in a range of defined situations amongst anxious patients suggested 
that fear conditioning could be a mechanism for anxiety after stroke and TIA. 
Narratives from my psychiatric interviews suggested that after a stroke or TIA 
event, some patients became conditioned to developing unpleasant anxious 
feelings and anxiety-provoking thinking in otherwise neutral situations, e.g. going 
out alone, taking the bus, going into a crowded shop, taking a shower, having a 
headache or ‘twinge’. The anxiety-provoking thinking pattern was usually related 
to events that could threaten their safety or health: ‘something bad, like a stroke, 
is going to happen to me’. The three anonymised interview extracts below help 
illustrate this. 
 
Extract 1, a 45 year-old woman after a posterior circulation 3 months ago with no 
residual neurological symptoms: 
‘I walked into a street that was very crowded. I felt I couldn’t breathe. I was 
sweating and my chest felt funny. I had tingling down my arms. 
I stepped out of the crowd and told myself to calm down.  
I didn’t want people to see me looking crazy! 
The same thing happened again in the supermarket. 
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I suddenly felt like something bad was going to happen. I just wanted to 
get out of the shop as quickly as possible. I left quickly and didn’t even 
finish paying for my shopping.  
I felt better once I got back to my car. I definitely don't go out as much as I 
used to anymore. 
I just felt something bad was going to happen, may be a stroke, or 
collapse, something like that.’ 
 
Extract 2, a 65 year-old man after a TIA 3 months ago: 
‘I had my TIA when I was having a shower. Since then I felt very anxious 
going into the shower. I would feel my heart pounding, breathless, 
nervous and panicky. It felt like I was having my TIA again, except there 
was no weakness down one side this time. I dread having a shower each 
day. My wife has to be in the bathroom while I shower very quickly. Even 
then I still feel very anxious. I just can’t help feeling this way.’ 
 
Extract 3, a 69 year-old lady after a lacunar stroke 3 months ago with mild 
residual left arm weakness: 
‘I couldn't get on the bus after my stroke. It was so bizarre!  
I used to take the bus everywhere without any problems.  
The first time I tried since my stroke, I felt so frightened at the bus stop 
that I left the bus stop without getting on the bus! I worried about 
something happening, like a stroke, or I could fall on the bus.’ 
 
Other anxious patients expressed a fear of having to interact with people 
socially. They would find it distressing when other people enquired about their 
illness, or noticed their deficits. They feared these situations to the extent that 
they would avoid social gatherings or interactions with family, friends and 




Extract 4, a 42 year-old man, lacunar stroke 3 months ago with no residual 
neurological symptoms: 
 
‘I just wanted to be at home alone. I didn't want to see anybody, not even 
my friends.  
I felt like I was being judged when people looked at me and I hated it! 
When people were looking at me I would start to panic.  
When people saw me getting nervous it just made me panic even more! 
Once, I found myself looking to the ground, avoiding eye contact when I 
was talking to a potential client for some building works. I was worried that 
I was coming across as stupid, and the client would not give me the job. 
This was not like me at all. I used to be very confident before my stroke.’  
 
Many anxious patients did not understand why they had become anxious 
in everyday situations. They reported anxiety or panic feelings in these situations. 
The anxiety feelings were so unpleasant that they avoided these situations to the 
extent that their day-to-day life was affected. 
The predominant thinking pattern amongst anxious individuals was fear of 
having another stroke, or other similarly dangerous or embarrassing mishaps e.g. 
falls, collapse, looking odd or stupid. I found many of the anxious individuals to 
perceive their risk of stroke to be far higher than the realistic risk of stroke 
recurrence in the long-term. They selectively paid more attention to the stimuli 
and situations e.g. odd sensations, headaches, physical exertion, going out 
alone, which they thought were associated with a risk of stroke or other 
dangerous mishaps. These stimuli further perpetuated their anxiety feelings (both 
affective and physiological) which reinforced their belief that these stimuli/ 
situations represented danger. Their avoidant behaviour was safety-seeking. 
These patients fitted well in the cognitive model described by Aaron Beck(47). 
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Maladaptive avoidant behaviours and unhelpful thinking patterns are the potential 
targets for my TASK intervention. 
 
5.2.2 Step 2: Clarify which causal or contextual factors are modifiable 
and have the greatest scope for change 
 
My 6SQUID Step 1 suggested that maladaptive avoidance and thinking 
patterns (e.g. exaggerated risk of stroke recurrence) were frequently reported in 
people with anxiety post-stroke or TIA and so could be targeted by CBT. 
Considering the existing RCT evidence on CBT’s effectiveness in treating anxiety 
in non-stroke populations, adapting CBT approaches should offer the greatest 
scope for change in my TASK intervention. Medication (e.g. antidepressant) is 
also an evidence-based treatment for GAD. While my TASK trial will not include a 
pharmacological component, it would be possible to include a component in my 
TASK intervention that tells participants about medication being a possible helpful 
adjunct, and that should they wish to take this option, they should have a 
discussion with their general practitioner.  
 
5.2.3 Step 3: Theory of change  
Aside from maladaptive avoidance and thinking patterns, there are many 
other potential factors, theoretical or evidence-supported, which may contribute to 
anxiety after stroke. Younger age and a previous history of anxiety and 
depression are the most consistent predictors for anxiety after stroke/TIA. A 
systematic review did not find sufficient evidence to support any association with 
potentially modifiable psychological factors such as locus of control, coping style 
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or confidence, which have been implicated in anxiety in other disease populations 
e.g. multiple sclerosis(106, 127). 
I summarized a list of potential contributory factors to anxiety after stroke 
in a ‘theory of change’ diagram, highlighting in red, factors that my TASK 
intervention hopes to address (Figure 20).  
 
 Figure 20. Theory of change in anxiety after stroke
 
  
5.2.4 Step 4: Theory of action 
The theory of action in Step 4 of the 6SQUID emphasises that 
researchers must think about what resources or assets are available, what is 
feasible, and what is acceptable and ethical in the given context when designing 
a complex intervention. Failure to consider this step early in intervention 
development could lead to a waste of resources and costly evaluation of an 




Feasibility of delivering CBT post-stroke 
In conventional CBT, a therapist delivers a course of face-to-face 
psychotherapy sessions of varying length between 6 weeks to 6 months. CBT is 
structured, time-limited, and goal orientated. Patient and therapist work 
collaboratively towards a defined goal by working through the key components of 
CBT: i) identify maladaptive thinking and behaviours, ii) self-monitoring, iii) 
psychoeducation, iv) cognitive restructuring, v) exposure techniques, vi) specific 
skills training (varies depending on patient’s needs e.g. problem solving, time 
management), and vii) ongoing self-management(128). Delivering CBT in a 
conventional format requires highly trained psychotherapists and repeated clinic 
attendance.  
A ‘theory of action’ is required to find a feasible way to deliver the ‘active 
ingredients’ of CBT to anxious stroke and TIA patients. I summarize the current 
context of psychological care post-stroke in the UK, and ways in which key 
stakeholders’ input has helped me determine the final design of the TASK 
intervention.  
 
Barriers in accessing psychological care post-stroke 
Inadequate service provision in psychological care and the lack of routine 
screening in stroke units and primary care post-stroke across the United Kingdom 
are evident from the reports of the Sentinel Stroke National Audit Programme in 
England, Wales and Northern Ireland(129) and the latest Royal College of 
Physicians Stoke Guideline(130). The Scottish Stroke Improvement Programme 
highlighted access to psychological care as a priority area for improvement in 
2017(131). The demand for better access to psychological care post-stroke has 
consistently been echoed by surveys and qualitative research of patients, carers 
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and health professionals, and through charitable organisations representing 
stroke patients(132-134). Delivering CBT in a conventional face-to-face format to 
all patients with anxiety post-stroke/TIA is not feasible in clinical practice given the 
high prevalence of anxiety and other common post-stroke neuropsychiatric 
complications in this population and limited resources. It is estimated that at least 
50% of stroke patients will suffer from depression, anxiety, cognitive impairments 
that would require psychological support(129). Our stakeholder activity involving 
the clinical leads of stroke and clinical psychology services from across Scotland 
agreed that this demand was unlikely to be met by primary care providers alone, 
nor the traditional paradigm of referring patients for face-to-face psychotherapy 
delivered by highly-trained specialists. 
 
5.2.4.1 Stakeholders input I: Clinical leads  
The Scottish Government’s Stroke Improvement Plan in 2017 set a priority 
to improve post-stroke access to clinical psychology services. The lead of this 
programme organised a workshop in September 2017, which was attended by 
the local leads of stroke clinical psychology services from across Scotland and 
the chair of Scottish Stroke Care Audit, Professor Martin Dennis, who was also 
my supervisor. I attended this meeting as an invited speaker. The workshop 
aimed to address ways of improving access to psychological support post-stroke. 
Everyone in attendance agreed that psychological care had to be provided to a 
large population of stroke patients who needed it—a quarter of stroke patients 
with anxiety was equal to an estimated 2000 to 3000 patients per year in Scotland 
(131). The shortage and geographical variation in the supply of highly trained 
psychotherapists in Scotland were evident from the local service evaluations 
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presented at the meeting. These were unlikely to be resolved in the foreseeable 
future within the NHS.  
The stepped care model of psychological care, one that has been 
advocated by the NHS and the Royal College of Physicians Stroke Guideline, 
was considered the most feasible model to provide psychological care post-stroke 
(135, 136). In this model, an allied health professional with stroke experience e.g. 
stroke nurse would deliver a low-intensity psychological intervention within the 
lower levels (Level 1 and 2) of this stepped care model while receiving 
appropriate supervision by a specialist e.g. a consultant clinical psychologist or 
psychiatrist. This stepped care model was considered a feasible option. Severe or 
refractory cases would be escalated to the top level of this stepped care model 
(Level 3) to receive a high-intensity psychological intervention from a specialist.  
Other potential barriers to accessing psychological therapy were 
discussed at this meeting. These included the inability to attend face-to-face 
appointments due to physical immobility and social stigma attached to seeking 
psychological treatment. Reluctance to travel in agoraphobia and the fear of 
being judged in social phobia are diagnosis-specific barriers to attending face-to-
face sessions. People with social phobia symptoms were three times more likely 
to report a fear of what others might think or say about them if they sought 
psychological treatment compared to people with other anxiety disorders(137). 
 
Conclusion from Stakeholder input I: 
Based on the above, I considered modifying the conventional CBT format, 
repackaging its ‘active ingredients’ in a way that would enable the intervention to 
be delivered entirely remotely by an appropriate allied health professional—in 
other words, a remote guided self-help CBT-based intervention.  
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Next, I carried out patient involvement in the second part of the 
stakeholder input for TASK in order to assess the acceptability of a remote 
treatment model and to co-produce my TASK intervention content.  
 
5.2.4.2 Stakeholder input II: Patient involvement  
Aim:  
To involve stroke patients who have experienced anxiety after stroke in 
order to co-produce the TASK intervention and design of the TASK RCT. 
Methods: 
I) A quantitative survey of patients on anxiety intervention design and 
mode of delivery 
II) A patient advisory group (PAG) meeting to co-produce the content and 
treatment materials 
 
I) A quantitative survey on intervention design and delivery 
This was done as part of my prospective cohort study. At the end of the 
telephone SCID interviews I invited participants who reported anxiety problems to 
take part in this additional survey. 27 out of 49 invited participants were able to 
complete this survey. The remainder declined due to the feelings of tiredness and 
inability to continue with more questioning. 
I administered nine-questions with set responses to choose from, on 







Table 28. A survey of patients on anxiety intervention design and mode of 
delivery 
If we were going to give you a treatment program to help with your 
anxiety…… 
 
 Choice of responses 
1) Would you prefer having it with 
or without guidance? 
 
‘prefer with guidance’ 
‘prefer self-help with no guidance’ 
 





‘don’t mind—either or both is fine’ 
‘none’ 
 
3) Would you find it acceptable to 
use online resources/ materials as 




4) Would you find it acceptable to 





5) Are you able to use the Internet?  
 
‘yes’ 
‘yes with help’ 
‘no’ 
 
6) Would you accept having family 












8) How often would you like to be 
contacted?  
‘once per week’ 
‘once every two weeks’ 
‘once every three weeks’ 
‘no contact at all’ 
 
9) When should the treatment 
program start? 
 
‘within first month’ 
‘within first two months’ 







II) A PAG meeting to co-design the content and treatment materials 
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The objective of this PAG meeting was for me to hear the perspectives of 
patients who experienced anxiety after stroke and to learn what they wished to 
include as part of the TASK intervention.  
 
Selection of patients for the PAG 
I contacted participants from my prospective cohort study who were 
anxious and also consented to be contacted again for future involvement in the 
design of my anxiety intervention. The local South East Scotland Research Ethics 
Office agreed that the proposed meeting was considered patient involvement 
activity so would not require further ethical review. I selected those who were 
anxious in order to maximize the relevance of their perspectives in the design of 
my TASK intervention. I sent a letter of invitation along with an event programme 
to ten people, followed by a telephone call the following week. Eight people 
confirmed intention to attend but only three turned up on the day of the meeting.  
 
Structure and topic for the PAG 
I referred to the ‘INVOLVE Briefing notes for researchers: public 
involvement in NHS, public health and social care research’ published by the 
National Institute for Health Research(138) and the guidance at a workshop—‘A  
Practical Guide to Patient and Public Involvement in Research’ at the Wellcome 
Trust Clinical Research Facility in Edinburgh in September 2015. I used a set of 
PowerPoint slides to guide the patient advisors through the PAG meeting. There 





Table 29. Topics and prompts for open discussions at the Patient Advisors Group 
meeting 
First open discussion (40minutes) 
 




What were your anxiety, worries or fear after your stroke? 
 
What help or support, if any, did you receive? 
 
What would you have wanted from the stroke service? 
 
Second open discussion (30minutes) 
 
Topic: Treatment content and design of treatment materials 
This discussion follows a review of existing resources e.g. leaflets, booklets, 




What are your initial thoughts about these materials? 
 
What recommendations do you have for designing the materials for 
anxiety after stroke? 
 
What messages do you think are most effective? Least effective? 
 
 
Third open discussion (10minutes) 
 




What makes people drop out of a clinical trial? 
 
What can we do to encourage people to: 
 
complete trial treatment?  
 










I chaired the PAG meeting and acted as the facilitator for the open 
discussions. Two other researchers assisted at the event. One scribed and audio-
recorded the open discussions on a digital recorder.  Professor Gillian Mead was 
present at the meeting. 
 
Consent to audio-recording, photography and publication of narrative 
All patient advisors gave verbal consent to have their discussions audio-
recorded and photographs taken. All consented to the publication of their 
narratives anonymously. 
 
The PAG reviewed the following stroke resources:  
 ‘Feeling overwhelmed—the emotional impact of stroke’, a booklet 
published by the Stroke Association’s ‘Life After Stroke Campaign’ in 
the Summer, 2013(134) 
 ‘Living with stress and anxiety’ leaflet F23, September 2013, by Chest 
Heart & Stroke Scotland(139). 
 A selection of leaflets and booklets by Chest Heart stroke Scotland 
(CHSS) on other issues e.g. air travel, sex after stroke illness, thinking 
and behaviour issues after stroke, stroke in younger people  
 ‘Stroke workbook’, a supported self-management programme 
published by Lothian Health Board, 2011(140) 
 Self-help for stroke website http://selfhelp4stroke.org/, developed by 
CHSS, in partnership with NHS Scotland, the University of Edinburgh 





I) Quantitative survey of 27 patients with anxiety disorder  
The survey results (Figure 21) showed an overwhelming preference (24/27, 
89%) for a guided intervention rather than unguided self-help. Most preferred 
having treatment at home or had no preference (21/27, 78%); Two thirds did not 
mind whether the intervention was delivered face-to-face or by telephone (18/27, 
66%). Over two thirds found it acceptable to use online materials as part of the 
intervention (17/27, 63%). Over two thirds were capable of using the Internet with 
or without help (20/27, 70%).   
 
Figure 21. Quantitative survey of 27 patients with anxiety disorder 
 
 
1) Would you prefer to have it with or without guidance (n) 
 
With guidance (24) 
Without  (3) 
 
 
2) How would you like to receive the guidance? 
Either face-to-face 
or telephone (18) 
Face-to-face (6) 
Telephone (2) 
No contact (1) 
 
 3) Would you find it acceptable to use online resources/ materials as part 






























Yes with help (2) 
 
6) Would you accept having family involved in your treatment? 
 
Yes (12) 
No  (12) 
Maybe (3) 
 
7) Where would you prefer having your treatment? 
 
Home (13) 





8) How often would you like to be contacted? 
 
Once every 3 weeks 
(12) 
Once per week (8) 
Once every 2 weeks 
(6) 
No contact at all (1) 
 
9) When should treatment program begin? 
Within the first month 
of stroke (25) 
Within first 2 
months(2)  




II) Patient involvement in developing TASK intervention 
I extracted the relevant narratives from my patient advisors for each question 
(Table 30). To summarise, the fear of ‘completely losing control in a public place 
in case of another stroke’ was the most frightening thought for all of my patient 
advisors. They feared for not only their own safety, but also how other people 
would react to them losing control of their body or speech. In addition, the 



















pains, accompanied by the uncertainty of whether these symptoms represented 
stroke recurrence provoked a great deal of anxiety in our patient advisors.  
 
Table 30. Narrative extracts from the PAG 





What were your anxiety, 





































Patient Advisor 1 (age 73) 
 
“It was a total shock for me. I just didn’t understand 
why I got a stroke when I was the fit one. My first 
anxiety was that it was going to happen again” 
 
“I was afraid to go out for some time. I had this 
horrible vision that something awful would happen 
to me if I took the train” 
 
“It took me a long time even to get on the bus to 
visit my daughter. I was afraid of something 
happening.” 
 
“My daughter was getting married not long after my 
stroke so I knew I had to turn up. So I did it and 
that was that!” 
 
“I thought to myself I could either sit here or get a 
grip. I told myself not to be silly”  
 
Patient Advisor 2 (age 72) 
 
“The anxiety was about leaving the house. The 
first six weeks was very difficult. When I took the 
bus or drove my car I just wanted to get back 
home.” 
 
“A flash in the head would make me wonder—oops 
is there something wrong?” 
 
“It took a lot of effort. It took about 6 weeks before I 
could do a trip to London and to stay overnight. I 
had to work quite hard to persuade myself that I 
had to do it. I succeeded and so just got on with it.” 
 
 “I think we were all (Patient advisors 1 and 3 
agreed) dreading the thought of being caught ill in 
a public place, and the total loss of control. That is 









What help or support, if 



























What would you have 

















“Living alone meant that one just had to get on with 
it! No choice in the matter. I still got work to do. No 
point sitting here twiddling my fingers. Forget 
yesterday and think about tomorrow.” 
 
Patient Advisor 3 (age 62) 
“I was still very wobbly on my feet. I had other 
medical problems already and the stroke was 
another thing to add to my list.” 
 
Patient Advisor 1: 
“I did not receive any help. Nobody asked me how 
I was.” 
 
Patient Advisor 2: 
 
“I was visited by the Chest Heart Stroke Scotland 
community nurse at home. I didn’t think it would be 
of any use initially, but he turned out to be 
excellent. I found him extremely helpful. He gave 
me a lot of information. We chatted for an hour. He 
offered contact details in case I needed anything”   
 
“I was pleased my GP surgery asked me to have 
my blood pressure checked quarterly”  
 
Patient Advisor 3:  
 
“I found the biggest support was by going to the 
community stroke service (Craighall)”  
 
“I found being amongst other people in the same 
situation really helped, to know that I was not odd.” 
 
 “It was easier to talk to strangers who had similar 
experience than talking about it at home.” 
 
“They gave me confidence to try things”  
 
Patient Advisor 1: 
 
“I was just told everything was going to be fine but 
of course that was not the case.” 
 















Further comments on 





Patient advisor 2: 
 
“it’s surprising that there is no follow-up after a 
stroke…while there was follow-up for my heart 
attack and after my hip operation” 
 
 
Patient advisor 3: 
 
“I would have liked some information on what 
services would be available after discharge?” 
 
“I only stumbled upon the stroke community centre 
by accident” 
 
Patient advisor 1 
“being told not to worry is not terribly helpful” 
 
Patient advisor 2 
 
“you have got to have something in place, have a 
list of emergency numbers in your wallet, and on 
your desk at home (if you live alone)” 
 
“I never leave my house without my mobile phone 
in my pocket” 
 
“for people who live alone, I would recommend a 
pendant alarm (pointing at his) and a note with 
emergency contact details”  
 
“A patient group will not work for me but it does for 





Discussion 2: Treatment content and design of treatment materials 
This discussion follows a review of existing resources e.g. leaflets, booklets, 





What are your initial 




do you have for designing 
Referring to the Stroke Association’s ‘Feeling 
overwhelmed’ booklet  
 
Patient advisor 2 
 “this is excellent and it is most interesting reading 
about other people’s experiences” 
 
Patient advisor 3 
“It is very valuable to learn from other people’s 
experiences and how stroke affects other people. It 
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the materials for anxiety 
after stroke? 
 
What messages do you 




makes me less afraid to talk about things that I 
would otherwise tend to shy away from…” 
 
Referring to information leaflets and website 
 
Patient advisor 1 
 
“I would like information explaining this (stroke) is 
what happened to you, we don’t know what caused 
it but these are the things that could help”  
 
“Acknowledging uncertainty is important” 
 
“I like the use of pictures—it’s a way of learning 
things. Also the use of boxes—can really grab 
attention” 
 
“there is so much on the Internet, it’s hard to know 
what is reliable” 
 
Patient advisor 2 
 
“I would highlight these particular sentences in a 
different colour—learn how to recognise anxiety 
symptoms, you may often mistake your 
symptoms for illness….this was absolutely key to 
what my symptoms were (I had odd sensations, 
headache)” 
 
“The busier you are the better. When I was busy I 
never noticed any of these symptoms”  
 
“it was important to keep myself both mentally and 
physically active” 
 
Patient advisor 3 
 
“any information is valuable” 
  
“I also found some exercises from a website to 
help with my balance” 
 
Referring to the Stroke Workbook  
 
Patient advisor 1 
 
“Wouldn’t work at all for me. I already have the 
answers to what’s in the book.  It is not going to 
alleviate any stress I have. I need something to 
banish what’s on my mind—the thoughts that 




Patient advisor 3 
 
“I personally quite like reading this. I like the 
pictures. It is an easy way for me to learn things” 
 




“Language needs to be simple and non-
patronising” 
 
“A book with too much text makes people think 
they have to sit down properly to read it. With 
leaflets, you can just pick it up to have a read.” 
 
“need positivity all the way through, try to get 
people with anxiety to think about what is stopping 
them from returning to their activities, then get 
them to think about how they used to enjoy these 
activities, and the positive things that came out of 
it” 
 
“for people who avoid social situations—it may 
help to tell other people that you have had a 









What makes people drop 




What can we do to 
encourage people to: 
 








Patient advisor 3: 
 
“people are always more enthusiastic at the 
beginning” 
 
Patient advisor 1: 
 
“there could be so many reasons, you’d probably 
have to ask the people who did not turn up to this 
meeting today and ask them why in a non-
confrontational manner” 
 
Patient advisor 1: 
 
“establish people’s expectations—often our 
expectations are very high for the trial treatment” 
 
“make us feel like we are all involved in the trial, 




“make people realise there is an end goal—we 
want to know the results of any research we take 
part in” 
 
“tell us how our participation helps contribute to 
developing better treatment/care for other people, 
and how you will use this research” 
 
“emphasize on our participation and our 
involvement in the research instead of using the 
words like ‘treatment’ or ‘intervention’--feels like 
something is being done to you” 
 
Patient advisor 2: 
 
“incentivise people by explaining that there will be 
something valuable yielded at the end. I was 
personally very fascinated to see the paper at the 
end of this cardiac MRI study I took part in” 





What were your anxiety, 

























Patient Advisor 1 (age 73) 
 
“It was a total shock for me. I just didn’t understand 
why I got a stroke when I was the fit one. My first 
anxiety was that it was going to happen again” 
 
“I was afraid to go out for some time. I had this 
horrible vision that something awful would happen 
to me if I took the train” 
 
“It took me a long time even to get on the bus to 
visit my daughter. I was afraid of something 
happening.” 
 
“My daughter was getting married not long after my 
stroke so I knew I had to turn up. So I did it and 
that was that!” 
 
“I thought to myself I could either sit here or get a 
grip. I told myself not to be silly”  
 
Patient Advisor 2 (age 72) 
 
“The anxiety was about leaving the house. The 
first six weeks were very difficult. When I took the 






















What help or support, if 



























What would you have 





“A flash in the head would make me wonder—oops 
is there something wrong?” 
 
“It took a lot of effort. It took about 6 weeks before I 
could do a trip to London and to stay overnight. I 
had to work quite hard to persuade myself that I 
had to do it. I succeeded and so just got on with it.” 
 
 “I think we were all (Patient advisors 1 and 3 
agreed) dreading the thought of being caught ill in 
a public place, and the total loss of control. That is 
the greatest fear of all.”  
 
“Living alone meant that one just had to get on with 
it! No choice in the matter, still got work to do. No 
point sitting here twiddling my fingers. Forget 
yesterday and think about tomorrow.” 
 
Patient Advisor 3 (age 62) 
“I was still very wobbly on my feet. I had other 
medical problems already and the stroke was 
another thing to add to my list.” 
Patient Advisor 1: 
“I did not receive any help. Nobody asked me how 
I was.” 
 
Patient Advisor 2: 
 
“I was visited by the Chest Heart Stroke Scotland 
community nurse at home. I didn’t think it would be 
of any use initially, but he turned out to be 
excellent. I found him extremely helpful. He gave 
me a lot of information. We chatted for an hour. He 
offered contact details in case I needed anything”   
 
“I was pleased my GP surgery asked me to have 
my blood pressure checked quarterly”  
 
Patient Advisor 3:  
 
“I found the biggest support was by going to the 
community stroke service (Craighall)”  
 
“I found being amongst other people in the same 
situation really helped, to know that I was not odd.” 
 
 “It was easier to talk to strangers who had similar 
experience than talking about it at home.” 
 






















Further comments on 






Patient Advisor 1: 
 
“I was just told everything was going to be fine but 
of course that was not the case.” 
 
“I would have liked more information given to me 
after discharge” 
 
Patient advisor 2: 
 
“it’s surprising that there is no follow-up after a 
stroke…while there was follow-up for my heart 
attack and after my hip operation” 
 
 
Patient advisor 3: 
 
“I would have liked some information on what 
services would be available after discharge?” 
 
“I only stumbled upon the stroke community centre 
by accident” 
Patient advisor 1 
 
“being told not to worry is not terribly helpful” 
 
Patient advisor 2 
 
“you have got to have something in place, have a 
list of emergency numbers in your wallet, and on 
your desk at home (if you live alone)” 
 
“I never leave my house without my mobile phone 
in my pocket” 
 
“for people who live alone, I would recommend a 
pendant alarm (pointing at his) and a note with 
emergency contact details”  
 
“A patient group will not work for me but it does for 






Discussion 2: Treatment content and design of treatment materials 
This discussion follows a review of existing resources e.g. leaflets, booklets, 







What are your initial 




do you have for designing 
the materials for anxiety 
after stroke? 
 
What messages do you 




Referring to the Stroke Association’s ‘Feeling 
overwhelmed’ booklet  
 
Patient advisor 2 
 “this is excellent and it is most interesting reading 
about other people’s experiences” 
 
Patient advisor 3 
“It is very valuable to learn from other people’s 
experiences and how stroke affects other people. It 
makes me less afraid to talk about things that I 
would otherwise tend to shy away from…” 
 
Referring to information leaflets and website 
 
Patient advisor 1 
 
“I would like information explaining this (stroke) is 
what happened to you, we don’t know what caused 
it but these are the things that could help”  
 
“Acknowledging uncertainty is important” 
 
“I like the use of pictures—it’s a way of learning 
things. Also the use of boxes—can really grab 
attention” 
“there is so much on the Internet, it’s hard to know 
what is reliable” 
 
Patient advisor 2 
 
“I would highlight these particular sentences in a 
different colour—learn how to recognise anxiety 
symptoms, you may often mistake your 
symptoms for illness….this was absolutely key to 
what my symptoms were (I had odd sensations, 
headache)” 
 
“The busier you are the better. When I was busy I 
never noticed any of these symptoms”  
 
“it was important to keep myself both mentally and 
physically active” 
 
Patient advisor 3 
 
“any information is valuable” 
  
“I also found some exercises from a website to 




Referring to the Stroke Workbook  
 
Patient advisor 1 
 
“Wouldn’t work at all for me. I already have the 
answers to what’s in the book.  It is not going to 
alleviate any stress I have. I need something to 
banish what’s on my mind—the thoughts that 
things are going to happen to me again” 
 
Patient advisor 3 
 
“I personally quite like reading this. I like the 
pictures. It is an easy way for me to learn things” 
 




“Language needs to be simple and unpatronising” 
 
“A book with too much text makes people think 
they have to sit down properly to read it. With 
leaflets, you can just pick it up to have a read.” 
 
“need positivity all the way through, try to get 
people with anxiety to think about what is stopping 
them from returning to their activities, then get 
them to think about how they used to enjoy these 
activities, and the positive things that came out of 
it” 
 
“for people who avoid social situations—it may 
help to tell other people that you have had a 









What makes people drop 




What can we do to 
encourage people to: 
 
Patient advisor 3: 
 
“people are always more enthusiastic at the 
beginning” 
 
Patient advisor 1: 
 
“there could be so many reasons, you’d probably 
have to ask the people who did not turn up to this 













Patient advisor 1: 
 
“establish people’s expectations—often our 
expectations are very high for the trial treatment” 
 
“make us feel like we are all involved in the trial, 
and not just merely finishing a trial treatment” 
 
“make people realise there is an end goal—we 
want to know the results of any research we take 
part in” 
 
“tell us how our participation helps contribute to 
developing better treatment/care for other people, 
and how you will use this research” 
 
“emphasize on our participation and our 
involvement in the research instead of using the 
words like ‘treatment’ or ‘intervention’--feels like 
something is being done to you” 
 
Patient advisor 2: 
 
“incentivise people by explaining that there will be 
something valuable yielded at the end. I was 
personally very fascinated to see the paper at the 
end of this cardiac MRI study I took part in” 
 
Qualitative evidence 
In addition to patient involvement work, systematic reviews of qualitative 
research(141-143) conducted independently of my work complemented my 
research findings. Patients and carers expressed themes and gave narratives 
about the fear of stroke recurrence(141), insecurity about going out and going on 
the bus(142), fear of falling(144), and the feeling of body not under own 
control(141).  
 
Patients’ co-production of TASK intervention 
To take into account of the patient perspectives and to co-produce the 
TASK intervention with my patient advisors, I plan to include patient stories in my 
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TASK intervention, and to place emphasis on the specific topics of agoraphobia, 
fear of losing control, bodily symptoms, and fear of stroke recurrence. I also plan 
to include a component that reminds patients to schedule an enjoyable activity to 
do regularly.  
 
5.2.5 Modelling processes and outcomes of the TASK intervention 
I conclude my TASK intervention development in a logic model diagram 
(Figure 22), which displays all the processes and outcomes of the TASK 
intervention—an essential step in the MRC framework of intervention 
development. This diagram encompasses the program theory (theory of change 
and theory of action), the final hypothesised model of the processes, the intended 
outcomes, and the mediators of the intended outcomes of my TASK intervention.  
 
5.2.6 TASK intervention content 
As my TASK intervention is a guided self-help CBT intervention, it will be 
referred to as the TASK-CBT intervention hereafter. I summarise the key features 
and the intended advantages of my TASK-CBT intervention. 
 
Centralised delivery by telemedicine 
In line with the views of the stakeholders, I designed my TASK-CBT 
intervention to be delivered by an appropriately trained health professional with 
experience working with stroke patients e.g. stroke nurse, stroke physician, stroke 
rehabilitation therapists under supervision of a specialist e.g. psychiatrist or 
clinical psychologist. The TASK-CBT intervention represents a low-level 
psychological intervention (steps 1 and 2) in the stepped care model(52).  
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Delivering CBT remotely via telemedicine would enable centralization of 
resources for staff, training, quality monitoring, and cross covering of different 
geographical areas, reducing travel time for therapists as well as patients. Digital 
content and treatment approaches in a telemedicine intervention could be 
updated and refined easily, thus making use of the latest best evidence. The 
provision, maintenance and updating of digital content could be commissioned or 
delivered via charitable organisations. Organisation delivering the intervention 
can continue to invest in research and development to utilise the latest 
technology to deliver the treatment content at lower costs.  At present, it is not yet 






Figure 22. Modelling processes and outcomes of TASK-CBT 
Inputs/ Resources Potential activities/ materials Theoretical mediators 
of outcomes 
Intended Outcomes 
Short term         Long term Key stakeholders 
Scottish Government’s Stroke  
Improvement Programme 2017 
 
Stroke clinical leads: national and local 
 
Service leads in clinical psychology  
 
Patients with anxiety post-stroke/TIA  
 -Survey on mode of delivery 
 -Patient advisors 
  
 
Organisational (Health Service) 
- Centralised delivery 
- Individualised, guided CBT-based intervention 
- Delivery via telemedicine (telephone, web, email, 
mobile text) 
- Non-specialist stroke health professional as 
therapist 
- Stepped-care model to deliver psychological care 
 
Eligible patients can 
access TASK 
intervention remotely 
Improve access to 
psychological therapy 
for stroke and TIA 
population 
Overcome shortage of 





- Time limited, goal orientated, individualised guided 
CBT-based therapy 
- 6 telephone therapy sessions + online multimedia 
psychoeducational content 
- Online tasks to practice CBT skills 
- Text and email reminders 
- Ongoing access to treatment website for self-
management 
To promote adherence & intervention fidelity 
- Weekly text reminders to patient’s mobile phone 
- Participant record card 
- TASK Therapist’s Manual and Record   
-  
To assess intervention fidelity 
- Validate Therapist’s Record with audio-recording 
of telephone sessions 
- Electronic capture of online task completion 
- Web usage analytics  
Prospective cohort study at 3 
months post-stroke/TIA 
- anxiety subtypes 
- avoidant behaviour 
- maladaptive thinking 
 
Systematic reviews 
- Anxiety interventions in stroke 
and acquired brain injury 
 
- Anxiety interventions in general 
adults 
 
- Observational studies of anxiety 




- Narratives of anxious patients in 
prospective cohort 
 
- Patient advisors’ involvement 
 
- Qualitative research 
(independent of our research) 
 
 
Assumptions: patients can communicate on telephone; has 
internet access; patients have returned to community  
Individualised therapist-
patient alliance is maintained 
Exposure therapy reduces 
maladaptive avoidant 
behaviour and unpleasant 
anxiety feelings 
Cognitive restructuring 
corrects maladaptive thinking 
patterns e.g. exaggerated 
risk of stroke recurrence, 
catastrophic thinking 
Relaxation techniques to 
overcome autonomic 
hyperarousal, used in 
conjunction with exposure 
therapy 
Encourage positive thinking 
and actions 
Encourage ongoing self-
management of anxiety long-
term 
Relieve unpleasant 











anxiety using CBT 
skills learnt 






Maintaining an individualised patient-therapist alliance 
Telemedicine could offer a way to overcome the barriers in accessing 
psychological therapy by treating patients remotely while maintaining an 
individualised therapist-patient alliance that is integral to CBT. Meta-analyses 
demonstrated guided internet-based CBT to be superior to waitlist control, and as 
efficacious as face-to-face CBT in treating anxiety disorders or depression in 
general adults, with face-to-face CBT spending 7 times more therapist time than 
guided internet-based CBT(54, 55). It is not yet certain whether these findings 
could be generalised to stroke and TIA patients, who tend to be older, have 
neurological deficits, and medical co-morbidities. The effect of such interventions 
on patient outcomes after stroke/TIA need to be evaluated in RCTs. To-date, 
RCTs of guided internet-delivered CBT for anxiety and depressive disorder in 
general adults have shown good patient adherence and satisfaction(54, 55). 
 
Delivery of ‘active ingredients’ of TASK-CBT by telephone and web 
I present the key ‘active ingredients’ of my TASK-CBT intervention in 
Figure 23. The TASK therapist delivers a course of six individualized telephone 
CBT sessions, 35-45 minutes each, at least one week apart, with the use of an 
electronic TASK Therapist’s Manual and Record. Each session is supplemented 
by the prescription of an online task, and one or more of the psychoeducational 
videos on the TASK-CBT treatment website (Figure 24). To encourage 
adherence, a mobile text is sent to remind participant to complete the online task 
each week and to use the treatment website as much as possible via a computer, 
tablet or smartphone. This concludes the design of my TASK-CBT, a prototype 
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anxiety intervention for treating anxiety after stroke and TIA. Next chapter details 
the feasibility testing of the TASK-CBT intervention, step 5 of 6SQuID. 
 
Figure 23. ‘Active ingredients’ of my TASK-CBT intervention 
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Treating Anxiety after StroKe (TASK): Feasibility Phase of a Novel 
Streamlined Web-enabled RCT 
 
Publication status and acknowledgement of contributions 
This chapter contains the TASK trial protocol, which has been published in 
the August 2018 issue of Pilot and Feasibility Studies (Appendix C).  
My supervisors provided the vision of designing an efficient streamlined 
trial, one that could be conducted centrally and remotely. We held numerous 
discussions on all aspects of the TASK trial design. I followed our shared vision 
and designed all of the innovative trial procedures.  
I led the TASK trial as the chief investigator and produced all trial-related 
documents and materials with comments from my supervisors. I carried out all of 
the TASK trial procedures. Professor Alan Carson provided training and 
supervision of my TASK-CBT telephone sessions. 
Our collaborator, Surgical Informatics at the Centre for Medical 
Informatics, Usher Institute granted me access to the Research Electronic Data 
Capture (REDCap) application.  
I obtained extra funding from the Royal College of Physicians of 
Edinburgh for a smartwatch wearable sub study to be embedded within the TASK 
RCT. I designed this sub study and will be working in collaboration with Dr 
Thanasis Tsanas, a data scientist at the Centre for Medical Informatics on the 







My TASK-CBT needs to be tested for feasibility on a small scale to enable 
further refinements prior to its definitive evaluation in a large-scale RCT. This 
represents the fifth step of the 6SQUID methodology. I will be able to identify first 
hand, the practical problems that may arise in delivering TASK-CBT down to the 
smallest detail.  
The use of telemedicine to deliver TASK-CBT generated a unique 
opportunity for me to design my own RCT, a rarely afforded experience to a 
doctoral student researcher. Following numerous discussions with my 
supervisors, who had vast experience in conducting multicentre RCTs, we 
envisioned the current TASK trial to be:  
 as close to the eventual design of the definitive RCT as possible 
 efficient, with innovative solutions to overcome the challenges faced 
by clinical trialists in conducting large-scale RCTs 
 of a high quality design with minimal bias 
This trial represents my first attempt to find innovative solutions to overcome 
the administrative and practical barriers in running large-scale RCTs. 
 
6.1.1 What is a randomised controlled trial? 
An RCT is widely accepted as the most rigorous and reliable study design 
for determining treatment benefit. Randomisation helps distribute any known or 
unknown confounders between the treatment and control groups equally to 
minimise any systematic error or bias. However, randomisation alone does not 
ensure a trial will be free of bias. Bias might be introduced following 




By convention, there are five phases of clinical studies (Phase I – IV) to 
denote the development and testing of a new pharmacological intervention(145). 
Phase I refers to the non-randomised testing of the trial drug in a small group of 
healthy volunteers to establish the pharmacokinetics, metabolism, and toxicity of 
a new compound in humans. Phase II trials, which may or may not be 
randomised trials, involves testing the compound in a small group of patients with 
the target disorder in order to set and confirm dosage required for the desired 
pharmacodynamics effect, monitor toxicity, and to confirm the anticipated 
pharmacokinetic and metabolic effects. Phase III represents the full-scale efficacy 
RCT, which requires a sample size large enough with sufficient power to detect 
the minimally important difference. Determining the minimally important difference 
is not an exact science, but rather a decision based on a combination of the 
estimated effect and variability on the outcome measure, and what is important 
and meaningful to the patients clinically. A phase IV study refers to the post-
marketing surveillance for rare and adverse outcomes of a new drug.  While 
TASK-CBT is not a pharmacological intervention, the present TASK trial can be 
considered as equivalent to an early Phase II RCT, which aims to assess the 
feasibility—acceptability, practicality e.g. adherence, ‘dosing’ of the TASK CBT 
intervention.  
 
6.1.2 What is a well-designed RCT? 
A well-designed RCT should ask an important clinical question, answer it 
reliably, and keep trial participants safe. An important clinical question is one 
where there is uncertainty—‘a genuine uncertainty on the part of the expert 
clinical community about the comparative merits of two or more treatments for a 
defined group of patients or population’(146). An RCT should have a clear plan, a 
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protocol with all elements of it well thought through in advance, and following the 
Patient, Intervention, Comparator, Outcome (PICO) format. The reliability of trial 
results may be influenced by the following methodological factors: 
 Choice of study design e.g. parallel group, cross-over 
 Sample size 
 Duration of follow-up 
 Trial procedures 
 Randomisation 
 Allocation concealment 
 Adjudication of outcomes 
All of these factors need to be considered carefully when designing an RCT to 
minimise systematic bias.  
 
6.1.3 What challenges do I anticipate in conducting the definitive 
TASK RCT?  
The experiences of the Edinburgh Stroke Research Group at conducting 
large-scale RCTs highlighted a number of key issues in running such trials. 
 
Recruitment in a multicentre trial  
A definitive RCT needs to recruit sample size large enough to have 
sufficient power to detect a clinically relevant treatment effect. Recruiting 
hundreds or thousands of patients usually involve recruiting from multiple centres 
nationally or internationally. One of the major costs of traditional multicentre trials 
is the setting up of multiple centres which includes establishing legal contract 
between the sponsor and  local sites, identification and training of local staff, site 
initiation visits, monitoring, local closeout and  archiving. Setting up local sites is 
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time-consuming and costly. Even after spending large sums of the trial budget, 
large-scale trials often fail to reach recruitment targets.  
 
Recruiting community-based patients and consent 
My experience at recruiting research participants for my prospective 
cohort was time-consuming and labour-intensive. Recruiting community-based 
stroke and TIA patients was particular challenging. The lack of a follow-up service 
for stroke and TIA patients in NHS Lothian and the strict ethical guidance that 
researchers must not be the first to approach potentially eligible patients meant 
that there was no easy way to provide study information to people once they had 
left the ward or clinic. Not only would this be a major barrier to recruiting sufficient 
patients to the definitive TASK RCT, it also raises the ethical question as to why 
patients are being disempowered by not being given access to the clinical trials 
that they are eligible to participate in. At present, I can only access community-
based patients for research by sending them postal invitations. The current set up 
for trial recruitment is a hindrance to research progress in the field of ‘life after 
stroke’—an area of stroke care that has been consistently voiced by stroke 
patients as a priority, but one which has been largely neglected in stroke 
research. 
 
Quality assurance in intervention delivery 
In trials of psychological interventions, many therapists are employed to 
deliver the trial intervention. This raises difficulty in quality assurance and 
monitoring. There is a risk of therapists systematically introducing non-protocolled 
‘active ingredients’ while delivering the intervention, thus reducing the internal 
validity of the entire trial. Therapist training, the use of a manual, and methods to 
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monitor the therapists sessions e.g. audio-recording are some of the ways to help 
ensure intervention fidelity.  
 
Attrition  
Loss of follow-up or attrition leads to biased results and reduces the power 
of the study. Having made the colossal effort of recruiting sufficient number of 
patients to a large-scale trial just to fail on completing follow-ups would be a major 
waste of valuable research resources and time—a heart-breaking defeat. My 
experience as a researcher telephoning participants to complete their 6 and 12-
month follow-ups in the multicentre FOCUS RCT (Fluoxetine or Control Under 
Supervision) taught me this simple fact—patients or their family simply had better 
things to do than to complete and return a lengthy postal follow-up research 
questionnaire. The less the effort participants have to put in, the easier it is to 
minimise attrition of follow-up data. In a trial of a psychological intervention such 
as TASK, self-reported measures would still play a central role as outcome 
measures. Simpler, more convenient ways of collecting patient reported 
outcomes, or alternative measures that require minimal or no effort from 
participants e.g. a wearable device, using routinely collected data could help 
overcome the challenge of attrition.  
 
6.1.4 Applying technologies to make TASK RCT streamlined and 
efficient 
 
The time and budget constraints of my fellowship meant that I had to find 
the quickest and best possible ways of designing, conducting and completing the 
TASK feasibility RCT which I envisaged (Figure 25).  
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In my vision, patients from all over the country or the world would be 
eager to sign up to a clinical trial. Patients would have access to information on 
ongoing recruiting trials. They would be empowered to recruit themselves to a 
trial that they are eligible to take part in. I envisaged patients screening 
themselves, recruiting themselves, and completing electronic informed consent 
forms remotely. A centrally-based research team would verify and confirm 
eligbilty using electronic health records and the telephone, collect baseline data, 
and randomise immediately. Allocated intervention would then be delivered or 
174 
 
despatched to the participants. Automated follow-ups would be sent to 
participants at scheduled timepoints.  
 
Research Electronic Data Capture (REDCap) 
Hiring a programmer or developer to design the TASK RCT was out of the 
question owing to my time and budget constraints. Through collaborative links 
with another research group at the University of Edinburgh, I gained access to 
REDcap, a secure web-based data management application created by 
Vanderbilt University in the United States, designed especially with the clinical 
researcher in mind(140). REDCap enables researchers to build a high quality 
database, data collection forms and surveys quickly and easily with no 
programming skills required.  
The user interface is intuitive for both the researchers and research 
participants. Advanced features include data validation, branching logic, 
calculated fields, slider scales, randomisation module, and many more ways to 
customise each project. REDCap automatically generates the project’s data 
dictionary and labels of all the variables created. Modifications are tracked and 
logged in an audit trail. Datasets can be exported easily in formats used by 
common statistical packages. Training resources on how to use REDCap are 
freely available. REDCap adheres to the HIPAA (Health Insurance Portability and 
Accountability Act of 1996, US) Security guidance to ensure the confidentiality, 
integrity and security of protected health information(147). REDCap at the 
University of Edinburgh is hosted within the University’s Virtual Machine 
architecture, which is physically secured. Figure 26 shows screenshots of my 
REDCap project user interface for the researcher (26a), part of the study sign-up 
and consent form (26b), and electronic signature for informed consent (26c). I 
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embedded the electronic informed consent form on the TASK RCT recruitment 
website: www.task4stroke.org (Figure 27).  
 
Figure 26. Screenshots of the REDCap project user interface 















Figure 26b. TASK study sign-up and consent form                           26c. Electronic signature on the TASK consent form 
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I had to create three websites, one for online self-recruitment, one for the 
TASK-CBT intervention and one for the comparator, TASK-Relax. To create the 
websites quickly, I used an industry-led cloud-based web development platform 
for website building, designed for people with no knowledge in coding or script 
language. I directed Google analytics to all my websites to assess whether it 
would be possible to monitor aggregate usage. 
 
Use of smartwatches to collect continuous data on activity/rest in an RCT  
While designing the TASK RCT, I added a smartwatch sub study to 
measure actigraphy (non-invasive method of monitoring rest/activity cycles) as a 
study within a trial to investigate whether this method of collecting outcomes 
would be feasible in stroke and TIA patients. Anxious patients after stroke 
showed higher levels of avoidant behaviour across a range of situations e.g. 
going out alone, physical exertion, social situations compared with those who 
were not anxious. Disturbed sleep is a feature common to both anxiety and 
depression. RCTs of psychological interventions have conventionally relied on 
self-reported outcomes using questionnaires. This requires effort from 
participants. Non-responders (attrition) can bias results and reduce the power of 
the study, resulting in a waste of valuable research resources. A wrist-worn 
smartwatch that records actigraphy continuously could provide data on activity 
and sleep, offering the potential of measuring objective outcomes throughout the 
entire RCT with minimal patient effort. The feasibility of long-term continuous 
monitoring using this method has not previously been tested for feasibility in 
RCTs of psychological intervention, or RCTs of stroke/TIA patients. Data 
collected using this smartwatch could be analysed for correlations with clinical 
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outcomes e.g. mRS, anxiety levels. These smartwatches could be scalable 
methods of measuring objective outcomes in a large-scale RCT. 
 
6.1.5 Objectives of the TASK feasibility RCT 
This study aims to evaluate the feasibility of i) novel web-enabled trial 
procedures, ii) the TASK-CBT intervention, and iii) use of actigraph smartwatches 
to collect continuous data throughout the entire trial in stroke/TIA patients. 
 
6.2 Methods 
The report of this protocol follows the Standard Protocol Items: 
Recommendations for Intervention Trials (SPIRIT) checklist[18]. Description of 
TASK-CBT adheres to items on TIDier (Template for intervention description and 
replication) [19]. The trial protocol is registered at ClinicalTrials.gov 
(NCT03439813). 
 
6.2.1 Trial design 
The TASK feasibility trial is a parallel two-armed RCT comparing TASK-
CBT with TASK-Relax. Figure 28 illustrates the participant timeline in a 
schematic.   
Information technology used in the design of the TASK feasibility RCT 
Using REDCap, I embedded data collection forms in my recruitment 
website (www.task4stroke.org) for self-screening for eligibility and informed 
consent. On my TASK-CBT treatment website, I embedded data collection forms 
as individual weekly online tasks. Usage of all websites is monitored with Google 
Analytics. In my smartwatch sub study I am testing the feasibility of GENEActiv 
Original smartwatch (Activinsights, www.activinsights.com/products/geneactiv/), a 
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device designed primarily for research with validation data. Continuous data 
(triaxial accelerometry, temperature, light) are recorded and can be downloaded 
from each device for analysis of physical activity and sleep. No data are stored on 
a commercial ‘cloud’, and no patient identifiable data are stored on the device. 
 
Figure 28. TASK RCT schematic 
 
 
6.2.2 Participants and recruitment 
Patient population: inclusion and exclusion criteria 
I aimed to recruit 40 community-based residents within NHS Lothian 
(United Kingdom postcodes EH and FK1) who were aged 18 or above, with a 
diagnosis of stroke or TIA (probable or definite, cerebral or ocular), at least one 
month after being discharged to the community from clinic or hospital ward. 
Participants had to have capacity to give informed consent, be able to 
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communicate in English on the telephone, have internet access, and report at 
least one positive response on our 6-item anxiety screening questions (Figure 
29). I derived these items from the GAD-7 and modified Fear Questionnaire using 
psychometric techniques including factor analysis and analysis of internal 
consistency to maximise the spectrum of anxiety levels included. I excluded 
people already taking part in a clinical trial of treatment intended to improve 
psychosocial outcomes post-stroke.  
 
Recruitment methods 
The TASK recruitment website: www.task4stroke.org was publically 
accessible, where participant information was available via a video or a readable 
format. Interested potential participants could complete the ‘Sign Up and Consent 
Form’ on the website. I disseminated the website address as widely as possible 
amongst patients, community stroke nurses, stroke physicians, stroke 
rehabilitation therapists, and stroke charities using printed ‘business cards’, flyers 
and social media. I offered trial information to stroke and TIA patients during their 
one-month telephone follow-up which I carried out as part of routine stroke care. 
In addition, I sent postal invitations to the eligible participants identified from the 
NHS Lothian Stroke Audit registry, which I screened retrospectively.  
 
Screening of NHS Lothian Scottish Stroke Audit 
 I obtained the list of patients recorded as having had a stroke/TIA in a six-
month period from the audit database manager. Using electronic health records I 
checked the potential eligibility for each patient on the list and excluded those 




On receiving the completed ‘Sign Up and Consent Form’, I verified the 
eligibility and identity of the potential participant using electronic health records 
and over the telephone with the participant within five working days. Baseline 
data were immediately collected at this point (T0), followed by randomisation. 
 






6.2.3 Intervention and comparator 
I designed the TASK-CBT intervention to be delivered via telemedicine—
telephone, website, email and mobile text. The TASK-CBT intervention 
represented a low-intensity, guided self-help psychological intervention in a 
stepped care model. I delivered the TASK-CBT telephone sessions under the 
training and supervision of a neuropsychiatrist.  
 
Delivery of ‘active ingredients’ of TASK-CBT by telephone and web 
I summarized the key ‘active ingredients’ of the TASK-CBT intervention in 
Figure 23. In brief, the TASK therapist delivers a course of six individualized 
telephone CBT sessions, 35-45 minutes each, at least one week apart, with the 
use of an electronic TASK Therapist’s Manual and Record I created on REDCap 
(Figure 30).   
Each session was supplemented by the prescription of an online task, and 
one or more of the psychoeducational videos on the TASK-CBT treatment 
website.  
To encourage adherence, I sent a mobile text to remind participants to 
complete their online task each week and to use the treatment website as much 
as possible via a computer, tablet or smartphone.  
 
Active comparator: TASK-Relax  
TASK-Relax is a web-based self-guided relaxation programme. 
Relaxation therapy is a commonly used comparator in RCTs of CBT in psychiatry 
research. The TASK-Relax website consisted of an introductory video, followed 
by five relaxation tasks: i) audio and visually-guided breathing exercise, ii) 
relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided 
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progressive muscle relaxation, and v) a selection of sounds of nature (Figure 31). 
All relaxation videos or audios on the TASK-Relax website were also publically 
available on YouTube. Participants allocated to TASK-Relax received instructions 
to try out all of the relaxation exercises and to select their favourite one(s) to 
practice daily, for at least 5 minutes throughout their trial participation.  
 




Figure 31. Screenshot of the homepage of TASK-Relax 
 
 
Components common to both groups 
Participants of both arms received weekly mobile text reminder and a 
participant record card to record progress and completion of follow-up surveys. 
Data collection occurs at T1 and T2 (primary endpoint) via emailed links to self-
completed electronic surveys. Once the follow-up survey at T2 is complete, all 
participants are offered access to the website given to the other group for a 
further ten weeks.  
 
Concomitant care and interventions 
Concomitant standard clinical care and interventions (pharmacological or 
non-pharmacological) for anxiety or mood disorders, e.g. antidepressants, 
benzodiazepines were permitted and recorded in the follow-up surveys. 
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6.2.4 Randomisation and allocation concealment 
A member of the research staff not involved in conducting the TASK trial 
generated a permuted block randomisation sequence with random block sizes 
using STATA14. The sequence was uploaded to the in-built randomisation 
module within REDCap, which was inaccessible to me. Once baseline data 
collection was complete, I randomised the participant and emailed him/her the 
allocated treatment website address and login details. Participants received my 
instructions on commencing the allocated treatment over the telephone. 
Participants allocated to TASK-CBT also received an appointment with me to 
have their first telephone session.  
 
6.2.5 Masking 
I was enrolling participants and delivering the allocated intervention in this 
feasibility trial. I was not blinded to the treatment group assignment. I attempted 
to mask participants to our hypothesis that one treatment was superior to the 
other by not revealing the exact contents and type of treatment in each group on 
the participant information (Figure 32), or at recruitment.  At enrolment, I simply 
gave them this instruction over the telephone,  
‘You will get one of the two treatment websites we designed. After 
completing your final follow-up survey, you will get access to the website 
given to the other group’.  
The two treatment website addresses did not reveal content of the intervention 






Figure 32. Screenshot of the electronic participant information sheet 
 
 
6.2.6 Smartwatch sub study  
In the smartwatch sub study, all TASK participants were invited to wear 
the actigraph smartwatch. Once consented, the smartwatch was posted to the 
participant with simple care instructions. At two months, the battery of the 
smartwatch would run out. With the participant’s agreement and on the safe 
return of the first smartwatch, a second smartwatch was sent to the participant, so 
he/she could wear it for the rest of the trial. All smartwatches were returned using 







6.2.7 Feasibility Outcomes to be reported 
 
Feasibility of the trial procedures: Recruitment (number per month); % 
completed consent, online or by post; time taken to complete remote eligibility 
confirmation via electronic health records (date of randomisation - date of ‘Sign 
Up and Consent Form’ received); self-completion of electronic follow-up surveys 
at T1, T2 (% completed surveys). 
 
Feasibility of the TASK-CBT intervention: % drop out after fewer than three 
telephone TASK-CBT sessions; intervention fidelity—agreement with audio 
recording transcript and TASK therapist record, completion of online tasks, and 
web usage analytics. 
 
No-go criteria 
My supervisors and I defined a lack of feasibility of TASK-CBT and the current 
trial design as 1) recruitment number of <2 per month; 2) >50% of TASK-CBT 
patients dropping out after fewer than three telephone sessions; 3) >10% non-
completion of follow-up surveys at T2, 4) participants reporting harm from the 
intervention. 
Treatment relevant outcomes (Table 31) include the mRS for 
disability(20), EQ-5D5L(93), GAD-7(112), modified FQ(92), and a single question 
to elicit concurrent treatment for mood or anxiety. A user feedback survey 






Table 31. Treatment relevant data collection in the TASK RCT 
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Continuous monitoring throughout the trial from T0 to T2 
 
mRS, modified Rankin Scale; EQ5D5L-VAS, EuroQol-5D5L-Visual analog score; GAD-7, 
7-item Generalised Anxiety Disorder Questionnaire; PHQ-2, 2-item Patient Health 









Visual sliders for the FQ 
Each item on the modified FQ was scored using a visual slider (Figure 33) on the 
electronic survey throughout the trial, giving a score on a scale of 0-100. Scores 
were converted to a scale of 0 - 8 (by dividing by 12.5). 
 
Figure 33. Visual sliders used in the modified FQ in the TASK RCT 
 
 
Feasibility outcomes of the smartwatch sub study  
I assessed the percentage of TASK participants who also consented to 
wearing the smartwatch; the ‘wear time’—duration of the smartwatch being worn 
by each participant using the data recorded on the smartwatch; percentage of 
participants of this sub study who agreed to wear the smartwatch again after two 






6.2.8 Assessing intervention fidelity and quality monitoring  
For intervention fidelity, I aimed to assess i) % agreement between the 
Therapist’s Record and transcripts of audio-recording of telephone sessions, 
assessed by a clinician independent of the study; ii) automated data capture of 
online task completion; iii) summary web usage data from Google Analytics.  
 
6.2.9 Strategies to improve adherence in both arms 
I sent a participant record card to every participant by postal mail and sent 
weekly text reminders to their mobile phone throughout their participation. All 
participants received text and email reminders to complete the follow-up surveys 
at T1 and T2. Non-responders would receive further text and email reminders, 
and a final phone call from a researcher blinded to the treatment allocation to 
complete unfilled online surveys over the telephone. 
 
6.2.10 Discontinuation criteria  
Participants were free to withdraw from the study at any point or a 
participant could be withdrawn by one of the TASK trial investigators if he/ she 
lost capacity during the study period. 
 
6.2.11 Safety protocol 
All participants had contact details of the TASK research team from the 
start of the trial. They were informed that if severe cases of anxiety or depression 
were identified during the trial, the TASK research team would liaise with their 





6.2.12 Data management 
All study data were collected and managed using REDCap electronic data 
capture tools hosted at University of Edinburgh. Identifiable data were only 
accessible by the managing team of the REDCap database and myself. Statistical 
analysis was performed using STATA software. Anonymised data from all 
smartwatch devices were uploaded for analysis by a collaborating data scientist 
at the Centre for Medical Informatics, Usher Institute, University of Edinburgh for 
analysis. 
 
Data monitoring body 
There is no data monitoring committee planned for this study 
 
6.2.13 Statistical analyses and power calculation 
As this was a feasibility study I did not perform power calculation. 
Feasibility outcomes were summarized descriptively. All electronic items on the 
follow-up surveys had to be scored to permit submission, preventing any missing 
values. Only my supervisors and I had access to the final trial dataset.  
 
6.3 Results 
I enrolled 27 participants from 29/1/18 to 3/4/18 to the TASK feasiblity 
RCT from three main sources, the Scottish Stroke Care Audit Registry from a six-
month period (1/6/17-30/12/17), my prospective 1-month telephone screening of 
all clinic patients from 1/1/18-3/2/18, and patients identified from two 
observational studies (Figure 34). 
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1481 patients were screened, of whom 31% (458/1481) were potentially 
eligible for the TASK RCT. I approached 30% (438/1481) by telephone and/ or by 
post and enrolled 2% (27/1481) of all patients screened (Figure 35). 
 
Figure 34. Sources of TASK RCT participants 
 






Recruitment rate was around two to three participants per week, 
exceeding our pre-defined feasibility outcome of recruiting at least two 
participants per month. I stopped recruitment on 3/4/18 due to my fellowship’s 
time constraints. Figure 36 shows that if recruitment was to continue at a rate of 2 
per week (dashed line), a sample size of 40 would have been reached by the 
beginning of June, 2018.  Five members of the public contacted me by phone and 
email wishing to sign up but were not eligible as they resided outside Lothian or 
contacted me after the trial recruitment had closed. 
 
Figure 36. TASK recruitment rate projection 
 
 
Of the 27 participants enrolled (mean age [SD]: 65 [10]; men: 15/27, 
56%), about two-thirds received a diagnosis of stroke (17/27, 63%) and one-third 
TIA (10/27, 37%) (Table 32). About half of the participants enrolled reported a 
past history of anxiety disorder or depression (15/27, 56%). At baseline (pre-
randomisation), the majority reported a mRS of 0-2 (80%, 22/27). On the EQ5D-
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5L, participants reported more problems on the domains of ‘usual care’, ‘pain and 
discomfort’, and ‘anxiety/depression’ than the domains on ‘mobility’ and ‘self-care’ 
(Figure 37). Participants had a range of anxiety symptoms and severity on GAD-7 
and FQ subscales (Figure 38) at baseline. The median time from stroke/TIA event 




Table 32. Baseline characteristics (pre-randomisation) of sample in TASK RCT 
  Total 
n = 27 
 
  




Age (mean, SD) 65 (10) 
range 39-81 
 64 (10)  65 (10)  
Men  15 56%  10 71% 5 38% 
Diagnosis         
 Stroke 
  Ischaemic 











 TIA 10 37%  4 29% 6 46% 
 median IQR  median IQR median IQR 
Time (weeks) since stroke/TIA 19 12-33  21  13-33 18  7-31 
Past history         
 Stroke/TIA 5 19%  1 7% 4 31% 
 Myocardial infarction 2 7%  2 14% 0 0% 




15 56%  8 57% 7 54% 
Current psychotropics        
 Medication e.g. 
SSRI/SNRI/NaSSA/T
CA/BZ 
(not necessarily for 
anxiety/mood) 
8 30%  5 36% 3 23% 
On treatment to help with 
anxiety or mood 
5 19%  1 7% 4 31% 
  median  IQR  median  IQR median  IQR 
Verbal fluency  
number of words per minute 
13  
 
8-15  14  12-16 11 7-13 
 median IQR  median IQR median IQR 
Disability        
 mRS score 1 0-2  1 1-2 1 0-2 
 mRS 0-1 17 63%  10 71% 7 54% 
 mRS >=2 10 37%  4 29% 6 46% 
 mean SD  mean SD mean SD 
EQ5D-5L-Visual analog 63 18  67 19 58 16 
 median IQR  median IQR median  IQR 
Generalised anxiety        
  GAD-7 (  /21) 9 7-12  9 8-11 7 7-13 
Number of probable GAD (>=6)  23 85%  11 79% 12 92% 
Phobic anxiety        
FQ-Agoraphobia  (  /40) 19 3-24  11 2-22 22 10-31 
Number of probable 
agoraphobic (>=7) 
18 67%  7 50% 11 85% 
FQ-Social phobia  (  /40) 19 6-25  10 5-23 20 14-28 
FQ-Specific phobia (  /40) 17 6-29  16 6-25 19 11-38 
Depression         
 PHQ-2   (  /6) 2 0-2  2 0-3 2 1-2 
SNRI, serotonin-norepinephrine reuptake inhibitor; NaSSA, noradrenergic and 








Figure 37. Baseline functional independence and health-related quality of life 




Figure 38. Histograms show distribution of baseline scores on all anxiety measures (n=27) 
 
                      
GAD-7 (gad7total), FQ-Agoraphobia (fqagtotal), FQ-Social phobia (fqsoctotal), FQ-Specific phobia (fqsptotal) subscales  
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6.3.1 Feasibility of the TASK trial procedures 
I conducted the TASK-RCT entirely remotely using the telephone and 
internet.  
Electronic informed consent completion 
All participants were recruited remotely. Just over a third of participants 
(10/27, 37%) completed the electronic informed consent forms on the recruitment 
website (Figure 39). The remainder returned the paper consent forms by post. 
 
Figure 39. Proportion of TASK participants completed electronic consent 
 
Eligibility confirmation by electronic health records 
All participants had their eligibility confirmed using the electronic health 
records system in NHS Lothian. Median time taken between consent to 
randomisation was one day (IQR 0-3). 
 
Completion of automated electronic follow-up survey 
 All participants (27/27) completed the automated electronic follow-up 
survey at T1 and T2. Most participants (21/27) completed the follow-up survey 
without any further reminders. I sent nine mobile text reminders to six participants 








6.3.2 Feasibility of TASK-CBT intervention 
All 14 participants randomised to TASK-CBT completed all six telephone 
sessions with no drop-out. Median duration of each session ranged from 14 to 28 
minutes. After the first two telephone sessions, the median duration decreased 
with each successive session (Figure 40). 
 
Figure 40. Duration of TASK-CBT telephone sessions 
 
Thick line indicates median, box indicates IQR, whiskers indicate range 
 
I carried out a total of 84 telephone sessions (6 sessions per TASK-CBT 
participant). One participant did not consent to audio-recording. I recorded 51/84 
sessions in 13 participants using a digital recorder but transcribed only 13 
sessions of three participants. The additional costs of transcription and 
administrative tasks of finding an independent clinician to review the transcripts 
led me to stop recording and paying for transcription. On average, transcript for 




Online task completion in the TASK-CBT group was automatically 
captured. Most participants completed the first three tasks, with some participants 
completing the same task more than once (Table 33). Tasks 4 and 6 had lower 
completion compared to tasks 1 to 3. 
 
Table 33. Completion of online tasks by TASK-CBT participants (n = 14) 
Online 
tasks 














13 93 14 
2 Identify unhelpful thinking styles 
 
14 100 17 
3 Fear of stroke recurrence/ losing 
control 
 
12 86 14 




8 57 12 
5 Relaxation for 5 minutes/ day 
 
Not recorded 
6 Schedule an enjoyable activity 
 
8 57 13 
 
 
6.3.3 Feasibility of wearing a smartwatch in the TASK RCT 
 
All TASK participants (27/27) consented to wearing the smartwatch. 21/27 
agreed to wear a second smartwatch. The return of smartwatches is ongoing. So 
far, all participants have returned their first smartwatches by pre-paid post when 
requested (24/24). Three participants reported having to stop wearing the 
smartwatch and returned their smartwatches (1 ‘strap too tight’; 1 ‘had a broken 
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arm’, 1 ‘too itchy’). ‘Wear time’ data will be analysed once all smartwatches have 
been returned.  
 
6.3.4 Exploratory data on clinical outcomes at T1 
Disability 
All participants completed T1 follow-up at median 7 weeks (IQR 42-56 
days) post-randomisation. mRS scores were similar between the two groups 
(median mRS in TASK-CBT: 1, IQR 0-1; TASK-Relax: 1, IQR 1-3). 12/14 (86%) 
was independent (scored mRS 0-2) in TASK-CBT compared to 9/13 (69%) in 
TASK-Relax (Figure 41).  
 
Quality of life 
While none of the participants scored ‘I am not anxious or depressed’ on EQ5D-
5L at baseline, some patients did at T1 (TASK-CBT 7/14, 50%; TASK-Relax 2/13, 
15%) (Figure 41). Participants scored their overall health using the EQ5D5L 
visual analogue scale (TASK-CBT median, IQR: 80, 72-86; TASK-Relax: 68, 41-
























Concurrent treatment for anxiety and mood problems  
5 participants were receiving concurrent treatment (drug or non-drug) for 
anxiety or mood at baseline, and 6 participants at T1 (Figure 43) 
 
Figure 43. Concurrent treatment (drug or non-drug) for anxiety or mood at 
baseline and at T1, by treatment allocation 
 
Anxiety measures 
Figure 44 shows the median, interquartile range, and range of scores on 
all anxiety measures at baseline and at T1, by treatment group. 
Generalised anxiety  
On GAD-7 (maximum score 21), participants in the TASK-CBT scored 
lower than participants in the TASK-Relax at T1 (TASK-CBT: median 3.5, IQR 0-
5; TASK-Relax: median 8.0, IQR 6-15). At a cut-point of  >=6 on GAD-7 , 3/14 
(21%)  TASK-CBT had a probable diagnosis of GAD compared to 11/13 (85%) in 
TASK-Relax. The TASK-CBT group was less likely to have a probable GAD 





At T1, FQ-agoraphobia subscale score (maximum score 40) was lower in 
the TASK-CBT group compared to TASK-Relax (TASK-CBT: median 1, IQR 0-7; 
TASK-Relax: median 20, IQR 10-24). At a cut point of >=7 on the FQ-
agoraphobia subscale, 4/14 (29%) participants in the TASK-CBT group had 
probable agoraphobia compared to 10/13 (77%) participants in the TASK-Relax 
group.  
I found similar trends on the FQ-social phobia and FQ-specific subscales 
at T1 (median FQ-social phobia [IQR]: TASK-CBT 2 [1-4]; TASK-Relax 13 [11-
24]; FQ-specific phobia: TASK-CBT 2 [1-5]; TASK-Relax 15 [9-27] (Figure 44). 
 
Does TASK-CBT predict disability or diagnosis of GAD?—an exploratory 
analysis using logistic regression 
 
At T1 (about 7 weeks post-randomisation), TASK-CBT greatly reduced the 
odds of having 'probable GAD' compared to TASK-Relax (‘probable GAD’ [GAD-
7 >=6]: OR 0.05, 95%CI 0.01-0.36), though there was no detectable difference in 












Figure 44. Scores on a) GAD-7, b) FQ-agoraphobia, c) FQ-social phobia, and d) 





Thick line indicates median, box indicates IQR, whiskers indicate range 
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44b) FQ-agoraphobia subscale at baseline and at T1, by treatment group   
 
 
Thick line indicates median, box indicates IQR, whiskers indicate range 
209 
 
44c) FQ-social phobia subscale at baseline and at T1, by treatment group   
 
 
Thick line indicates median, box indicates IQR, whiskers indicate range 
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44d) FQ-specific phobia subscale at baseline and at T1, by treatment group   
 
 




6.4.1 Key findings 
My novel technology-enabled trial procedures and the TASK-CBT 
intervention are feasible in a small scale. This is a streamlined RCT that 
evaluates a CBT-based intervention remotely for anxiety after stroke. The final 
data collection of this current study is ongoing so further feasibility outcomes will 
be reported after completion of my thesis. I have identified the limitations of the 
current trial and intervention design which I will need to address before the 
definitive TASK RCT.  
Generalisability 
The TASK trial participants were not representative of the general stroke 
population as they were younger and had a good outcome as defined by mRS 0-
2 at baseline. The sample was probably representative of the anxious population 
after mild stroke/ TIA as their characteristics were similar to the anxious 
participants from my prospective cohort—younger and had a past history of 
anxiety or depression. Younger age and a past history of anxiety or depression 
are consistent predictors for developing anxiety after stroke or TIA(56, 59). The 
characteristics of my sample probably reflect the use of anxiety screening as an 
inclusion criterion for the TASK trial. I designed the anxiety screening criteria to 
be as inclusive as possible across the wide spectrum of anxiety levels.  
The TASK trial design and the TASK-CBT intervention require individuals 
to communicate on the telephone and to use the Internet. This design therefore 
excludes stroke patients with aphasia, cognitive impairment, and severe motor 
dysfunction. In principle, CBT requires the ability to be aware of, examine, and 
understand own thoughts and feelings. CBT is therefore not a suitable treatment 
for anxiety in stroke patients with significant cognitive or communication 
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difficulties. It is likely that these patients would require highly specialised 
interventions, delivered by therapists skilled in using alternative means of 
communicating feelings and thoughts, or therapy that emphasises on behavioural 
techniques rather than cognitive abilities.  
The web-enabled design excludes people who have no access to the 
Internet, or those who do not have a minimum level of skills in information 
technology. This is likely to be overcome by the trend towards wider adoption of 
home broadband and user-friendly devices amongst older people(148). Having 
carers or relatives to teach patients how to use the Internet and mobile devices, 
offering devices and formal training to trial participants are some of the potential 
solutions to overcome the barrier in using digital health interventions.  
The TASK trial design has wide applicability, which extends beyond the 
stroke and TIA population. Its design was geared towards testing any 
interventions that could be delivered remotely e.g. guided or unguided self-
management, remote symptom or physiological monitoring, remote drug dosing, 
clinic consultation via telemedicine.  
 
6.4.2 TASK trial design 
Recruitment strategy 
While my recruitment rate of two to three participants per week exceeded 
the pre-defined feasibility outcome of recruiting two per month, it was clear that 
my recruitment strategy in the TASK trial was labour-intensive and time-
consuming. I screened nearly one and a half thousand patients to enrol 27 
participants in the TASK trial. The definitive TASK trial will need to recruit 
hundreds of patients or more. If the same recruitment strategy is to be used, it will 
need to be made efficient since thousands or tens of thousands of patients will 
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have to be screened. Screening huge numbers of patients from a registry or 
primary care routine data, and sending invitations en masse could be made 
efficient by automation technology. 
Using technology to follow up patients after their discharge could improve 
patient care, patient access to clinical trials and trial recruitment. For example, the 
use of mobile text, mobile applications, tele-consultations could help address the 
lack of ‘life after stroke’ services after discharge—an experience likened to being 
abandoned according to patient reports from stroke charities(134). I envisage the 
potential of routinely sending all patients a ‘follow up’ mobile message at 1 month 
following their discharge from the ward or clinic. Those who respond with ongoing 
issues would receive a link to a website with information on ongoing clinical trials 
and useful life-after stroke services. 
A change in attitude and practice in how patients should be approached 
for research could improve trial recruitment. Empowering patients with information 
about ongoing trials and the ability to recruit themselves to a trial of their own 
choosing would seem sensible and ethical. It would also remove the need for 
patients to be ‘selected’ by healthcare or research staff, potentially improving the 
generalisability of the research. Examples of trials that enable self-screening in 
other populations include the Migraine Intervention with STARFlex RCT (n=432) 
(149) and the Treatment in Morning versus Evening study RCT which evaluates 
morning and evening dosing of hypertensive medications (n = 21,116)(150). 
Similarly, the TASK trial’s streamlined procedures for self-screening, self-
recruitment, electronic informed consent, and remote eligibility confirmation would 
potentially enable a centralised model to recruit eligible patients anywhere in the 
country, or anywhere in the world without the need to have locally-based principal 
investigators or research staff. Larger sample sizes could be reached more easily 
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without significantly raising extra costs associated with setting up multiple local 
sites.  
Verifying and confirming eligibility remotely using electronic health records 
was only achievable in the current study because the study was confined within 
one NHS health board. Making this centralised model of remote recruitment 
feasible nationwide or internationally would require more innovative solutions to 
confirm the identity and eligibility of potential participants. For example, potential 
participants could provide electronic proof of identity and eligibility to the research 
centre by sending a digital photograph of their driving license and a clinic letter 
detailing their stroke via a secure online form, email, or mobile messaging. A 
centrally-based research team could verify eligibility in a number of ways e.g. 
using electronic health records for local patients, sending a brief electronic 
confirmation form to the participant’s GP, or local stroke services via secure 
email. Having named contacts across the country’s stroke services such as 
stroke clinicians and using established clinical research network e.g. research 
nurses across the country could help facilitate this process without the need to 
establish multiple trial recruitment sites formally.  
Technological innovations will make a centralised trial logistically possible. 
The regulatory complications, not technological ones will most likely be the 
barriers to running a large-scale centralised RCT.  
 
Maximising the reach of trial recruitment advertisement 
An efficient advertising strategy was necessary as patients could only self-
recruit if they knew about the trial. Without an adequate ‘life after stroke’ service, I 
had no easy way of informing patients of the TASK trial’s self-recruitment website 
www.task4stroke.org. My advertising campaign included posting on Twitter during 
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the recruitment period, handing out TASK ‘business cards’ to stroke clinicians, 
rehabilitation therapists and community stroke nurses, and emailing electronic 
flyers to clinicians of the local stroke services in NHS Lothian. I also contacted the 
Stroke Association Scotland, a major stroke charity, which tweeted the TASK trial 
advert separately. I found handing out business cards and sending out flyers to 
clinicians did not yield any TASK participants. Five patients contacted me on the 
TASK team mobile and via email wishing to sign up to the trial. They were from 
outside NHS Lothian, so were ineligible. One of them was referred by a stroke 
physician in London, who saw my tweet and felt that his patient would be a 
suitable participant. For two of the patients, their wife and son found out about the 
TASK trial while searching online for information on anxiety after stroke. These 
anecdotes showed that, if the TASK trial was open to patients regardless of 
where they lived, I would have enrolled additional participants within the 
recruitment period with minimal effort on my part. Working collaboratively with 
patient groups and charities, as well as local stroke rehabilitation services are 
potential ways to maximise the reach of trial recruitment advertisement. 
 
Randomisation, allocation concealment 
Owing to the small sample size intended for the current study, a permuted 
block randomisation sequence with random block sizes was used. For the 
definitive trial, stratified randomisation or minimisation may be required to 
distribute potential confounders equally between the two groups. Variables that 
could influence treatment outcome include age, sex, past history of anxiety and 
depression, concurrent use of psychotropic medications, disability, baseline 
anxiety. Allocation concealment was achieved in this current study using 
REDCap’s in-built randomisation module. Using REDCap, a person independent 
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of trial enrolment was able to generate the randomisation sequence from a 
statistical software, upload the sequence while restricting access to it. In the 
current study, I had no access to the allocation sequence but I was not blind to 
the participants’ treatment allocation. I found I was trying to predict which 
treatment group the next participant was likely to be allocated. For instance, after 
four participants had been randomised to TASK-Relax consecutively, I would 
predict the next participant to be allocated to TASK-CBT. As such, when I had 
multiple participants to randomise, it was possible for me to choose which 
participant to randomise first, based on my perception of their likelihood to benefit 
from TASK-CBT. As the current study was a very small trial, my predictions had a 
high chance of being correct even with varying block sizes. This should no longer 
be problematic in a large trial using stratified randomisation or minimisation, 
where the chance of anyone’s predictions would be unlikely to be correct.  
 
Intervention and comparator, masking 
The use of a treatment website and the telephone to deliver TASK-CBT 
remotely made it technically straightforward to design a matching comparator. I 
simply created a comparator website, the TASK-Relax. Having a matching 
comparator is preferable to using ‘usual care’ or waitlist as controls, as these 
latter controls are known to exaggerate effect size in trials of psychological 
interventions(151). My systematic review (Chapter 2) showed that most trials of 
anxiety interventions in stroke used ‘usual care’ or waitlist as comparators. The 
description of what constituted ‘usual care’ was minimal across the included 
studies(46). My TASK-Relax website is transparent and reproducible. It also 
provides a degree of masking of trial participants. To enhance matching of the 
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TASK-Relax to TASK-CBT in the future, brief scripted or automated telephone 
prompts could be added to the TASK-Relax intervention. 
It is possible that TASK-relax will have some effect on patient’s anxiety, 
thus confounding the effect of TASK-CBT. Our hypothesis is that TASK-CBT is 
superior to TASK-Relax in the longer term at 20 weeks post-randomisation (T2). 
This remains to be tested in definitive TASK RCT(152). 
My supervisors and I considered the appropriateness of a cross-over 
study design, in which we would extend the trial to measure outcomes after 
participants have completed the second intervention. A cross-over design is not 
appropriate given that CBT teaches participants to apply their newly learnt skills 
to self-manage their own anxiety for life. As such, there is not a washout period 
as would be expected from some pharmacological cross-over trial designs. One 
could consider collecting treatment outcomes again in TASK-Relax participants 
who then went on to use the TASK-CBT website. Doing so could provide pre- and 
post-treatment data in this group to support the effect of TASK-CBT without 
telephone guidance. 
I could not assess the extent to which participants were masked to our 
hypothesis that TASK-CBT was superior to TASK-Relax. It was theoretically 
possible for participants to find out the detailed description of the TASK trial on 
publically accessible trial register. Our attempt at masking relies on the 
participants’ perception that both treatment groups were designed to help with 
anxiety.  
 
Automated electronic follow-up 
 There was no attrition at all follow-ups. The scheduling function for 
sending out electronic follow-up surveys automatically to participants’ emails on 
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REDCap worked efficiently without any practical issues. Follow-up at T2 is 
currently ongoing and will be reported after completion of this thesis. Only 
minimal effort was required to achieve completion of all T1 follow-ups. I sent a 
standard text reminder describing the importance of completing the follow-up 
survey to participants who had not completed their scheduled survey:  
Dear [participant’s name] 
Hope you are well.  
I would be grateful if you could complete your final follow-up survey for the 
TASK study. 
Your completion of the TASK survey is very important for our research. 
Please complete the survey even if you have not used the TASK 
treatment website. 






6.4.3 TASK intervention design 
 Intervention adherence to the TASK-CBT was good with zero drop out of 
the telephone sessions. The TASK-CBT therapist manual and record (Figure 30) 
enabled me to discuss each case with a neuropsychiatrist at weekly supervision. I 
designed three ways of capturing fidelity to intervention: i) validating the TASK 
therapist record with transcripts of audio-recording, ii) automated electronic 
capture of online task completion, and iii) web usage data. 
219 
 
With a limited project budget, I found the costs of transcribing all 
telephone sessions prohibitive (£36 per session). The transcripts from the current 
study are still to be validated by a clinician independent of the trial. Reading each 
transcript is likely to be time consuming and may not be feasible in a large-scale 
TASK trial.  An alternative way of validating treatment sessions without the need 
of transcribing would be for the independent clinician to listen to randomly 
selected audio-recorded sessions stored in a database.  
Having a better audio-recording set up, automated voice-recognition and 
transcription technology, and the use of natural language processing for 
automated transcript validation could make this method of assessing intervention 
fidelity more efficient.  
Telephone session duration decreased with each successive session. I 
designed the first session to gather information from the participants on their 
anxiety problem before setting a specific goal and introducing them to the task of 
self-monitoring. The second session began to introduce CBT techniques so 
participants could start practising them during the week. Subsequent sessions 
involved recapping the participant’s progress that week and their use of CBT 
techniques, which could vary in length depending on the individual. There is not 
an optimal session duration applicable to all patients. I found having a flexible 
session duration between 20-40 minutes to be reasonable. The flexibility would 
enable the TASK therapist to tailor the session according to the individual’s 
needs. 
Online task completion was excellent for the first few tasks but less so for 
the later tasks. This was in spite of all participants receiving a standard weekly 
text reminder to complete their online tasks. It was likely that I had influenced task 
completion by placing more emphasis on completing the first three tasks than the 
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later tasks during my telephone sessions. The first three tasks were on the core 
topics of CBT, relevant to all TASK-CBT participants. On the other hand, not all 
participants had phobic anxiety, so would find task 4 irrelevant. I designed these 
online tasks to make the TASK-CBT intervention interactive outside the telephone 
sessions. These tasks served to consolidate the CBT skills that I introduced to 
participants during their telephone sessions. Having a specific task on exposure 
therapy (task 4) enabled me to tailor the TASK-CBT intervention to those who 
suffered from predominantly phobic symptoms. 
I have not analysed the data collected using Google Analytics in the 
current study. It became apparent that there were many issues associated with 
using Google Analytics in clinical trials, including its validity, inability to collect all 
the interaction data needed, and the inability to collect individual participant data. 
The absence of informatics support at the time of designing the TASK trial 
prevented me from setting up the TASK trial’s own customised web usage 
monitoring. With appropriate informatics support, it would be possible to embed 
an in-house web usage analytic program within the TASK treatment websites to 
collect precisely the data required. 
 
TASK therapist training 
The TASK therapist training materials are still to be developed and 
therapist’s manual needs to be refined based on my experience in the current 
trial, the anonymised audio transcripts, and my supervisors’ experience in 






6.4.4 Exploratory findings on clinical outcomes 
Based on the exploratory analysis, TASK-CBT greatly lowered the odds of 
probable GAD compared to TASK-Relax without any detectable difference in 
disability on the mRS. Our current trial suggest that TASK-CBT may be effective.  
The mRS is a widely accepted primary outcome in stroke trials. The 
conventional definition for a non-disabling stroke is an mRS of 0-2. At baseline, 
the majority of my sample were in the mRS 0-2 category. This probably reflects 
the characteristics of a sample of minor stroke and TIA. mRS may not be 
appropriate as a primary outcome in a trial that targets the milder spectrum of 
stroke patients, or one that evaluates an intervention that does not target motor-
related functions. mRS may not be sensitive to a change in the clinical status of 
participants in the TASK RCT. To determine an appropriate primary outcome 
measure to be used in the definitive TASK trial, a range of candidate outcome 
measures of anxiety, disability, quality of life, and participation should be 
considered. Selection of the primary outcome will be based on the measure’s 
sensitivity to change or difference between groups, its practicality for use in large-
scale RCT, and its clinical meaningfulness.  
Patients after stroke/TIA can present, to varying degree, predominantly 
phobic, predominantly generalised, or mixed anxiety types. This poses an 
additional challenge as different anxiety measures are required to assess the two 
anxiety subtypes. It may be necessary to have different primary outcomes defined 
for different anxiety subtypes. Other considerations include how to define the 
responder’s anxiety status; whether to use the minimal relevant change from 
baseline, or dichotomised outcome, or an absolute anxiety level post-intervention 
to assess the between-group difference. 
222 
 
 GAD-7, paper or electronic version, is a validated measure of GAD in 
primary care and stroke. My research showed that GAD-7 could be a candidate 
anxiety measure in the definitive RCT. The use of FQ is limited to specialist 
clinics and its validation data is scarce. The FQ is rarely used in general adults or 
stroke, probably reflecting the low prevalence of phobic disorders amongst adults. 
In the TASK trial, my supervisors and I changed the format of our modified FQ by 
using a horizontal visual slider to indicate the level of avoidant behaviour for each 
FQ item. We felt that visual sliders would maximise the ease of use, generate a 
continuous variable, which would be more powerful, and potentially improve the 
clinical meaningfulness of the measure. However, I did not perform any formal 
validation of this latest version.  
  
6.4.5 Further results to be reported 
The final follow-up of the current study is ongoing. I intend to report all 
feasibility outcomes in a future publication once the trial has completed. Further 
outcomes to be reported from this study include the completion of T2 follow-up, 
return of the first and second smartwatches, smartwatch ‘wear time’, intervention 
fidelity, feedback survey on TASK-CBT and TASK-Relax, and any harmful effects 
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7.1 A summary of my research 
The aims of my thesis were to develop an intervention for anxiety after 
stroke and TIA, provide some information on its acceptability and ease of 
delivery, and test the feasibility of the TASK RCT procedures. 
 
Anxiety after stroke  
To develop an intervention tailored to the anxiety problems for stroke 
patients I had to gain a thorough understanding of the anxiety problems that 
these patients experienced. SCID, a semi-structured psychiatric interview, was 
regarded as the ‘gold-standard’ diagnostic tool in psychiatry research. The use of 
SCID enabled me to investigate the frequency of different anxiety subtypes and 
provided me an opportunity to obtain more qualitative information on patients’ 
experiences of anxiety after stroke/TIA. I could not have achieved this by 
administering simple anxiety measures. My findings that phobic anxiety was the 
predominant anxiety subtype post-stroke/TIA, together with the descriptive data 
on specific anxiety-provoking situations had immediate implications in how I 
would design the TASK intervention. It became clear from my prospective cohort 
study and my patient involvement work that my TASK intervention had to include 
components on exposure therapy, agoraphobia, risk of stroke recurrence, and 
bodily symptoms that might be mistaken as stroke or illnesses. Integrating these 
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specific components with the general principles of CBT would make the 
intervention relevant to anxious stroke or TIA patients. 
 My experience at conducting the SCID interviews and delivering the 
TASK-CBT intervention as the therapist provided further insights into people’s 
anxiety after stroke/TIA. Anxiety was ubiquitous in people’s daily life and could be 
adaptive. Given that stroke was a potentially life-threatening and severe 
debilitating condition, it was unsurprising to find that participants felt some anxiety 
about their future after a stroke/TIA. What became very clear to me was that not 
all anxiety was adaptive. People could become severely limited in their activities 
because of their anxiety and the maladaptive behaviours that ensued. 
Participants gave vivid description of their disproportionate fear in normal daily 
situations since the onset of their stroke/TIA e.g. going into the shower alone, 
getting on a crowded train, walking alone. They often described these 
experiences as peculiar, out-of-character, and completely novel to them. In my 
experience, exposure techniques seemed to have helped the participants in 
overcoming their phobic fears. Some participants, without realising it themselves, 
were already applying exposure techniques to overcome their feared situations 
even before therapy. They simply understood the need to face their fears and 
were able to confront the situations with little formal support. Other participants 
found it difficult to apply exposure techniques without any formal guidance. These 
participants gave a description of consistently escaping or avoiding their feared 
situations in order to seek relief and comfort. These participants tended to have 
more severe anxiety symptoms or even panic attacks. Their anticipatory anxiety 
could be so severe that it prevented them from even imagining themselves 
confronting their feared situations.  
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I designed the exposure therapy component of the TASK-CBT 
intervention to teach participants to recognise their maladaptive behaviours—
escape and avoidance, and the techniques for confronting their fears in a gradual 
hierarchical fashion. The aim of this component was to equip participants with the 
skills so that they could continue applying exposure techniques themselves after 
completion of the six telephone-guided sessions.  
Anecdotally, I found participants with generalised anxiety were those who 
had always had the tendency to worry about many things, or even a past 
diagnosis of GAD before their stroke. The principles of cognitive restructuring are 
the same for anxious individuals regardless of whether they have a stroke or not. 
My role was to repackage these CBT principles into contents that were easily 
comprehensible and relevant to stroke and TIA patients so that they could learn, 
practice, and continue applying these techniques independently after the six 
telephone-guided sessions.  
In my prospective cohort and TASK RCT, I found anxious participants to 
have a distorted perception of their risk of stroke recurrence. They selectively 
paid more attention to the stimuli and situations e.g. odd sensations, headaches, 
physical exertion, going out alone, which they thought were associated with a risk 
of stroke or other dangerous mishaps. These stimuli further perpetuated their 
anxiety feelings (both affective and physiological) which reinforced their belief that 
these stimuli/ situations represented danger. Their avoidant behaviour was 
safety-seeking. These patients fitted well in the cognitive model described by 
Aaron Beck(47). Accordingly, I designed the TASK-CBT intervention to provide 
anxious patients an alternative view of their risk of stroke recurrence in order to 
guide them to correct their own distorted thinking. Simply asking participants how 
high they thought their stroke risk was, followed by the reassuring statement that 
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their stroke risk was no more than 2-5% per year in the long term was often all it 
took to relieve their anxiety feelings. Of course, this statement had to be 
supplemented by a general education on stroke risk reduction including 
maximising secondary prevention and promotion of a healthy lifestyle etc. 
Through explaining the cognitive behavioural model with the TASK-CBT 
participants, I guided them to recognise their own maladaptive thinking patterns 
and unhelpful avoidant behaviours. 
 
Anxiety assessment in clinical trials 
Identifying that there were two main anxiety subtypes post-stroke/TIA 
generated another problem, the assessment and screening of anxiety in this 
population. Prior to my research, none of the RCTs of anxiety intervention in 
stroke used measures that were designed or validated for detecting phobic 
anxiety. These trials assumed all anxiety was generalised. The use of SCID or 
similar diagnostic interviews would be too time-consuming to be practical for use 
in a large-scale clinical trial or in day-to-day clinical practice. GAD-7 was an 
obvious choice for detecting GAD, given its derivation from the DSM-IV criteria 
and validation data in primary care. Initially, my supervisors and I selected and 
modified the FQ so that I could obtain data on phobic avoidance and specific 
anxiety-provoking situations in my prospective cohort study. I saw the opportunity 
to incorporate a diagnostic accuracy study within the prospective cohort. This 
generated the first validation data for our modified FQ, demonstrating preliminary 
findings supporting the use of FQ-agoraphobic subscale in patients after 
stroke/TIA. Agoraphobia accounted for most of the phobic disorder cases, which 
probably explained why the FQ-agoraphobic subscale performed well at detecting 
‘any phobic disorder’. Issues remain as to how best to measure phobic anxiety 
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when present in other specific phobic situations post-stroke: social situations, 
physical exertion, having sex, being home alone. A desirable item or scale for 
phobic disorder would measure the presence of phobic avoidance irrespective of 
the situation. GAD-7 may be able to detect some phobic patients who regularly 
experience anxiety feelings but may not detect those who completely avoid 
confronting or imagining their feared situations. Further scale development work 
is likely required.  
 
Selecting outcome meaures for TASK RCT 
Given that TASK-CBT is an intervention on anxiety, an anxiety measure should 
be included in assessing the effect of this intervention in a clinical trial. However, 
changes in the scoring of an anxiety scale may not translate to clinically relevant 
improvement. A functional measure or a measure of social participation, such as 
the WSAS might be more clinically relevant given that the goal of treating 
someone’s anxiety is to help that individual return to normal functioning and 
activities. Unfortunately, I did not test the feasibility of WSAS in my feasibility RCT 
and chose the mRS, a crude but more widely used functional measure in stroke. 
WSAS is short and simple so should not pose a feasibility issue in a large-scale 
RCT. For the next phase of TASK RCT, I plan to pilot a selection of potential 
primary outcome measures including the WSAS to assess their sensitivity to 
change and responsiveness.  
 
Complex intervention development 
The 6SQuID’s systematic, logical, and evidence-based approach in 
developing a complex intervention gave me a clear framework to follow when 
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designing my TASK-CBT. It ensured my TASK-CBT development was 
transparent and reproducible for the wider research community.  
Another strength of this approach was that it made me consider the wider 
context of our health service, the barriers to accessing psychological therapies, 
and the views of our stakeholders. These factors were all crucial in ensuring that 
the eventual intervention was going to be feasible for large-scale evaluation and 
fit for implementation in the future.  
 
Designing an innovative efficient clinical trial 
My supervisors are clinical researchers with experience in conducting 
RCTs. Their insights in the practical issues and inner workings of large scale 
RCTs inspired me to take on the challenge of designing novel technology-
enabled trial procedures to improve efficiency of RCTs.  The design of TASK RCT 
was geared towards evaluating any remotely delivered interventions such as 
TASK-CBT. Our vision to design an efficient, streamlined centralised trial that 
could be conducted remotely from start to finish seemed ambitious, but not 
unfeasible. In order to achieve our envisioned trial, I had to identify and apply 
technological solutions in the design of all trial procedures. These technological 
solutions enabled me to design, execute, and complete the TASK feasibility trial 
all within the time and budget constraints of my fellowship. The absence of any 
technical support led me to the incredibly useful REDCap application, a versatile 
tool which I used to design all the trial procedures and data collection 
instruments. Having full creative control of the trial database, data collection 
instruments, and the trial websites gave me the freedom to design novel features 





The biggest limitation of my entire programme of research in this thesis 
was generalisability. My findings were not generalisable to the stroke population. 
Findings from my prospective cohort were probably generalisable to the mild 
stroke and TIA population. Studying the anxiety issues in severe stroke patients 
with cognitive and communication difficulties would require specialised methods 
and expertise, and likely involve family and caregivers. My findings that phobic 
anxiety was present after stroke/TIA could at least provide a starting point for 
those embarking on anxiety research in this particular group of patients. One 
could make observations of the behavioural manifestations of phobic fears e.g. 
escaping, avoiding, and the autonomic symptoms of anxiety e.g. shaking, cold 
sweats, being startled easily. Exposure therapy could be adapted to enable 
caregivers to help phobic patients confront their feared daily situations.  
The exclusion of people without internet access and those who do not 
have the technical ability to use the Internet also limited the generalisability of the 
TASK-CBT intervention and the TASK RCT. Potential solutions to overcome this 
technological barrier include involving caregivers and family members, supplying 
user-friendly mobile devices, offering training etc. Technological barriers will no 
longer exist in the near future when all strata of the society have access to the 
Internet and the availability of user-friendly devices or specially-adapted devices 
for people with disabilities.   
 
 
7.2 Future and wider implications of my work 
Designing and testing the TASK-CBT intervention and the TASK RCT go 
hand-in-hand towards achieving the vision of the latest Scottish Government’s 
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Digital Health and Care Strategy, which recognises the potential of digital 
technology in transforming the way in which the public interact with the health 
service(153). The effective use of data, improving broadband coverage, 
increasing digital participation are some of the key goals set out in this 
strategy(153). The design and testing of TASK-CBT in particular, is firmly in line 
with the Scottish Government’s Mental Health Strategy for 2017-2027, which 
includes the action points: to test and evaluate the most effective and sustainable 
models of supporting mental health in primary care; to develop more accessible 
psychological self-help resources and support national rollout of computerised 
CBT within the NHS(154) .  
My TASK-CBT intervention would enable centralisation of resources for 
staff, training, quality monitoring, and cross covering of different geographical 
areas, reducing travel time for therapists as well as patients. Digital content and 
treatment approaches in a telemedicine intervention could be updated and refined 
easily, thus making use of the latest best evidence. The provision, maintenance, 
and updating of digital content could be commissioned or delivered via charitable 
organisations. Organisations delivering the intervention could continue to invest in 
research and development to utilise the latest technology to deliver the treatment 
content at lower costs.  At present, it is not yet clear whether TASK-CBT is cost-
effective in stroke and TIA patients. I plan to include a health economic analysis 
of the TASK-CBT intervention using EQ5D-5L data in the definitive TASK RCT. 
The TASK trial design is geared towards testing any intervention that 
could be delivered remotely e.g. digital self-management interventions, remote 
symptom or physiological monitoring, drug management and dosing. The designs 
of my TASK RCT and TASK-CBT intervention are potentially applicable in many 
other patient groups. 
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Applying informatics in efficient clinical trial design 
I am likely to encounter many logistical challenges at scaling up the TASK 
trial in the future. Many of these challenges can be overcome by evolving 
innovative technologies. The most laborious repetitive tasks should be automated 
e.g. screening patient registry, sending out postal invites, data entry, or at least 
be made more efficient by centralising resources. Having an online platform 
where the public can access information on ongoing clinical trials, screen and 
recruit themselves could improve trial recruitment. Reducing the effort required by 
participants when collecting outcomes in trials could help minimise attrition e.g. 
use of wearable technology. 
The creation of pseudo-anonymised copy of the entire electronic health 
records system for research, use of natural language processing technologies 
including mining semantic data from clinical notes; customised queries that allow 
clinical researchers to use Google-like search engines to find patients with 
particular phenotypes; automated generation of patient summaries etc. are just 
some of the innovative technologies that could make trial recruitment and 
measuring outcomes more efficient.  
 Secure ways of sending personal identifiable information between patients 
and researchers that also satisfy data protection regulations would make 
conducting a large-scale centralised trial feasible across the whole country or 
internationally. REDCap already made it feasible for me to recruit TASK 
participants remotely in our local health board. Verifying eligibility remotely for 
participants outside our health board without the costly set up of a local 
recruitment centre remains a big challenge. Innovative ways of confirming 
eligibility with the patient, the patient’s primary or secondary care provider would 
be necessary to achieve our vision. 
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7.3 A final note 
My thesis addresses the topic of anxiety, a common and debilitating 
complication affecting around a quarter of people after a stroke or TIA. Definitive 
evidence for its treatment is still unavailable. Efficient trials will enable clinical 
trialists to speed up the generation of high quality evidence for a range of 
treatments, which ultimately will improve patient care. This thesis represents 
merely my first step in designing scalable procedures to enable centralised large-
scale RCTs to be conducted efficiently in the future. Building on what I have 
learnt from the feasibility testing, I will now refine the TASK-CBT intervention and 
the scalable TASK-RCT trial procedures in preparation for TASK-II, a large-scale  
RCT. The role of informatics specialists will be crucial as they continue to develop 
innovative technologies, with which I will apply in future trial design in order to 
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